Hepatitis C infection in the west of Scotland : epidemiology, treatment and disease progression by Thorburn, Douglas
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
Thorburn, Douglas (2001) Hepatitis C infection in the west of Scotland : 
epidemiology, treatment and disease progression. MD thesis. 
 
 
 
http://theses.gla.ac.uk/5374/ 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given. 
 
MDTHESIS
HEPATITIS C INFECTION IN THE WEST OF
SCOTLAND: EPIDEMIOLOGY, TREATMENT
AND DISEASE PROGRESSION
Dr Douglas Thorburn
MB ChB (Glasgow 1990)
MRCP (UK) (1993)
Thesis presented to the University of Glasgow for
the degree of Doctor of Medicine
from the:
Institute of Virology, Gastroenterology Unit,
University of Glasgow, Level 8, Gartnavel
Church Street, General Hospital,
Glasgow, 1053 Great Western Road,
GIl 5JR. Glasgow, G12 OYN.
Submitted September 2001
1
ABSTRACT
After the discovery of and development of diagnostic tests for hepatitis A and B it
became apparent that a parenterally transmissible agent was responsible for cases
of non-A non-B hepatitis. It was not until 1989, a further fifteen years later, that
the agent responsible for most cases, the hepatitis C virus (HCV), was identified.
This virus was initially thought to cause a mild self-limiting hepatitis. With the
introduction of serological screening tests for HCV, it was soon apparent that it
caused a chronic asymptomatic hepatitis which could be accompanied by
significant fibrosis and sometimes cirrhosis and hepatocellular carcinoma.
Epidemiological studies have since revealed that up to eighty percent of those
infected develop chronic infection and that in the developed world hepatitis C virus
infection is widespread. An estimated 0.5% of the UK population and 1.8% of the
population in the USA are infected. It is now accepted that HCV can cause an
asymptomatic indolent infection that can progress over decades with the
development of cirrhosis. Hepatitis C infection is now established as the single
most common condition referred to hepatologists and the leading indication for
hepatic transplantation in Europe and the USA.
Since the discovery of the hepatitis C virus much research has focussed on the
epidemiology, natural history and treatment of the condition. The first chapter
provides an overview of HCV and places in context the research contained in this
thesis. In western countries the role of the healthcare setting in transmitting
hepatitis C virus is poorly understood. We performed a large retrospective
serological survey of hepatitis C virus infection in healthcare workers from the
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West of Scotland. This revealed the overall prevalence of HCY infection in
healthcare workers to be low regardless of involvement in exposure-prone
procedures. This indicates that the risk of acquisition of hepatitis C virus infection
by healthcare workers in an area with a large HCY infected intravenous drug using
population is small and that the risk posed to patients by contact with the HCY
infected healthcare workers is also low.
Liver biopsy is the gold standard for assessing the extent of liver injury and
determining prognosis in chronic hepatitis C. Non-invasive markers of liver injury
have proved disappointing such that serial liver biopsies are required to monitor
disease progression. In this thesis the hepatocellular enzyme a-glutathione s-
transferase is studied as a non-invasive marker of liver injury and as a means of
assessing response to treatment with a - interferon. Disappointingly a-glutathione
s-transferase performed poorly as a non-invasive marker of liver injury but showed
some promise as a marker of response to interferon therapy.
Three chapters of this thesis then focus on factors that may influence the natural
history of chronic hepatitis C virus infection and in particular account for the
variable rates of progression of liver fibrosis observed in chronic HCY. The role of
iron and polymorphisms in the haemochromatosis gene (HFE) were studied.
Carriage of HFE mutations was not related to the serum and liver markers of iron
accumulation or the progression of liver fibrosis. Elevated liver iron concentrations
were rarely observed, occurring in patients with more severe liver disease, and
whether this was the cause or result of hepatocellular injury was unclear. Carriage
of genetic polymorphisms in the renin-angiotensin system, which are associated
with increased systemic renin-angiotensin system activity, were studied. This novel
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study was designed to explore whether these polymorphisms, known to influence
the progression of renal and cardiac fibrosis in a number of cardiovascular
diseases, influenced the progression of liver fibrosis in chronic HCY. In this study
no association between these functional renin-angiotensin polymorphisms and the
progression of liver fibrosis was observed. Hepatitis G virus infection was sought
in a cohort of hepatitis C virus infected blood donors to investigate whether co-
infection with this virus influenced the severity of hepatitis C virus related liver
injury. Although hepatitis G virus co-infection was frequently observed it did not
effect the severity of liver injury assessed biochemically and histologically. The
factors that account for the variable rates of progression of chronic hepatitis C
virus infection remain to be elucidated.
Finally in this thesis the role of a - interferon therapy in the management of
asymptomatic blood donors found to have hepatitis C virus infection at blood
donation is studied. Most patients detected in this manner have only mild hepatitis
with minimal fibrosis and little data exists as to whether they are appropriate
candidates for treatment. In a randomised crossover study these patients were
observed to tolerate a. - interferon therapy and have comparable response rates to
other patient groups with chronic hepatitis C infection. These patients appear to be
suitable candidates for treatment, although more data are required to establish what
the prognosis is for these individuals if chronic HCV is left untreated.
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1.2 VIRAL HEPATITIS AND THE IDENTIFICATION OF HEPATITIS C
VIRUS
1.2.1 Recognition and Characterisation of the Non-A. Non-B Hepatitis Virus
As long ago as the 1950s it was recognised that at least two types of hepatitis agent
existed. Definitive evidence for two distinct agents was provided by the work of
Krugman and colleagues in the 1960s who recognised and categorised MS 1
(formerly "infectious" and now type A) and MS2 (formerly "serum" and now type
B) hepatitis (Krugman, S., et al. 1967).
About the same time the work of Blumberg et a1. led to the identification of the
hepatitis B virus (Blumberg, B.S., et a1. 1965, Blumberg, B.S., et a1. 1967). They
discovered that an antigen first detected in the serum of an Australian aboriginal
reacted with antibodies from multiply transfused patients and was associated with
viral hepatitis. Prince proceeded to demonstrate that this antigen was specifically
associated with transfusion associated, hepatitis B (Prince, A.M. 1968). Shortly
thereafter the Australia antigen was shown to be the surface antigen of a virus like
particle (the Dane particle) detected in patients with hepatitis B. This antigen was
renamed hepatitis B surface antigen (HBsAg) and became the basis of the test
employed in blood donor screening. The hepatitis A virus was identified in 1973
when Feinstone and colleagues found a 27-run virus-like particles in the faeces of
volunteers infected with the MS 1 strain and diagnostic tests for the hepatitis A
virus soon followed (Feinstone, S.M., et al. 1973).
When the new tests for hepatitis A virus were applied to the serum of patients with
non-B post-transfusion hepatitis none of the cases were found to have been caused
26
by hepatitis A and were termed non-A, non-B hepatitis (NANBH) (Fein stone,
S.M., et al. 1975). At that time three-quarters of cases of post-transfusion hepatitis
were NANBH. Successful passage of serum from patients with NANBH to
chimpanzees established this to be caused by one or more transmissible agents
(Tabor, E., et al. 1978).
In the early 1980s, Feinstone and colleagues established that one type of NANBH
virus contained essential lipids (and hence was enveloped) by establishing that the
lipid solvent chloroform destroyed it's infectivity (Feinstone, S.M., et al. 1983).
Subsequently He et al. determined that the main strain of NANBH was 30 to 60
nm in diameter by filtering it through various sized polycarbonate filters (He, L-I.,
et al. 1987). Thus prior to the identification of the hepatitis C virus (HCY) as the
causative agent of NANBH some of its physical characteristics had been
established. These studies were essential preliminaries to the later molecular
characterisation ofHCY.
1.2.2 Cloning of the hepatitis C virus.
In a collaboration between Chiron Corporation (Emeryville, California) and the
Centre for Disease Control and Prevention (CDC) the virus responsible for most
cases of NANBH was finally identified in 1989. The RNA sequence of this viral
genome was determined by an elegant combination of molecular biological
techniques and detection of the proteins encoded by the RNA by sera from
"pedigreed" NANBH cases (Choo, Q.L., et al. 1989). Serological assays were then
developed to detect antibodies to the protein product of these clones (Kuo, G., et
al. 1989).
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The initial step in this process was the extraction of nucleic acid from a pellet
produced by ultracentrifugation of chimpanzee plasma that had previously been
shown to have a high infectivity titre. Prior to the synthesis of complementary
DNA (cDNA), the extracted nucleic acid was denatured so that both DNA and
RNA could act as a template. The cDNA was then inserted into a cloning vector
that allowed the viral proteins to be expressed in Escherichia Coli. After lysis of
the bacteria the expressed proteins were screened initially in a radio-immunoassay
with serum from a patient who had had NANBH. Using this method, a single
positive clone (C I00) was identified after testing I x 106 specimens and further
RNA sequence was assembled using the CIOO clone to screen for overlapping
clones.
This C I00 clone became the capture antigen in the original imunoassays for HCY.
This assay was tested on a reference panel of serum from patients with known
NANBH and revealed that 70% to 90% of cases were related to this agent. Within
a year the whole genome was sequenced and named the hepatitis C virus (HCY).
Subsequently the hepatotropism of HCY has been confirmed by the demonstration
of this spherical enveloped virus 50 om in diameter within human hepatocytes by
electron microscopy (Shimizu, Y.K., et al. 1996).
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1.3 STRTJCTURE AND FUNCTION OF THE HCV GENOME.
1.3.1 Genome organisation.
The genome of HCV consists of a positive sensed single-stranded RNA molecule
approximately 9.5 kilobases in length. A large open reading frame, flanked by 5'
and 3' untranslated regions encodes a precursor viral protein of 3008 to 3037
amino acids in length (Choo, Q.L., et at. 1989). Comparative analysis of the full-
length sequences of HCV isolates suggest that the virus is closely related to the
pesti- and flavivirus families within the genus Flaviviridae (Miller, R.H. & Purcell,
R.H., 1990). HCV has been assigned to a separate genus within this family
(hepacivirus, which also contains GB virus-C / hepatitis G virus) as similarity with
pestiviruses and flaviviruses is limited. The organisation of the HCV genome is
schematically represented in Figure 1.1. The HCV polyprotein undergoes post-
translational cleavage mediated by both cellular and viral proteases to generate
both structural (S) and non-structural (NS) proteins (Grakoui, A., et at. 1993).
1.3.1.1 5' Untranslated region (UTR).
The 5' untranslated region of HCV is highly conserved and around 319 to 340
nucleotides in length (Okamoto, H. & Mishoro, S. 1994). It contains an internal
ribosome entry site which directs ribosomes to bind internally on the HCV genome
and initiate translation at one of the AUG start codons contained within this region.
This essential function of the 5'UTR was confirmed by Wang and colleagues and
explains the highly conserved nature of this region (Wang c., et at. 1993).
Modification to this region limits the translation of the HCV genome and is a site
of potential therapeutic importance (Tang, S., et at. 1999).
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1.3.1.2 HeV Structural Proteins.
The structural proteins of HCV are located at the N terminus of the HCV
polyprotein and are processed by host-encoded proteases (Ralston, R., et al. 1993).
Three putatitive structural proteins have been identified; core, Eland E2.
Core
The first 191 amino acids of the polyprotein precursor encode a 21 kilo Dalton
protein which is the putative nucleocapsid of the Hev virion (Grakoui, A., et al.
1993). Expression of core protein in a variety of human and non-human cell lines
reveals that full length core protein is associated with the endoplasmic reticulum;
however after core has undergone cleavage it is associated with the cell nucleus.
Whether this cleavage event occurs in-vivo is controversial. Core protein has been
reported as having a wide variety of functions including a role in Hev persistence
by suppressing apoptotic cell death (Ray, R.B., et al. 1996) and disease
pathogenesis by binding to immunoregulatory cytokines (Matsumoto, M., et al.
1997). How many of its purported functions are relevant in vivo is debatable
(McLaughlin, 1. 2000).
Envelope Proteins
Downstream of the core protein are located the two putative envelope proteins
named El (31 - 35 kiloDalton in size) and E2 (68 - 72 kiloDalton in size)
respectively. There is evidence that El and E2 form complexes which are either
non-covalently associated (Ralston, R., et al. 1993) or have disulphide links
(Grakoui, A., et al. 1993). The predominant complex is formed non-covalently
within the endoplasmic reticulum. The E2 envelope protein contains the most
variable region of the HeV genome, named the hypervariable region. This region
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is further discussed in Section 1.3.2.2. The E2 envelope protein also contains a
binding site for CDS 1, a tetraspanin expressed on hepatocytes, B lymphocytes and
many other tissues, which may function as a cellular receptor or co-receptor for the
virus (pileri, P., et al. 1998).
1.3.1.3 HCV Non-Structural Proteins
The remainder of the HeV polyprotein encodes six non-structural (NS) proteins
(review: Neddermann, P., et al. 1997). These proteins have a critical function in the
life cycle of hepatitis C virus and represent attractive targets for antiviral therapy
(Kolykhalov, AA, et al. 2000).
NS2
This gene encodes a 21-23 kiloDalton protein which is closely associated with the
structural proteins (Grakoui, A, et al. 1993). The biological function of NS2
remains unclear, however a potential zinc-dependant metalloproteinase which is
encoded by nucleotides which bridge the NS2 and NS3 regions has been identified
(Grakoui, A, et aI. 1993).
NS3
The NS3 (70 kiloDaltons in size) has several diverse biochemical functions. In
addition to the putative zinc-dependant metalloproteinase function with NS2, it has
a serine-like protease domain and a RNA-helicase domain (Miller, R.H. et al.
1990, Houghton, M., et al. 1991).
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NS4A and NS4B
The function of these proteins remains unclear. The NS4A (8 kilo Daltons in size)
appears to act as a NS3 protease cofactor and its presence is required for the
efficient post-translational cleavage of the non-structural proteins (Failla, C., et al.
1994). The role ofNS4B has not been established.
NS5A
The full length NS5A interacts with the NS3 RNA-helicase within cytoplasm but
the mechanism of this interaction is unclear. NS5A has been demonstrated as a
potential transcription activator (Kato, N., et al. 1997). Many carcinogenic viruses,
such as human papillomavirus, encode transcription activators and it is possible
that the NS5A may playa role in the generation of hepatocellular carcinoma by
HCY. A region within the NS5A, the so-called interferon sensitivity determining
region (ISDR), has been identified. In studies from Japan the ISDR has been
proposed to mediate interferon resistance (Herion, D. & Hoofnagle, J.H. 1997). A
putative mechanism for this resistance to interferon has been proposed (Gale, M.
Jr. & Katze, M.G. 1998). Studies of HCV isolates from the UK and USA do not
support this role for the ISDR (McKechnie, V.M., et al. 2000, Chung, RT., et al.
1999).
NS5B
The role of NS5B as an RNA-dependent RNA-polymerase was predicted by Miller
and Purcell in 1990 and this has subsequently been confirmed (Miller, R.H. &
Purcell, R.H. 1990). NS5B protein has recently been shown to locate in the nuclear
periplasmic membrane along with NS5A and may participate in a membrane
bound replication complex (Hwang, S.B., et al. 1997).
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1.3.1.4 3' Untranslated Region (UTR).
Downstream of the stop codon of the open reading frame of the HCV genome is
the 3' untranslated region (UTR). This has three distinct regions with the 3'
terminus 98 nucleotide sequence highly conserved even between genotypes
(Kolykhalov, A.A., et al. 1996). Forty-six bases of this highly conserved region
forms a stem loop structure (Kolykhalov, A.A., et al. 1996) which may playa role
in the initiation of viral replication (Clarke, B. 1997). Modification to the 3'
untranslated region impairs virus replication in vivo and again may be a site for
targeting therapy against hepatitis C virus infection (Kolykhalov, A.A., et al.
2000).
1.3.2 Genetic variability of the HeV Genome
1.3.2.1 Genotypes ofacv.
After the full-length sequence of the hepatitis C virus was cloned it became clear
that there was significant viral heterogeneity at the nucleotide level. Phylogenetic
analyses have allowed the classification of the majority of HCV isolates into 6
major groups (Genotypes 1 to 6) and these genotypes are further subdivided into
more than 80 subtypes (Simmonds, P., et al. 1994). The evolution of HCV
genotypes is the result of random nucleotide errors by the RNA-dependant RNA
polymerase. This produces mutations which may be viable or non-viable
depending on the site. The high rate of random nucleotide substitutions results in
slow genetic evolution accounting for the great genetic heterogeneity of HeV.
Differences between genotypes are relatively large with nucleotide differences in
more than 30% of the viral sequence, while subtypes differ by up to 20%. Isolates
within a specific subtype have more than 90% homology in genome nucleotide
sequence (Smith D.B. 1995). Within an individual patient, the virus exists as a
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quasr species, a group of related variants which may have 1 - 2% nucleotide
heterogeneity depending on the region of the genome examined.
Direct comparison of full length HeV sequences is laborious and time consuming.
Analysis of the 5' untranslated region by restriction fragment length polymorphism
(RFLP) has consequently found favour as a more rapid and cheaper method of
genotyping Hev isolates for clinical purposes (Davidson, F., et al. 1995). To allow
further subtyping of Hev isolates, sequence analysis of additional regions of the
genome such as core, E 1 or NS5 is required.
Throughout the world Hev genotypes differ with geographic region. In the USA
genotype 1 predominates, accounting for over two-thirds of cases (Alter, M.J, et
al. 1999). In Europe genotype 1 remains most common however genotype 3 can be
found in up to 50% of cases (McOmish, F., et al. 1994). Genotype 4 is found
almost exclusively in the Middle East, genotype 5 in South Africa and genotype 6
largely in Hong Kong (Mellor, J, et al. 1995). The relative frequency of genotypes
varies within populations depending on population migration and route of
transmission. In Western Europe genotype 1b is more common in patients over
fifty years of age, who largely acquired Hev through blood transfusion, while
genotypes 1a and 3a predominate in younger age groups, who are more likely to
have acquired HeV through intravenous drug use (Webster, G., et al. 2000). With
the dramatic reduction in HeV transmission by blood transfusion as the result of
blood donor screening the relative frequency of infections with genotypes 1a and
3a will increase.
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The role of HCV genotype on the clinical course of HCV infection and response to
treatment is discussed later in Sections 1.6.3.1 and 1.7.3 respectively.
1.3.2.2 Variability in the HeV genome
Variation is found throughout the whole length of the Hev genome although it is
not uniformly spread. Areas of the genome with crucial functions tend to be most
highly conserved as mutations in these regions usually result in an alteration in
structure which impairs function. The 3' UTR is the most conserved region of the
genome with the 5' UTR also highly conserved (Bukh, 1., et al. 1995). Core is the
most highly conserved of the Hev proteins followed by conserved regions in NS3
and NS5B proteins (Okamoto, H., et al. 1992). Comparison of full length HCV
nucleotide and deduced amino-acid sequences have identified two distinct
hypervariable regions lying within the putative envelope 2 (E2) region termed
hypervariable regions 1 (HVRl) and 2 (HVR2).
The hypervariable regions account for 30 - 47% of all nucleotide differences and
40 - 63% of all amino acid differences observed between Hev isolates (Weiner,
A.1., et al. 1991). Despite the high degree of variability in the hypervariable
regions, conserved structural elements are found in the envelope region. Twenty-
six cysteine residues are conserved within the envelope region of all HCV isolates.
These may be essential for the conformation of the envelope proteins through the
formation of disulphide bonds. In contrast no consistent sequences are found in the
hypervariable regions between isolates such that there can be no consistency to the
secondary structure of these regions. This variability in the putative envelope
protein of HCV may contribute to the persistence of HCV through evasion of the
host immune response.
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1.3.2.3 Viral quasispecies
The term quasi species is defined as a swarm of related genetic variants within an
individual with only minor sequence differences of less than 5% of the viral
genome. This occurs as the result of the aforementioned error-prone process of
Hev replication generating a heterogeneous population of distinct but closely
related genomic sequences. The circulation of HeV as a population of different but
related variants may be an important factor in the ability of HeV to cause
persistent infection and evade the host immune response. Even if the host mounts a
neutralizing immune response to the dominant strain any of the other variants
present already can continue to replicate and become the predominant strain.
Studies of chimpanzee inoculated with human sera at various time points after
infection has shown that humans develop neutralizing antibodies to HeV but that
these antibodies are highly strain specific and incapable of preventing the
emergence of viral variants that can maintain the infection (Farci, P., et al. 1992).
Quasispecies diversity may have further clinical relevance as some studies have
suggested that increased quasi species complexity is correlated with more severe
liver disease. This is discussed further in Sections 1.6.3.1. In addition patients with
greater quasi species diversity may respond poorly to interferon therapy (Gonzalez-
Peralta, R.P., et at. 1996).
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1.4 DIAGNOSIS OF HEPATITIS e
1.4.1 Diagnostic testing for HeV
1.4.1.1 General considerations
Serological assays are generally robust and can be performed on any form of blood
sample although poor storage conditions may influence the sensitivity and
specificity of these tests. In contrast, molecular biological tests are easily
influenced by conditions of sample collection and storage (Busch, M.P., et al.
1992). Serum and plasma are acceptable for these assays however samples should
ideally be separated and frozen within three hours of sampling. It is mandatory that
samples are stored for prolonged periods at -70°C or -80°C and to avoid freeze
thaw cycles to avoid degradation of RNA (Busch, M.P., et al. 1992, Damen, M., et
al. 1998).
1.4.1.2 HeV antibody detection
These tests are based on the use of enzyme linked immunoabsorbent assays
(ELISA) and use synthetic peptides or recombinant HCV antigens to capture
antibodies to HCY (anti-HCY) onto the wells of a microtitre plate. The presence of
anti-HCY is detected by the addition of anti-IgG antibodies labelled with an
enzyme that catalyses the conversion of a colourless substrate into a coloured
compound. Changes in the optical density in the well can be assessed by an
automated reader and is proportional to the amount of anti-HCY antibody in the
sample. The newer third generation ELISAs have superseded the second
generation tests by having an improved sensitivity for detecting antibodies to the
core, NS3 and NS4 proteins and including NS5 as an antigen (Huber, K.R., et al.
1996). In high prevalence immunocompetent populations sensitivities of 98.8 -
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100% and specificities of 99.3 - 100% have been observed (Vrielink, H., et al.
1995). False negative results can be observed in immunocompromised patients,
while false positives can be observed in patients with immunological conditions
and hypergammaglobulinaemia.With these assays anti-Hey can be detected in 50
-70% of patients with acute HeV infection at presentation and in 90% within 6
months. (National Institute of Health. 1997).
Due to the lack of specificity of the first generation ELISA assays recombinant
immuno-blot assays (RIBA) were introduced as confirmatory tests for anti-Hf'V.
These assays are based on the detection of anti-Hey by means of Hev antigens
coated as parallel bands onto nitrocellulose strips. With the improved sensitivity of
the newer third-generation ELISAs these assays have little additional to offer
(Pawlotsky, I.M., et al. 1997). They may however retain a role in confirming that
patients who are reactive by ELISA and persistently RT peR negative do have
anti-HCV.
1.4.1.3 Detection of HeV RNA
These assays are based on the amplificationof Hev RNA using a cyclic enzymatic
reaction (polymerase chain reaction, PCR) to generate many copies after the
extraction of viral RNA and a reverse transcription (RT) step to produce double
stranded complementary DNA (cDNA). The product of this reaction can then be
identified by comparison with known positive samples and molecular markers run
on agarose gels or by hybridisation with specific probes. In order to detect the low
circulating levels of HCV RNA in body fluids this amplification process is
required and can detect as few as 100 to 1,000 copies ofHCV RNA per millilitre.
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Many different assays for Hey RT Pf'R have been described and there is poor
standardisation between laboratories with respect to methods, specimen handling
and storage. These problems have been addressed by the introduction of
international Hey RNA reference panels (Damen, M., et al. 1996) and lead to the
development of standardised qualitative RT PCR assays such as the Amplicor test
from Roche Molecular Diagnostics (Young, K., et al. 1995).
From these initial qualitative molecular biological tests for Hey RNA there have
developed tests for quantifying Hey RNA in blood and hence estimates of the
patients 'viral load'. A number of quantitative assays are available and the best
evaluated is the branched DNA-based signal amplification assay from Bayer
Diagnostics. This assay is less sensitive than qualitative RT peR assays with a cut-
off of 200,000 copies per ml and should not be used in the place of qualitative
Hey RT peR to confirm viral clearance.
1.4.1.4 HeV Genotype determination
The reference method for HCY genotype determination is genome sequence
analysis and alignment followed by phylogenetic analysis. This process is however
laborious and not suitable for diagnostic virology. Restriction fragment length
polymorphism (RFLP) of the highly conserved 5' untranslated region has
consequently found favour as a more rapid and cheaper method with satisfactory
sensitivity (Davidson, F., et at. 1995). The main disadvantages of this technique are
its lack of standardisation and inability to detect mixed genotype infections in most
cases.
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1.4.1.5 Local Protocol for HCV diagnosis
The protocol for HCV testing now employed by the West of Scotland Regional
Virus Laboratory is outlined in Appendix 1. Serum samples are initially screened
for anti-HCV using a third generation ELISA (Ortho Diagnostics, Raritan, NJ).
Confirmatory testing of reactive samples is by RT PCR using the second
generation Amplicor test (Roche Diagnostics). Supplemental third generation
RIBA testing (Ortho Diagnostics, Raritan, NJ) is reserved for patients who are RT
PCR negative. HCV genotyping is performed only on those patients RT PCR
positive who are being considered for treatment.
1.4.2 Evaluation of disease severity in chronic HCV infection
1.4.2.1 Non-invasive assessment of disease severity
Most patients detected with HCV infection are asymptomatic and hence history
and clinical examination are not useful for assessing the severity of liver disease
unless there is evidence of hepatic decompensation. Unfortunately the use of
standard non-invasive serum tests of liver function has proved unreliable in
determining the activity of liver disease. Histological evidence of chronic hepatitis
can be seen in up to 70% of RT PCR positive patients with normal serum
transaminases. However patients with persistently normal alanine aminotransferase
(ALT) levels are less likely to have significant liver disease on liver biopsy than
patients whose ALT levels are persistently elevated (Silini, E., et al. 1995). At best
the correlation between the ALT and liver grade and stage of chronic hepatitis is
poor (Haber, M.M., et al. 1995). This is discussed further in Chapter 4.
Numerous studies have attempted to correlate HCV genotype and RNA load with
liver histology and have found no consistent correlation (review: Fried, M.W.,
40
1997). This is discussed further in Section l.6.3.l. Thus in the absence of signs of
hepatic decompensation liver biopsy is the gold standard to determine the extent of
HeV -related liver injury.
1.4.2.2 Pathology of Hev
The histological features of chronic HeV are diverse but commonly include portal
inflammation with lymphoid aggregates, macro vesicular steatosis, lobular
inflammation (rarely amounting to confluent necrosis) and portal and septal
fibrosis. A number of scoring systems for the quantitative assessment of liver
histology in chronic HeV have been proposed (Scheur, P.J., et al. 1991, Ishak, K.,
et al. 1995, Bedossa, P. & Poynard T. 1996) and each allows the classification of
chronic hepatitis into mild, moderate and severe disease as initially proposed
(Knodell, RG., et al. 1981). By histologically grading the severity of
necroinflammatory activity and staging the degree of fibrosis on liver biopsy of
patients infected with HeV, it is almost possible to predict those patients at risk of
progressing to cirrhosis (Yano, M., et al. 1996). Histological assessment is
therefore important to assess the current severity of HeV -related liver injury and
also the interval until the development of cirrhosis such that appropriate patients
can be offered treatment.
The grading and staging systems employed in this thesis are those of Scheuer
(Scheuer, PJ. 1991) (Chapter 4) and Ishak et al. (Ishak, K., et al. 1995) (Chapters 5
to 8) and are summarised in Table 1.1
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1.5 EPIDEMIOLOGY OF Hev
1.5.1 Prevalence of HeV infection
As chronic HCV is largely asymptomatic, its prevalence in a population is difficult
to estimate without an extensive programme of screening. The World Health
Organisation. estimates that 3% of the world's population are chronically infected
(World Health Organisation, 1997). This figure is an average with reported rates
worldwide showing great geographical variation. Egypt has the highest reported
prevalence worldwide with an estimated prevalence of 24% (Cohen, 1. 1999).
Within Europe the prevalence in blood donors ranges from approximately 0.04%
in northern countries to 2% in southern Mediterranean areas (Hepatitis C European
network for Co-operative Research. 1998). A prevalence as high as 11% has been
reported in areas of southern Italy (Guadagnino, v., et al. 1997). In the United
Kingdom, as with the rest of the world, there is a lack of population based
serological studies of HCV prevalence. It is possible to estimate a minimum
population prevalence of HCV by centralised recording of all reported HCY
infections. From 1991 to 1997 there were 2161 individuals who tested positive for
HCV in the Greater Glasgow Health Board catchment area (prevalence 0.42%
[3807 / 906,000]) (SCIEH Weekly Report, 2000). This compares with a 0.05%
(2546 of 5.12 million) prevalence of known HCV antibody positivity in the Trent
region of England (Mohsen, A.H. et al. 2001). These figures are likely to be an
underestimate of the true population prevalence of Hey, as many asymptomatic
patients remain undiagnosed.
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1.5.2 Transmission of HeV
On the introduction of screening tests for HCV the commonest risk factors for
acquisition of the infection were a history of blood transfusion or intravenous drug
use, which were present in from 60% to 80% of cases (Serfaty, L., et al. 1993,
Zeuzem, S., et al. 1996). With the increased sensitivity of third generation
screening tests, the risk of transfusion associated HCV infection is estimated at
0.01% to 0.001% per unit transfused (Schreiber, G.B., et al. 1996). No recipients of
blood in Scotland are known to have been exposed to HCV contaminated
transfusions since screening of donors was introduced in 1991. As a result of donor
screening, blood products and transfusion are no longer a major route of hepatitis
C transmission.
Intravenous drug use is currently the main risk factor for HCV transmission. The
prevalence of anti-HCV among intravenous drug users in the West of Scotland is
estimated to be 72% and is related to the duration of drug injection (Taylor, A, et
at. 2000). With the introduction of needle-exchange programmes and methadone
maintenance therapy in the early 1990s there has been a reduction in the frequency
with which injectors share injecting equipment (Bath, G.E., et at. 1993). There is
evidence that, even when duration of injection is controlled for, the incidence of
HCV among injectors has decreased over the same period (Taylor, A, et al. 2000,
Goldberg, D., et al. 1998). Despite these measures, new cases of HCV are still
occurring and this likely reflects the ongoing sharing of injecting equipment among
users despite the free availability of sterile needles and syringes (Information and
Statistics Division of the Common Services Agency, National Health Service in
Scotland. 1998).
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Sexual transmission of HCV is recognised but the frequency with which it occurs
is uncertain. In a recent study high-risk sexual behaviour, defined as an early age at
first intercourse or more than fifty lifetime sexual partners, was an independent risk
factor for the acquisition of HCV (Alter, M.J., et al. 1999). A study of non-
intravenous drug using genito-urinary clinic attenders in Scotland found a low
prevalence of anti-HCV in heterosexual males (0.8%) and females (0.3%) and
homosexual males (0.6%) compared with attenders that used intravenous drugs
(49%) (Goldberg, D., et al. 2001). In studies from the western world, the average
anti-HCV positivity rate among spouses of HCV infected cases who report no
other risk factors for infection is 1.3% again suggesting that HeV can be acquired
by sexual intercourse but the probability is low (Wasley, A & Alter, MJ. 2000).
Vertical transmission is recognised from mothers HCV RNA positive at the time of
delivery and occurs in 6% of deliveries increasing to 17% if the mother is co-
infected with mv (Wasley, A, et al. 2000).
Transmission of HCV in the healthcare setting may be from patient to patient, from
patient to healthcare worker or vice versa. In developing countries where the
provision of sterile medical equipment is inadequate, this is likely to be a major
route of transmission. This may account for the high prevalence of anti-HCY
observed in Egypt where the injection of anti-schistosomal treatment with reusable
equipment is widespread (Cohen, 1. 1999). In western countries, outbreaks ofHCV
have been observed among patients within haemodialysis units presumably as the
result of incorrect implementation of infection control policies by staff (Wasley, A
et al. 2000). There have been two reports of HCV transmission from infected
healthcare workers who perform invasive procedures to their patients when
infection control policies have been contravened (Bosch, X. 1998, Ross, R. S., et al.
44
2000). In addition there have been two reports of transmission ofHCY from health
care workers (both cardiothoracic surgeons) performing invasive procedures when
adequate infection control had been observed (Esteban, 1.1., et al. 1996,
Duckworth, GJ et al. 1999). As few patients develop symptoms following
infection the significance of the healthcare setting as a mechanism of HCY
transmission in western countries is not established.
In the USA only 10% of patients with acute or chronic hepatitis C infection do not
have a commonly identified risk factor for the acquisition of HCY (Wasley, A. et
al. 2000). Other plausible routes of HCY transmission have been proposed to
account for these cases however there is no evidence from studies that body
piercing, tattooing or commercial barbering transmit HCY.
1.5.3 Prevention ofHeV
No vaccine or effective post-exposure prophylaxis exists for hepatitis C V1ruS
infection hence the emphasis is on primary prevention for patients that are at high
risk of acquiring HCY infection and the counselling of infected persons so that
they can reduce the risk of transmitting to others. This includes education to reduce
the risk of HCY transmission in the healthcare setting by emphasizing the
importance of infection control and the avoidance of unsafe practices.
In developing countries, where programmes of blood donor screerung and
inactivation of blood products have not been implemented, these routes remain the
major source of transmission and hence improving the safety of the blood supply
remains the greatest priority (World Health Organisation. 1999). It 1S
recommended that programs should also be instituted for the sterilization or
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disinfection of medical supplies and the education of all health care practitioners in
the use of appropriate infection control practices.
In developed countries, primary prevention of intravenous drug use, which is the
single most common route of infection, should be the highest priority. In addition
although the relative importance of sexual transmission of HCV is unclear,
behavioural modification and appropriate barrier contraception should be endorsed
to reduce the risk of transmission of HCV and all other sexually transmitted
diseases. Healthcare professionals should be vigilant for patients with a history of
intravenous drug use or other high risk practices to identify individuals for
appropriate testing and counselling. Counselling and education to prevent initiation
of drug injecting and high-risk sexual practices and to modify behaviour in those
that already indulge in these practices but are not infected is necessary. The
establishment of needle exchange clinics has already been shown to prevent the
transmission ofHCV infection (Taylor, A., et al. 2000, Goldberg, D., et al. 1998).
Those persons known to be infected with HCV should be counselled on ways to
reduce their risk for transmitting HCV to others (Centre for Disease Control and
Prevention 1998). They should be advised not to donate blood, organs, tissue or
semen; not to share toothbrushes and razors and to cover cuts and sores. Those in
stable relationships need not change their behaviour however they should discuss
the need for counselling and testing with their partner and the couple should be
allowed to make an informed decision regarding the need for change in their sexual
practices. Infected individuals should be provided with information on ways of
preventing further harm to the liver through the avoidance of alcohol and
immunisation against hepatitis A and B where appropriate.
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1.6 NATURAL HISTORY OF Hev INFECTION
Hev infection is infrequently diagnosed during the acute phase of the infection
and is usually diagnosed in individuals who already have chronic infection
(persistent HCV viraemia for > 6 months). The infection is indolent and the
outcome of infection may not be known for many decades. At present, few studies
provide sufficient follow-up to conclusively record the natural history of chronic
Hev such that extrapolation is required beyond twenty years of infection. It
appears that for most HCV infected individuals the infection has a low morbidity
and mortality. The problem is that at present we cannot predict those individuals
who will develop progressive liver disease and hence a more dire outcome.
1.6.1 Acute HCV infection
This is an uncommon presentation of HeV infection. Clinical manifestations occur
in between 25% and 35% of cases, usually within 7 to 8 weeks (range 2 to 26
weeks) after exposure to Hev (National Institute of Health 1997). In those patients
that develop symptoms, they are usually mild and consist of nausea, malaise and
occasionally jaundice. Fulminant hepatitis at this stage has been described but is
very rare (Farci, P., et al. 1996). HCV infection is self-limited in the minority of
cases, as evidenced by clearance of HCV RNA from serum and return of liver
enzymes to normal within six months of infection. Initial studies reported
progression to chronicity and persistent viraemia in 74% to 86% of infections
(Alter, MJ., et al. 1999, Conry-Catalina, C., et al. 1996). Later studies with follow-
up over decades report rates of clearance of HeV RNA from serum of up to 45%
(Kenny-Walsh,E., et al. 1999).
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1.6.2 Chronic HCV infection
As already stated the natural history of chronic hepatitis C infection has largely
been documented in studies over the first 20 years of infection. Variable rates of
disease progression have been reported and these are often dependent on the study
design employed.
The most severe outcomes of HCV infection have been documented in
retrospective studies of patients already established to have chronic hepatitis,
where duration of infection has been estimated retrospectively (studies summarised
in Table 1.2). These studies do not include patients with subclinical, asymptomatic
disease or those that recovered from the infection. As a result it is clear that serious
liver disease can be anticipated in some patients with HCV infection however it is
not possible to determine what proportion of the total number infected this
represents.
Prospective studies originally designed to investigate the incidence and causes of
transfusion associated hepatitis were extended when it became apparent that many
patients developed persistent elevation of serum transaminases. Most of these
patients were subsequently identified as having HCV infection and this study
design allowed prospective follow-up on these patients. The results of these studies
are summarised in Table 1.3. These studies were however flawed in that some
patients received treatment, which may have modified outcomes, liver biopsy data
was only available on those individuals who had more severe biochemical hepatitis
and follow-up was documented only for the first couple of decades of the infection.
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Combined retrospective-prospective studies have also been performed when
patients with HCV infection have been identified retrospectively through the
testing of serum available at or soon after the time of development of hepatitis.
Prospective follow-up of these individuals was then possible, circumventing the
problems of retrospective and prospective studies. These studies include
'outbreaks' of HCV infection in groups of patients who have an identifiable
common source for HeV acquisition and are summarised in Table 1.4.
The rate of fibrosis progression to cirrhosis in HCV has been evaluated in a large
multicentre study in France, which recruited 2,235 patients who had biopsy proven
chronic HeV (Poynard, T, et al. 1997). Fibrosis progression was determined as a
ratio between the fibrosis stage (scale of 0 - 4 META VIR units) and the duration
of infection in years. Most patients had a single biopsy however 70 patients had
paired samples. The median rate of fibrosis progression was 0.133 units/year.
Thus, if fibrosis progression were linear it would take a median of thirty years to
progress from no fibrosis to cirrhosis. The rate of fibrosis progression was not
normally distributed and they concluded that there were three distinct groups of
patients with one third developing cirrhosis within 20 years, one third not
developing cirrhosis by fifty years and the final third in between. Males who drank
more than 50g of alcohol per day and were infected after the age of forty had the
worst prognosis. These findings are consistent with prospective studies of
transfusion associated hepatitis (Di Bisceglie, A.M., et al. 1991, Koretz, R.L., et al.
1993).
The reported prognosis of HeV -related cirrhosis has been found to be
unexpectedly good. In their study of 384 patients with HCV-related cirrhosis
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Fattovich et al. demonstrated a 9% five year mortality for liver related deaths,
rising to 21% at 10 years (Fattovich, G., et al. 1997b). If however patients had
evidence of hepatic decompensation the five year mortality was 50%. The annual
incidence of hepatocellular carcinoma was 1.4% and hepatic decompensation
developed in 18% of those that did not develop hepatocellular carcinoma over the
course of the study. Overall most patients survived without evidence of significant
liver complications. Subsequently this relatively benign prognosis has been
questioned by a similar study of 103 patients with HCV-related cirrhosis where the
four year survivalwas 84% (Serfaty, L., et al. 1998).
HCV can cause hepatocellular carcinoma usually through the development of
cirrhosis. Because HCV does not integrate into the host genome, the prevailing
concept is that malignant transformation is the result of numerous mitotic events
that accompany hepatic regeneration as the result of viral or immune mediated
hepatocellular destruction. Initial studies from Japan revealed that 74% to 94% of
cases of HBV-negative hepatocellular carcinomas have anti-HCV (Kiyosawa, K.,
et al. 1990, Nishioka, K., et al. 1991) In contrast, studies from western countries
have not identified such a strong link between serological markers of HCV and
hepatocellular carcinoma. The most compelling evidence for a role for HCV was
provided by Liang et al. who used serological and molecular methods to detect
HCV in the serum and liver tissue of patients from the USA with hepatocellular
carcinoma (Liang, TJ., et al. 1993). They found evidence ofHCV infection in 55%
of HBV-negative cases. The less significant role for Hey observed in the west
may reflect differing genetic susceptibilities in these populations. In addition it is
possible that the HCV epidemic began 10 - 20 years earlier in Japan, such that the
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role of HCV in hepatocellular carcinoma pathogenesis will increase in the west
over time.
1.6.3 Factors influencing the progression of fibrosis in chronic HeV infection
Based on the evidence outlined above it is speculated that of 100 persons acutely
infected with HCV, 20% (20 patients) will recover spontaneously and 80% (80
patients) will develop persistent infection. Of the 80 persons with persistent
infection (chronic HCV), it would appear that 30% (24 patients) will develop
progressive liver disease culminating in cirrhosis and / or hepatocellular carcinoma
and 30% (24 patients) will have stable liver disease that will not show progression.
The remaining 40% (32 patients) will develop slowly progressive liver disease
whose outcome cannot be predicted. Factors which alter the rate of progression of
liver fibrosis in this cohort are poorly understood. It would clearly be useful to
identify the 70% (56 patients) who will develop progressive liver disease such that
treatment can be targeted to this group before they develop significant
symptomatic liver disease. A number of factors which might influence the rate of
progression of hepatitis C related liver fibrosis have been studied. These include
viral, host and environmental factors and are summarised in Table 1.5. The
evidence for the statements in this table is given in the next few pages. Many
studies exploring the roles of these factors on the progression of fibrosis in chronic
HCV are hampered by the failure to exclude confounding variables already known
to influence disease progression in chronic HCV infection.
1.6.3.1 Viral factors
Viral factors including HCV genotype, viral load, quasispecies complexity and size
of inoculum have been studied. Studies exploring the role of Hev genotype on
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disease progression have been conflicting and inconsistent. Genotype 1b has been
proposed to be associated with the development of more significant liver disease
(Pozzato, G., et al. 1991). Further studies have not confirmed this role for genotype
lb (poynard, T., et al. 1997, Serfaty, L., et al. 1998). The explanation for these
inconsistencies may be that genotype 1b is more common in older patients who
acquired HeV through blood transfusion and have longer durations of infection
(see Section l.3.2.1). Hev viral load has not consistently been shown to be
associated with disease outcome (Gretch, D., et al. 1994). Initial evidence
suggested that increased quasi species complexity was associated with progression
of liver fibrosis and the putative mechanism for this was proposed to be the
presence of an increased number of targets for cytotoxic T-lymphocytes on
infected hepatocytes (Yuki, N., et al. 1997, Hayashi, 1., et al. 1997). More recently
this has been challenged and currently quasispecies diversity is not believed to be
associated with disease progression (Leone, F., et al. 1998, Lopez-Labrador, F.X.,
et al. 1999). Gordon et al. compared the long-term outcome in patients who
acquired HeV by blood transfusion with persons who had acquired Hev through
intravenous drug use (see Table 1.2) and found the outcome related to the mode of
transmission (Gordon, S.c., et al. 1993). This may be the result of a larger
inoculating viral load in those patients acquiring Hev by blood transfusion.
1.6.3.2 Host factors
A number of host factors which may influence the progression of HCV -related
liver injury have been studied (see Table 1.5). Age at acquisition of infection
seems to be an important determinant of disease progression. Children and adults
infected under the age of forty have the mildest outcomes (Vogt, M., et al. 1999,
Kenny-Walsh, E., et al. 1999, Seeff, L.B., et al. 1998b). In addition older age has
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been shown on multivariate analysis to be associated with more rapid progression
of fibrosis and decreased survival in chronic HCV (poynard, T., et al. 1997,
Niederau, C., et al. 1998). It is important however to distinguish age at infection
from age at diagnosis as duration of infection, which correlates with disease
progression, is likely to be longer in those diagnosed with HCV when older. As a
result it is unclear whether older age, and its effects on hepatic blood flow and the
immune system, directly influences the progression of HCY. Male gender is
associated with more rapid progression of hepatic fibrosis (Poynard, T., et al.
1997). Why females are protected against progression of hepatic fibrosis is unclear
but may be the result of oestrogens modulating fibrogenesis (Yasuda, M., et al.
1999). Host immunodeficiency is associated with a more rapid progression of
fibrosis in chronic HCV. Studies report that approximately a third of patients with
hypogammaglobulinaemia who acquired HCV through contaminated
immunoglobulin infusions develop cirrhosis within 10 years (Bjoro, K., et al.
1994). About 30-40% of mv infected individuals also carry HCV, often reflecting
a common mode of transmission through intravenous drugs or transfusion
(Soriano, V., et at. 1999, Dieterich, D.T. 1999). Studies of patients co-infected with
the human immunodeficiency virus and HCV have revealed a more rapid rate of
fibrosis than HCV infected controls (Garcia-Samaniego, J., et al. 1997, Benhamou,
Y., et al. 1999). The mechanism for this association is not well elucidated however
there appears to be an association between low CD4 count and rate of progression
(Benhamou, Y., et al. 1999). The role of co-infection with hepatitis G virus on the
progression of chronic Hev infection is discussed in Chapter 7.
The role of host genetic factors on the outcome ofHCV infection has been studied.
Specific human leukocyte antigen alleles have been identified to be linked with
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disease progression however studies are inconsistent (Thurz, M., et at. 1999,
Aikawa, T., et at. 1996). The role of functional polymorphisms in the genes for
pro-fibrotic cytokines which influence the activity of hepatic stellate cells have
been studied and are discussed further in Chapter 6. The role of hepatic iron and
haemochromatosis mutations on progression of fibrosis are discussed in Chapter 5.
Some histological features of chronic HCV infection have been shown to be
associated with disease progression. As already discussed, macrovesicular steatosis
is a common finding on liver biopsy in chronic HCV infection (see Section
1.4.2.2). The presence and severity of this steatosis has been found to be associated
with more rapid progression of HCV-related liver fibrosis (Adinolfini, L.E., et at.
2001). In addition by histologically grading the necroinflammatory activity and
staging the fibrosis on liver biopsy it is possible to predict the rate of ongoing
fibrosis. The assessment of necroinflammatory activity is not a good predictor of
fibrosis progression alone and the fibrosis score alone is the best predictor of
ongoing fibrogenesis (Paradis, V., et at. 1996). Thus far no studies have
demonstrated that activity grades are predictive of fibrosis progression
independently of fibrosis stage (Yano, M., et al. 1996).
1.6.3.3 Environmental factors
Excess alcohol consumption (> 50g / day) is the one environmental factor which
has consistently been shown to be associated with more rapid progression of
fibrosis in chronic HCV infection (Poynard, T. et al. 1997). Further evidence for its
role has been supplied by Corrao and Arico (Corrao, G. & Arico, S. 1998). They
compareci the rates of cirrhosis in tee-totalers and alcohol abusers (175g / day) with
and without HCV infection. Persons who did not drink and were HCV negative
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were the reference population. The relative risk of cirrhosis for Hey negative
patients who did drank excessively, Hey positive patients who were tee-total and
Hey infected alcohol abusers were 15 x, 9 x and 147 x respectively. It is therefore
generally accepted that Hey infected individuals should abstain or limit their
alcohol consumption to less than one drink per day.
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1.7 TREATMENT OF HCV INFECTION.
1.7.1 General measures
All Hev infected patients should be counselled to avoid alcohol and with advice to
minimise the risk ofHCV transmission to others (see Section 1.5.3).
1.7.2 Antiviral Therapy
1.7.2.1 Interferon monotherapy
Even before HCV was identified as the chief etiologic agent in non-A, non-B
hepatitis, ex. - interferon therapy was associated with normalization of ALT in some
patients with this condition (Hoofuagle, J.H., et al. 1986). In 1989 the first cases of
successful interferon treatment of HeV infection were documented with
normalisation of liver biochemistry in approximately 30% of patients after six
months of therapy (Davis, G.L., et al. 1989). High biochemical relapse rates were
observed and frequently necessitated retreatment, which was invariably
unsuccessful. Over time a number of different interferons were studied and all
demonstrate similar efficacy (National Institute of Health. 1997).
Later clinical trials have assessed response to treatment in terms of biochemical
response (normalisation of ALT), virological response (as defined by a negative
qualitative RT peR result for HeV RNA in serum) and in some cases histological
response, however in the clinical setting liver biopsy post-treatment is rarely
indicated. Since responses to therapy may not be maintained after treatment is
stopped, the response in clinical trials has been evaluated in terms of response at
the end of therapy (end of treatment response) and six months after the completion
of therapy (sustained treatment response). Patients with sustained virological
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response have a high probability of having a durable biochemical, virological and
histological response (Reichard, 0., et al. 1999). This has been shown to improve
quality of life, halt progression of the liver disease and to hopefully reduce risk of
hepatocellular carcinoma. Increase in patient survival has not yet been
demonstrated but awaits larger-scale studies with longer follow-up.
Using these more robust markers of response to treatment has proven that initial
studies overestimated the proportion of patients that eradicated the virus with only
6% of patients having been shown to have a sustained virological response after six
months of a - interferon therapy (McHutchison, J.G., et al. 1998). These poor
results with interferon monotherapy prompted studies employing longer durations
of therapy and higher doses of interferon. Increasing the duration of therapy led to
sustained response rates of up to 25% such that 12 months treatment is now
recommended (Poynard, T., et al. 1996). Increasing the dose of interferon also led
to improved response rates however this was offset by the number of patients who
were unable to tolerate the higher doses such that optimal dose and interval
between doses remains to be determined (Poynard, T, et al. 1996).
1.7.2.2 Interferon / Ribavirin combination therapy
Given the disappointing response rates with interferon monotherapy a variety of
other drugs were studied for the treatment of HCY infection. Ribavirin is an orally
active synthetic guanosine nucleoside analogue that has a broad spectrum of anti-
viral activity. It inhibits the replication of many viruses by inhibiting the initiation
of translation, RNA replication and viral RNA packaging (Smith, R. 1984). Initial
studies of ribavirin monotherapy in chronic hepatitis C showed that it improved
liver function tests without clearing HeV from serum. Studies of ribavirin in
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addition to interferon confirmed this combination to be supenor to interferon
monotherapy with sustained virological response rates of 38% and 43% after one
year's treatment reported in the initial studies (McHutchison, lG. & Poynard, T.
1999). The findings of these studies have since been reproduced such that
combination therapy has now been accepted as first line therapy for patients with
chronic HCY. The main benefit of combination therapy appears to be a 60%
reduction in the proportion of end of treatment responders that relapse compared
with interferon monotherapy.
1.7.2.3 Pegylated Interferon
Despite the documented improvement in response rates with combination therapy,
sustained response rates remain suboptimal. The most recent advance in the
treatment of chronic HCV has been the development of depot preparations of
interferon, produced by combining interferon with polyethylene glycol (so called
pegylated interferon). This can be administered once weekly and has the advantage
of avoiding fluctuations in the serum levels of ex. - interferon, minimising side-
effects and improving the tolerability of treatment. Two randornised controlled
trials of pegylated ex. - interferon monotherapy have now been published and report
sustained virological response rates of 39% in patients with moderate histological
changes and 30% in patients with severe fibrosis and cirrhosis (Zeuzem, S., et al.
2000, Heathcote, EJ., et al. 2000). In both studies response rates were superior to
standard ex. - interferon monotherapy with fewer side effects. Studies of
combination therapy with pegylated ex. - interferon and ribavirin have so far only
been published in abstract form but sustained virological response rates in excess
of 60% have been observed.
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Pegylated interferon alone and in combination with ribavirin is likely to become
the gold standard for treatment of interferon naive patients with chronic HeV,
however at present it is unavailable to NHS patients in the UK.
1.7.3 Predictors of response
From clinical trials a number of pre-treatment factors have now been identified
which are associated with a successful response to interferon therapy (see Table
l.6) (Davis, G.L. & Lau, 1.Y.N. 1997). This knowledge helps to target those
patients most likely to gain a sustained response to treatment to maximise the
limited resources for HeV treatment in the UK. The most clinically important of
these factors are HeV genotype, the level of HeV RNA and the histology of pre-
treatment liver biopsy. The role of viral factors are considered in more detail here
and the role of histological severity of liver disease is considered in Section 1.7.6.
Hev genotype
Studies comparing response rates according to viral genotype have consistently
shown that infection with HeV genotypes 1a and 1b are associated with a lower
probability of achieving a sustained virological response to interferon In their
detailed review, Davis and Lau analysed 15 studies of interferon monotherapy and
reported a sustained response rate of 18% for patients infected with genotype 1 and
54% for patients with non-genotype l. (Davis, G.L. & Lau, 1.Y.N. 1997). This
improvement in response rate according to HeV genotype is also observed in
studies of combination therapy (McHutchison, J.G., et al. 1999).
Viralloaq
Despite efforts to standardise assays for the quantification of HeV RNA no gold
standard exists and what is considered to be a high or low viral titre is
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consequently somewhat arbitrary. The cut-off between low and high viral load is
accepted to be 3.5 million copies / millilitre (Poynard, T. et al. 2000). The impact
of viral load on sustained virological response rate appears to be less for
combination therapy than for interferon monotherapy, particularly if treatment is
continued for 48 weeks (McHutchison, J.G., et al. 1999).
In an analysis of the two large studies comparing the combination of interferon and
ribavirin with interferon monotherapy the importance of pre-treatment viral factors
and choice and duration of therapy can be observed (McHutchison, J.G., et al.
1999). Patients infected with non-genotype one with low viral load who received
combination therapy for 48 weeks experienced a sustained virological response
rate of 64% compared with patients infected with genotype 1 and a high viral load
treated with interferon monotherapy for 24 weeks, where only 1% experienced a
sustained virological response.
1.7.4 Side effects of interferon and ribavirin treatment
a. - Interferon and ribavirin both have significant side-effects which are important
when selecting patients for treatment (see Table 1.7). Almost all patients receiving
a. - interferon develop some adverse effects. Common problems include influenza-
like reactions 6-8 hours after the initial injections, fatigue, malaise, headache and
mood changes (Dusheiko, G. 1997). Ribavirin is well tolerated, but causes a dose-
dependent haemolytic anaemia, skin rashes and risk of teratogenicity (Glue, P.
1999). In combination with interferon the only adverse effects occurring more
frequently than with interferon monotherapy alone are anorexia, dyspnoea, pruritus
and rash.
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Patients admitted to controlled clinical trials are generally fit and highly selected
from the pool of HCV patients. In daily clinical practice adverse reactions to
combination therapy may be more frequent, with withdrawals as high as 20% and
compliance with therapy less than optimal (Heathcote, E. J. 2000). Contra-
indications to combination therapy are listed in Table 1.8.
1.7.5 Management of untreated (naive) patients with chronic HeV
The indications for treatment of chronic Hev have gradually been clarified over
many years. Unfortunately, those patients most responsive to treatment also tend to
have the best untreated prognosis. The corollary to this is that the more the patient
is in need of treatment, because of risk of progressive liver disease, the less likely
one is to obtain a response. In addition, the published randomised clinical trials of
therapy have often been very selective in their patient entry criteria, such that it is
not always possible to reproduce the reported response rates (Reichard, 0., et al.
1999, Poynard, T., et al. 1998,McHutchison lG., et al. 1998).
As a consequence several organisations have published consensus conference
recommendations concerning indications for treatment (Booth, lC.L., et al. 2001,
Dhumeaux, D., et al. 1997, National Institute of Health. 1997, Canadian
Association for the Study of the Liver. 2000, European Association for the Study
of the Liver. 1999). The recommendations for naive (untreated) patients are
outlined in Table 1.9. The consensus is remarkably consistent in recommending
that treatment is restricted to patients with elevated serum transaminases for more
than six months, active viral replication as indicated by a positive RT PCR test for
serum HCV-RNA, and moderate or severe inflammation or fibrosis on liver
biopsy. Patients with mild change on liver biopsy should not be treated yet until
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there is a better understanding of their natural history and patients with
compensated cirrhosis may be treated at the discretion of the clinician.
The selection of patients for treatment is strongly influenced by the efficacy of
current therapy. Figure 1.2 illustrates the rapidly improving efficacy of therapy in
recent years with the promise of further advances to come. Improvement in
treatment responses comes at a cost, but the cost-effectiveness has been
demonstrated when compared to other routine medical interventions (Wong, 1.B.
1999). Nevertheless the resources available to pay for treatment of hepatitis C
within the NHS in the UK are limited and clinicians need to tailor their treatment
program to match local budgets. The Greater Glasgow Health Board has just
published a hepatitis C strategy review (Greater Glasgow Health Board. 2000).
One section of the review is a practical protocol for treatment and monitoring of
chronic HCV infection and extracts are shown in Appendix 2 and 3. The inclusion
and exclusion criteria match broadly those shown in Tale 1.9 but the upper age
limit is increased to 70 years and children are included.
1.7.6 Treatment of specific patient groups
The recommendations for treatment outlined above have to be interpreted
pragmatically as in clinical practice many patients do not fit neatly into these
categories. For example the long natural history of HCV mitigates against treating
older patients for whom the cost-benefit ratio rises rapidly above 60 years
(Bennett, W.G. et al. 1997). There are few data on the treatment of children and
hence treatment is recommended only within the confines of controlled clinical
trials (Schwimmer, J.B. et al. 2000). There is little evidence for the treatment of
asymptomatic blood donors with chronic HCV but expectations for treatment may
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be high as they have become patients as a consequence of their altruistic action
(see Chapter 8). Other categories of patient are considered in more detail:
Acute hep-atitis C
Presentation with acute HCY infection is uncommon (see Section 1.6.1) hence data
are limited. The evidence is that acute infection responds well to interferon
monotherapy (Quin, J.W. 1997) and patients should probably all now be
considered for combination therapy although no data on efficacy are yet available.
Normal serum transaminases
HCY is known to be associated with fluctuation in serum ALT levels so this
condition needs to be defined. It is suggested that both serum transaminases should
be within the normal range on several occasions at least one month apart over a
total period of at least 12 months (Di Bisceglie, A.M. 1999). Small numbers of
such patients have been treated with interferon monotherapy and have tended to
show similar response rates to patients with abnormal ALT and more severe
histological changes. In general, this group of patients have a favourable prognosis
and they should probably not be treated at present unless they have significant
histological liver disease.
Mild disease
Mild chronic hepatitis C is defined by liver biopsy criteria as scoring both < 4 for
grade of neero-inflammatory activity and < 3 for stage of fibrosis (Ishak, K., et al.
1995) or Metavir activity score < A2 (Bedossa, P., et al. 1996). There are few data
on the natural history and treatment of such patients (see Chapter 8). At present it
is recommended that this group should remain under observation with liver
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biopsies performed every three to five years such that treatment can be considered
if they develop evidence of progression.
Cirrhosis
Patients with compensated cirrhosis are clearly a priority group to consider for
treatment but, unfortunately, sustained virological responses to interferon
monotherapy and combination therapy with ribavirin are lower than in pre-
cirrhotic patients (Davis, G.L., et al. 1997, Bonino, F., et al. 1999). However,
useful sustained response rates of 36% can now be obtained in patients with
bridging fibrosis or cirrhosis given combination therapy for 12 months (Davis,
G.L. 2000) or 30% when treated with pegylated interferon monotherapy for 12
months (Heathcote, E.J., et al. 2000). In addition, therapy may delay progression to
liver failure and hepatocellular carcinoma in cirrhotic patients even when viral
clearance has not been achieved (Nishiguchi, S., et al. 1995, Fattovich, G., et al.
1997a).
Relapse after interferon monotherapy
Approximately 50% of HCV patients will have a successful end of treatment
response to interferon monotherapy with normal serum ALT level and negative
HCV-RNA assay. Relapse is defined as the re-appearance of serum HCV-RNA
within 6 months of an end of treatment response. These patients are clearly
responsive to treatment and are good candidates for additional measures.
Initially, re-treatment with interferon alone at increased dose or for longer duration
produced further sustained responses (Buti, M., et al. 1999). However, the real
advance came from combination therapy with ribavirin. In a randomised study of
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345 patients assigned to re-treatment with interferon alone or combination therapy
for 6 months, sustained responses were found in 5% and 49% of patients
respectively (Davis, G.L. et al. 1998). Therefore combination therapy is indicated
for the re-treatment of patients who have relapsed after a course of interferon
monotherapy. Combination therapy has now become the recommended initial
therapy for naive patients. The management of patients who relapse after
combination therapy remains uncertain.
Interferon monotherapy non-responders
Non-response to interferon monotherapy is defined as being serum HeY-RNA
positive at the end of treatment. Usually this is established when patients show no
response at 12 weeks into therapy and treatment is stopped. However, it also
includes those who show breakthrough by becoming serum HeV -RNA positive
again prior to the end of treatment despite having an initial response.
Possible options for these patients include dose escalation, changing the interferon,
using combination therapy, phlebotomy to reduce iron stores, long-term therapy or
observation (Bacon, B.R. 1999a). None of these measures is of proven benefit and
at present this group of patients is probably best managed by continuing
observation until more successful therapy is found.
my co-infection
The use of highly active anti-retroviral therapy (HAAR T) has improved the
prognosis of my infection. As a consequence Hey co-infection is assuming more
importance and liver failure becoming an increasing cause for mortality.
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Interferon monotherapy and combination therapy can produce similar sustained
responses for HCV infection inmv positive and negative patients (Soriano, V., et
aI. 1999, Landau, A., et aI. 2000). However, caution is required as there is a
theoretical interaction with ribavirin leading to reduced phosphorylation of
zidovudine and more data are required. In addition 10-15% of HIV positive
subjects experience a transient decrease in the CD4 count between the 6th to 14th
week of treatment and in a few cases this decline is irreversible.
HBV co-infection
Dual infection with HCV and HBV is frequent because of shared routes of
transmission. Co-infection with HBV leads to more severe liver disease and a
higher prevalence of cirrhosis and appear to have a synergistic effect leading to a
higher risk of hepatocellular carcinoma. Therefore dual chronic infection is a
strong indication to consider therapy however there are few data to guide us in the
most appropriate regime and duration of treatment.
Haemophilia
HCV infection is almost universal in the haemophiliac population who were
treated with clotting factor concentrates before the availabilityof heat-treatment in
the mid-1980s (Fried, M.W. 1999) Co-infection with HIV is common. Studies of
interferon monotherapy for 12 months in HIV negative patients reveal a sustained
response in 13% of patients (Rumi, M.G. et al. 1997). Results of combination
therapy studies are awaited. For mv -negative patients with end-stage liver
disease, liver transplantation is effective and also cures the underlying coagulation
disorder.
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Renal failure
HCV infection is common in patients on renal dialysis and several small studies
have demonstrated the efficacy of interferon mono therapy for these patients
(Carithers, RL. 1999). It is possible that reduced renal clearance of interferon
leads to improved efficacy but also a high incidence of side-effects. Interferon is
best avoided in renal transplant recipients, as there are several reports of allograft
rejection. Ribavirin should be avoided in patients with renal failure as reduced
renal excretion may produce uncontrollable haemolysis (Glue, P. 1999).
1.7.7 Developments in the treatment of chronic hepatitis e
The high prevalence of this chronic infection with serious long-term consequences
has stimulated the pharmaceutical industry to make substantial investments in
research into anti-viral therapy. Significant progress is being made with the
prospect that amantadine, rimantadine, and protease and helicase inhibitors may
become part of the therapeutic regime in the future (Clarke, B.E. 2000). However
much the treatment of HCV infection improves, the major long-term priorities are
to develop an effective vaccine and improve public health measures to prevent
initial infection.
1.7.8 Liver transplantation for chronic HeV
Liver transplantation is the only available treatment option for patients with
decompensated HCV -related cirrhosis and is also indicated for some patients with
early stages of hepatocellular carcinoma. Reinfection of the graft with HCV is
nearly inevitable, and the majority of patients will have histological evidence of
hepatitis and even cirrhosis (Feray, C., et al. 1999). Despite these drawbacks the
five year survival (72%) after liver transplantation is comparable to those with
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other common indications for liver transplantation (Feray, C; et al. 1999). The
main concern relates to the long-term survival post-transplantation. For that reason
many therapeutic modalities have been tried in an attempt to prevent HCY
recurrence or reduce the severity of liver disease once recurrent disease has
developed. Studies of interferon monotherapy have reported at best a delay in the
development of recurrent HCY without evidence of increased graft rejection. In
initial studies the combination of ribavirin and interferon has proved to be safe
with promising reports of sustained clearance of Hey RNA from serum (Bizollon,
T., et al. 1997). However further long-term controlled studies are required to
determine which agents are most effective and least harmful and for how long
therapy is required.
68
....
C
QIe
<II
<II
QI
<II
<II
<
QI...'::
S
.rd .'::
<II C QC
QI ~ ~ ~ ~ 1.0 "'=t ~ ..-4 \D
05 = I I= = 0 0 0 0 = =<II....;
""='.5 til Q)
'C 'Vi til t+=QI 0 ......
~... ts tile til 0- 'Vi II) "E=- 0 s:: ~ ~e I-< gp 'uo Q.
~
QI II) ...... s til ......~ s:: eo 'Vi (.).... c.S11 ""=' s:: 0 -U .... 'r:: t+= I-< s:: ~:= = .0 (.)QI a II) II) s 0 til""' e II) .;; -e s:: Q. ~ 'Vie <II (.) .~ I-< I-< C - + 0~ <II II) 0 ~ CIS ;; U
~
01
C QI '5. II) ..c 1.0<II II) - II) ...... .... -d'.... -< i .0 ~ ~ e +~ II) I-< II) U~ CIS QI II) ==~ .0 'C 6) ~ ~ 1 I.... QI 6) 0 .5<II + til.. ~ rJ') .-'C .':: rJ') 0 .€ I I < tilC e~ s I I I ..... ..... ........ II) II) II) .! s:: as as II) .0OJ) - II) t+=C " s:: s:: s:: til til til s::= 0 0 0 Col ~ .0 ~ 0 0... ~'C Z Z Z <: z ze -~
OJ) Col...
QI OJ); =-.. .s
~ <II...
<II .ce 'C til tilQI ',;jQI ~ 'Vi.... .~ 0<II ...
~ 'C I-<.f' = Q. (.)II) II)OJ) ,e. ~ ..c s::.5 :> s:: <II... .- II) til (.) 0 ~.. .! t) (.) .- f,~ til .~= CIS - e cCol Col VI § Col<II - ~ ~ ~ E (.) - <II- ..-4 C ~ II) e t>~ 0'1 t> .... .5 cCol 0'1 0 .s: '-' 0 CIS... C Q. - ..... ~ =OJ) ..-4 .... 'r:: .- . ~ s:: Q. ........ - .5= '-' ~ (.) ~ II) til ~~ e II) CIS 0 ;::I '-' e <II- Q. Q) .... - ~= ~ !a .. QI Q. ~ ] ~ e.... e - .... s:: =<II = " I-<... ~
~ - Col ~ II) 0 0 0 ~ Col:= ~ ;::I= .0 <II ~ U ~ ~ = <IIQ) .5 0 0 <II .:l .5 <II..-4 = .... < ~ U Q ..... ~ ~ <IIQI E <II ~ E =..-4 .c e .c ..Q) CJ CJ ~ ~ Col ~- r:I) Q) Q)~ ...Z ... Z ~~ - ~ -~ ~ ~'-' '-'
C)....
"C -.
t "*--- "0 "0 "0 "0~ iGo) ! ! ! !100 0 0 0 0
Go) Q c:l. c, c:l. e,rIl e e e e«I ....
Go) ~ b ~ ..... e-- ..... .....rIl 0 0 0._ .....
Z on Z Z Z"C ~ ...... ~
100
Go).~ a -.- ~"C - ~ "0Go) = !- e-= Q)rIl o 0._ 0 c,- 0.c ~ c e.s .....& ~ ~ 1.0 .....rIl ~ <0 0 0 r- oGo) ::t: u Z NN ...... ~ ......;:._
~
rIl -.1:1 ~C) ~e til
Go) .....
~ til0
rIi 'E ...... 00 0 0Go) 0 -0._ U on ...... on ......"C ~ on on ...... on N.a
rIl
Go)
~
....
0 viy
~
01) 0
Go) e e-=- arIl 5 * "0 "0
~ 0 -. ! tilc.l::l e ~ =Go) 0 0100 ta = >. 0'1 00 e, ce e til of N N e N Q)0 01) I I N g
~
c, .....
C)
~ ~
0 ~ 0 I 0'1 0~ ...... ...... Z 0'1 ...... N .S
1:1 <+-<
C) 0._.... Q)y til
~ ~ =1:1 <+-< = -0 ++ to> ~._
&::
Q) .....
;, 0 .~ ...... ...... 00 on on +-'.....C) rf') rf') 0 ~ ...... 0'1 .S Q)\.,) ',Q z c:l. N ...... t"'- oo N ...... til
==
«I .... =~ 0 01)c.. '.c = 2C) rIl 0
Go) ..... "0
Go) ;. <Il tile .5 t8 = =C) til 0 0
100 § ~
.....
5y cf: £ til.... ~= gC) rIl C ~ < ~ § < e~ = < =e .... 0 c:l. 00 0.. c3 00 00 0 f5 =1:1 U ~ ::> ~ ::> ::> ..t:: .-Go) Go) ca ..c: ..c:.... y 01) 01)
I
~ = =~ -«I 0 0 01:1 t: 0'1 00 ~ .... ....C)
~
0'1 0'1 ~ ~ .S i3 i3~ ~ 0'1 0'1 0'1...... on 1.0 ...... 0'1 0'1 ~ ~~ ="! > t 0'1 0'1 ~ ...... ...... 0 = =0'1 0'1,..; to I-.:' d' =" "0 til til...... ...... 0 0~ 0 0 Q)Go) «I 0 til 00 0' Q) <Il 0.. c:l.- ._ ..c: 0 "0 "0 "0 ~ ><: ><:.c 1: ..... >. =
~
Q) .... .... t:O f.I.l f.I.l«I = ..... 0 ..... c3 c3~ Go) < ~ ~ z * ++ to>....
--~--= ~Q'':
(,j Clc! ....
= CI).... > r- ~ \0 r-.....
.! ~ ~ ..... ..... ~
=(,j•'- a --Q ~
"0- ~~ = ~s - eCI)'': 0 0
~ 0 0 Q.= e.s ~ .....s fr ~ ~ -0 r-
~
::t: U 0 ..... z 0
1.... --'".e ~~
fI.I ell
fI.I .....
= ellQ 0
C ..s:: ~ \0I:: N 0 0~ U r--: 00 an~ ..... .....
~
~
....
'" *~ --E S ell vi!>. Ol) .....~ 0 r--o. cl:l e oJ 2'': Cd = eo "0(,j i:: til § ell~ 0 0 ~ =Co
~
Q. t- -.0 1.0 0fI.I ~ .... ~ c::e 0 0\ ..... ..... r--: CI)
Co ~e ,J:s
Q ~ .5~ c....= 0= CI)..... CI)Q ~ ell'': Q. =(,j c.... Cdc! 0 .....
= 0 an .~.... If) 0 ..... ~ .5~ Z 10 00 10 ..... ....u 0
== c::'- 0Q 'Vi
~ t.2e
~
c:: ell
Q CI) a
~ <: <: "0 !:l= ~ ..Q= 0 r/.l r/.l ~ EQ U ~ ~ r/.l 0E cl:l~ ..... Cd.. 0\ N i::IOil 0\ 0\ ~= ..... M 0\Q
~ oJ
~ 0\ ..... .5~ ..... 0\ 0\ d c::- 0\ .....I"l >< ~ ~ 0..... c::"~ ....~ 0 Jj - "0~ 0 ell 0 0 CI).....
~
E ell.c -5 ~ CI) ~.... CI) ~• < ..... 0 ....~ 0 ~ E-- *
~ f'-I~ ."c
f'-I ..e ... --"Q c. ~~ -.5 .c:: 1~ I=f'-I e= = 0e
oS "'"e Q)~ .- > r- 0'1 N
C. ~ ~ N lr\ 0 0 0- C.e =f'-I ~G,j ~ --.. e ~~ - :2.a - -~ ~00 Q) e
~ ~ u 0> 0~ ."c ~ c::.. ...~ CJ Q. ~i ~ Q) 0'1C. :t: u .- 0 0 0 0f'-I
~ e""> c.".,c
CJ ~~ ~ .-..c. t '::Rf'-I ~e
"" = ellC. e .iiiI 0
G,j
"" "E.~ ~ .- lr\ 0'1 0 ~ MCJ ~ U lr\ N 0 0~c. CJ
fIl "e .&:I B.!:: *e ~ a $ --~ ell vi= 0 ~ bI) N~ " tl::l ~ 2 r---~ CJ Q)".5 fIl ca ::s bO 0 '"0ell lr\.&:I ~ ~ 0 B ell.. I ::se ~
~
Q. 0e .a ~ "'" 0 lr\ r-- 0 r--- c::CJ 0 N ~ ..... N .... Q)fIl
~e =
~
e
~
::s.. .SfIl
= ~ Q) f+o<.- 0e f'-I ~".,c = Q)
~
Q. ellCJ - ::s~ 0 00 -;.51 ~ 0 M \0 .- 00> 0 r-- r-- 0 lr\ :'5> ."c Z .... .... M .... ~ c::CJ ....U G,j "'"= c. 0fIl c::- ee 0.-~ c. >. >. elle "" ~ '"0 fa fa ..ze elle ·c < < .3 § J ~CJ ::s... c. 0 00 00 ~ c3= u ::> ::> ee =.. 0 =E ·2 tl::l 001 ]~ .- 01 -;... ...
I " 0\ ~ ::s~ c. ..... Q.= ~ ..ci' ~ 0e .c::
~
.S Q.~ .c ell 0 +- u~ 00 0 - 0 0\ =~ .-~ ... 0\ 0 0\ ~= ~ 0 0~ 0\ 0 N 0\.-4 CJ - ""," .... N .... '"0 .-~ " ~ 0 >. Q)" Q) '"0- -5 'if ~ = ell ..r 1Q Q).&:I oS = Q) bI) ~= Q) tJ:l ~" .. e ~ Q) Q) Q) ~ 0~ ~ CJ 00 00 ~ > * +-
~.-><:
C1)-0..a
"C 0
~
C,)
<I.l= C1).- '"C ....Col C,)
C tIS C1)
rIl 0 0...< .....:l <I.l....- ~- ee :> ;sz 0
=e.,c
Col ~~ 0...5 <I.l 0
~ .-U ..00 I::1"'-1 co 0.,c
~-.c .£= e=- ~ .2:G.l ~..c: C"C ...c::Col .- ~.- ~ - <I.l= .... .-.S e ..0 til ~e ';:2 0Col .a 0.. -;;..c: c
~
Col 1"'-1 ;s 8 e
.51 .< C,) til ]0 C1) ;s ~.~ .5 <I.l G:l r--b E: C,) <I.lC,) .... I::1"'-1 ..... 0 <I.le .CI 0 .~ e i '8.- 01"'-1.c 1"'-1 C1)
~
=
~
C,)
~ C N c3 C1)r;3 .... zCol ~ 00.,c
==- *G.l >..c:
~
~
'- 0..0 0
= 00 .-0 ..0.-
~
~ I:: =1"'-1 <I.l 0 I:: 0rIl =e 0 ~ = C1) 0 .~0 ....';:2 ... ....OJ) -s .- 0 s ~C,) I:: ....e .- C,)= ~ C1) .~ '"c::I til I::=- 0 .... = ;s .-= C,) til I
oS
';:2 .- ... ~ = 0 .- til 0"C C,) ..... C1) 0 C,) til I:: C,)~ 0 '"c::I 0 0.- .a '"c::I .- '"c::I ... <I.l~ .5 = I:: t) .... ..0 C,) 2= C1) C1) of"C .- ~ 0 co I:: ~ t+=i '0 .-.- ;;..a Col -;; ;s = 0 ~ ...c::0 C1) C1) e " e 0 j:Q= rIl ... ~ .... C,).- rIl ~ ;s ~ 0 0 .-Col -< .s < tilC 0 U U ';:2.-rIl -;;
1"'-1= 0..~ C1)::tc - C,)- aCol '2= =~ 0G.l ...
~ e ...c::
...-I = U
G.l
C >- '"- f - ....,.Q 1"'-1 ~ ~= .- c =~ > == ~ *
Table 1.6 Factors reported to be predictive of a biochemical response to
interferon monotherapy.
Biochemical
Dose> 3 million units
Female sex
Younger age
History of injecting drug use
Unknown source of infection
Short duration of infection
Mild chronic hepatitis
Absence of fibrosis / cirrhosis
Low serum AST
Low gamma glutamyl transpeptidase
Low serum iron or ferritin
Drug
Demographics
Histology
Virological Low HCV RNA level
Genotype 2 or 3
Low number of quasispecies
Multiple amino acid differences from the resistant type
interferon sensitivity determining region ofNS5A.
Early normalization of serum ALT
Early loss of serum HCV RNA
Interferon response
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Table 1.7 Side-effects of a. - interferon and ribavirin therapy for chronic hepatitis
c.
Frequency of side effect a. - Interferon Ribavirin
>30% (very common) Influenza-like
Headache
Myalgia
Fatigue
Fever
Rigors
Myalgia
Thrombocytopenia
Induction of antibodies
Anorexia1 - 30% (common)
<1% (rare)
Reaction at injection site
Insomnia
Partial alopecia
Lack of motivation
Inability to concentrate
Irritability
Emotional lability
Depression
Diarrhoea
Induction of autoimmune disease
Leukocytopenia
Taste perversion
Polyneuropathy
Paranoia / Suicidal ideation
Diabetes mellitus
Retinopathy
Optic neuritis
Hearing impairment
Seizures
Loss of libido
Cardiotoxicity
Haemolysis
Nausea
Anaemia
Nasal congestion
Pruritus
Gout
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Table 1.8 Contra-indications to a - interferon and ribavirin therapy for chronic
hepatitis C.
Absolute Relative
Pregnancy
Inadequate contraception for both sexes
Renal failure
Continued intravenous drug use
Continued alcohol excess
Severe depression
Decompensated cirrhosis
Auto-immune hepatitis
Hyperthyroidism
Cardiac disease
Renal transplant
Seizures
Psoriasis
Retinopathy - diabetes or hypertension
Hypersplenism
Thrombocytopenia
Leucopenia
Anaemia
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CHAPTER 2
BACKGROUND TO THIS THESIS
As outlined in Chapter 1 there has been much progress in our understanding of
hepatitis C virus (HCY) over the twelve years that it has been recognised. There
remain many areas in which knowledge is lacking. The virus is blood borne and
transmitted in most cases by parenteral exposure although up to one third of those
infected have no clear risk factor. Many individuals infected with the hepatitis C virus
are asymptomatic or have only mild symptoms and as a result the population
prevalence and natural history of the infection is poorly documented. Why some
patients develop progressive liver disease and others do not is poorly understood.
Currently ex. - interferon in combination with ribavirin is the treatment of choice and a
sustained virological response to treatment is seen in approximately fifty percent of
patients. With limited resources for therapy in the UK, treatment should be targeted to
those who will experience the greatest benefit. The factors that predict a successful
response to treatment remain poorly understood.
The work contained in this thesis addresses a number of these questions. Intravenous
drug use is the most important mechanism for transmission of HCY in western
countries, yet up to one third of patients have sporadic HCY infection with no
identifiable route of infection. Whether the transmission of HCY from healthcare
workers to patients accounts for many of these sporadic cases is unknown. We
performed an anonymous retrospective cohort study of hepatitis C infection in over
10,000 healthcare workers in the West of Scotland which is reported in Chapter 3.
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Prevalence of hepatitis C antibodies was reported according to age and occupational
category such that the risk of transmission to those performing invasive procedures
and the risks posed to patients from those infected could be estimated.
Liver biopsy is the gold standard for assessing the severity of HCY-related liver
injury. The prolonged natural history of chronic HCY dictates that follow-up over
decades is required with serial liver biopsies necessary to monitor the condition.
However liver biopsy is associated with significant morbidity and mortality and
consequently non-invasive means of assessing the severity of liver injury would be
advantageous. In Chapter 4 we studied the hepatocellular enzyme a - glutathione s-
transferase in the grading of HCY-related chronic hepatitis and assessing the response
to a-interferon treatment.
The natural history of chronic HCY infection is controversial with variable rates of
progression observed. The mechanisms which account for these variations are poorly
defined. Hence it is not possible to predict in advance which patients with chronic
HCY will develop progressive liver disease with associated morbidity and mortality.
As a result it is not possible to target those patients with the worst prognosis before
they develop advanced liver disease, when they are most likely to respond to therapy.
In Chapters 5, 6 and 7 we studied a number of factors which might influence the rate
of progression in chronic HCY. In Chapter 5 the role of iron and haemochrornatosis
gene mutations on the progression of chronic HCY was assessed. Patients with chronic
HCY are recognised to have elevated serum iron studies and liver iron concentrations.
This has been reported to be associated with the progression of liver fibrosis. In
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addition carriage of mutations in the lIFE gene has been reported to be associated with
more advanced hepatic fibrosis in chronic HCY. In Chapter 5 we studied the
association between serum iron studies, liver iron concentration and carriage of
mutations in the HFE gene and the development of hepatic fibrosis in chronic HCY. In
Chapter 6 we studied the role of genetic polymorphisms in the renin-angiotensin
system on the development of hepatic fibrosis in chronic HCY. These functional
polymorphisms are recognised to influence the progression of cardiac and renal
fibrosis in a number of cardiovascular diseases and a role in the development of
hepatic fibrosis is untested. In Chapter 7 the influence of co-infection with the
hepatitis G virus on the severity ofHCY related liver injury is studied.
As HCY infected patients with advanced liver fibrosis have the lowest sustained
virological response rates to treatment, treating patients with mild liver disease before
they develop significant liver fibrosis might be expected to result in improved
response rates to treatment. There is little evidence to support this hypothesis. In
Chapter 8 we assessed the tolerability and efficacy of treatment with ex - interferon
alone in a cohort of asymptomatic patients with chronic HCY detected at blood donor
screening and with mild liver disease on liver biopsy.
Work for this thesis was largely performed between April 1996 and August 1998
when I was employed as the Kinnear-Brown Lecturer in Medicine and
Gastroenterology in the Department of Medicine at the Western Infirmary in Glasgow.
Dr Peter R Mills, Consultant Physician and Gastroenterologist supervised the work
and the patients with hepatitis C infection studied attended the viral hepatitis clinics at
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Gartnavel General Hospital. I performed the hepatitis G VlfUS PCR and Hev
genotyping under the supervision of Dr. Liz McCruden at the Institute of Virology,
University of Glasgow. Ethics approval for each study was obtained from the
Research Ethics Committee at the Western Infirmary. Ethics approvals for the
multicentre epidemiological study of healthcare workers was sought and obtained
from each of the NHS Trusts in the West of Scotland included in the study.
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3.2 SUMMARY
Whether healthcare workers have an increased prevalence of hepatitis C VIrUS
infection as a result of exposure to patient's blood and body fluids is controversial.
This study assesses the prevalence of hepatitis C virus infection in healthcare workers,
relates it to the performance of exposure-prone procedures and duration of
occupational exposure, allowing an estimate to be made of the incidence of
occupationally acquired hepatitis C infection among medical staff. This anonymous
retrospective cohort study estimates prevalence of hepatitis C infection in 10,654
healthcare workers. ELISA-3 testing was performed on pools of five sera collected
during immunisation against hepatitis B. Healthcare workers were arranged in five
occupational groups, according to degree of patient exposure, and three age bands
«30 years, 30-39 years, >40 years). Prevalence of antibodies to hepatitis C is 0.28%
(30 / 10,654), comparable in all occupational groups (p = 0.34) and unrelated to
duration of potential exposure. Assuming that all detected infections had been
occupationally acquired, the maximum estimated risk of hepatitis C infection in
exposure-prone medical staff is low: 1.4% for surgeons and 1.0% for physicians over a
thirty-five year professional career.
Hepatitis C infection is infrequent in the healthcare workers in Glasgow. Those
conducting exposure-prone procedures do not seem to be at higher risk than other
healthcare staff
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3.3 INTRODUCTION
The hepatitis C virus (HCV) was first identified in 1989 but has been prevalent for
many decades. In western countries, HCV is most commonly transmitted among
injecting drug users who share injecting equipment. Once infected most patients
develop chronic HCV infection, a disease with associated morbidity and mortality
(Niederau, C., et al. 1998). The incidence of HCV seroconversion after accidental
needlestick exposure is uncertain with reports ranging from 0 to 10% (Kiyosawa, K.,
et at. 1991, Mitsui, T., et al. 1992, Lanphear, B.P., et al. 1994, Puro, V., et al. 1995).
Whether healthcare workers have a higher prevalence of hepatitis C virus infection
than the general population through percutaneous occupational exposure is unclear
(Zuckerman, 1., et al. 1994, Neal KR, et al. 1997, Thomas, D.L., et al. 1993, Cooper,
B.W., et at. 1992, Panlilio, A.L., et al. 1995, Shapiro, C.N., et al. 1996, Thomas, D.L.,
et al. 1996). The aim of this study was to assess the prevalence ofHCV antibodies in
healthcare workers in Glasgow, a city where injecting drug use is common, and to
analyse rates in relation to specific occupational groupings and duration of potential
exposure to HCV. The study particularly focussed on staff performing exposure-prone
procedures, where injury to the worker may result in the exposure of the patient's open
tissues to the blood of the worker. These rates could then be compared with existing
prevalence data in other local populations to determine if certain health care workers
might be at increased risk of occupationally acquired HCV.
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3.4 PATIENTS. MATERIALS AND METHODS
3.4.1 Setting
This study was performed in the Greater Glasgow Health Board area, which
incorporates the largest city in Scotland and had a population of 909,000 in 1996. It is
estimated that around 80% of Glasgow's large injecting drug user population have
been infected with Hev (Frischer, M., et al. 1993, Goldberg, D., et al. 1998). Glasgow
is served by eight NHS Hospital Trusts, providing a full range of clinical services, a
single diagnostic virology laboratory service (Regional Virus Laboratory) and a
coordinated occupational health service integrated into each NHS Trust.
3.4.2 Study Population
All healthcare workers in Glasgow, who presented for hepatitis B VlfUS (HBV)
immunisation between October 1994 and October 1997 and had serum samples stored
for anti-HBs assay were identified. Employees from one NHS Trust, which denied
ethics approval, were excluded.
Of the 24,077 serum samples received by the Regional Virus Laboratory from
healthcare staff there were 11,577 individuals that had occupational health casenotes
available after duplicate samples had been removed. Samples from 10,654 (92%) of
these healthcare workers were located in the virology serum archive. According to
1997 Scottish Health Statistics payroll data, this sample represents 44% of the 24,150
healthcare workers employed in the seven Glasgow NBS Hospital Trusts studied
(personal communication). Included are: 1430 of 1972 (73%) hospital medical staff,
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203 of 547 (37%) dentists, 5,913 of 11,803 (50%) nursing and midwifery staff, and
3108 of 9828 (32%) others.
3.4.3.Study Procedure
This study was necessarily performed in an anonymous manner. Serum samples were
initially linked to the corresponding employee's immunisation records at the
occupational health clinics using a database consisting of employee's name, gender,
date of birth, location of employment and occupational group. When data collection
was complete, the age of each employee at the time of sample collection was derived.
Individuals were then grouped into one of five occupational categories by their degree
of patient exposure and three age bands (Table 3.1) to ensure that any combination of
the two contained more than 50 individuals, thus protecting any infected individual
against identification. All employee identifiers were then deleted from the database
leaving only non-identifying details of occupational category and age band, linked to
the stored serum laboratory number.
A unique non-identifying code was generated for each database entry and printed on
labels adjacent to the corresponding laboratory serum number. The appropriate sera
were then labelled with their unique code and transferred to a separate laboratory for
testing. By then deleting the laboratory serum numbers from the database, the HeV
antibody results could only be linked with the anonymised data (occupational category
and age band) via the unique non-identifying code.
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3.4.4 Samples for testing
Sera were initially stored by sequential laboratory number at either 4°C or -20°C on
the day of collection in the virology department. The study sera were then identified,
aliquoted into 2.5ml Sarstedt vials, labelled with the unique non-identifying code and
stored at -20°C for testing.
3.4.5 Hepatitis C Tests
Sera were screened for antibodies to the hepatitis C vuus by ELISA-3 (Ortho
Diagnostics, Raritan, NJ, USA). Reactive samples were only considered positive if
they were confirmed by RIBA-3 testing (Ortho Diagnostics, Raritan, NJ, USA). All
samples confirmed positive were further tested for the presence of HCV RNA by
reverse transcriptase polymerase chain reaction (RT PCR) using an in-house method
(Dow, B.c., et al. 1993). RT PCR positive samples were genotyped by restriction
fragment length polymorphism (McOmish, F., et al. 1993).
In view of the large number of sera to be tested a pooling protocol was developed.
Pools of five sera were tested by third generation ELISA. Twenty microlitres of each
of the five sera to be tested were pooled and mixed thoroughly. Fifty microlitres of
this pool was transferred into the test plate (the equivalent of 10 ul of each serum),
diluent was added to a total volume of 200 III and thereafter testing followed the Ortho
ELISA-3 protocol. The final dilution of each individual serum in the pool was 1 in 20
compared with individual testing with a 1 in 11 dilution. The five sera in any reactive
pool were then tested individually by ELISA-3 to identify the reactive samples
requiring confirmatory testing by RIBA-3.
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3.4.6 Statistics
The data were analysed as a prevalence of antibodies to HCV in each age band and
occupational group. The prevalence in each of these categories was compared using
the Chi-square test or Fisher's exact test.
By assuming that 24 years is the median age at which doctors qualify in the UK the
probability of acquiring HCV per 100 person-years of occupational exposure for the
medical staff was estimated to be:
Probability ofHCV infection No. positive for HCV antibodies x 100
=
/ 100 person-years exposure No. tested x (Median age in occupational group - 24)
This estimate IS a maxunum because it is possible that infections among Hev
antibody positive individuals were acquired before healthcare work was commenced
or through a non-occupational route. The median age for each occupational group was
available from the dates of birth on the original database.
3.4.7 Ethics
Ethics approval for this study was obtained from 7 of the 8 NHS Trust research ethics
committees in Glasgow. Employees of YorkhiU NHS University Trust, which did not
grant approval, were excluded.
90
3.5 RESULTS
3.5.1 Evaluation of Pooling
The pooling method was evaluated on the first 2190 serum samples from employees in
exposure-prone occupations. They were initially tested individually and then arranged
into 438 pools and tested by a single operator blinded to the location of the known
positive samples (Table 3.2). Nine of these pools contained a single serum sample
known to be reactive when tested individually by ELISA-3. On pooled testing, all five
sera confirmed positive by RIBA-3 individual testing and one serum considered
indeterminate by RIBA-3 testing (e33 2+ band only) were detected. Two pools were
reactive when individual ELISA-3 and RIBA-3 testing confirmed all ten sera to be
unreactive (false positive pools). Three pools containing sera known to be reactive by
individual ELISA-3 testing were unreactive. Two of these pools contained single
samples which were RIBA-3 negative and considered false positives for antibodies to
HeV and one was of indeterminate RIBA-3 reactivity (e33 2+ band only) and hence
of doubtful significance. With confirmatory testing by RIBA-3, our method of
pooling therefore had a sensitivity of 100% (5 / 5) and a specificity of 100% (433 /
433) for samples that were confirmed positive for antibodies to Hev.
3.5.2 HCV Prevalence
Thirty-eight (1.8%) of the 2131 pools tested were reactive by ELISA-3 and the
individual sera were analysed further (Figure 3.1). The overall prevalence of HCV
antibodies was 0.28% (30 / 10,654, 95% C.I. 0.19 - 0.41%). The occupational
category and age band of the employees tested are summarised in Table 3.1. There
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was no statistically significant difference in the prevalence of Hev antibodies
between the five occupational categories (p = 0.34) nor between exposure-prone staff
and all non-exposure-prone staff (0.23% v 0.30%, p = 0.59). The prevalence of
antibodies to HeV was significantly higher in the 30 to 39 years age band (p = 0.012).
Twelve (40%) of the thirty sera confirmed to contain antibodies to HeV had viral
RNA detectable in serum by RT peR These were typed as follows: 6 type 1, 4 type 3,
1 type 5 and 1 could not be typed.
3.5.3 Probability ofHCV infection
Within the exposure-prone category the median age and age ranges for each
occupational group were: surgeons 30 years (22 - 62 years), physicians 34 years (20-
63 years), dental staff 29 years (16 - 72 years) and nurses 34 years (17 - 64 years).
The maximum estimated probability of occupationally acquired Hev infection per
100 person years in the exposure-prone group was 0.04 for surgeons and 0.03 for
physicians, which would equate to a 1.4% and 1% risk respectively over a professional
career of thirty-five years.
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3.6 DISCUSSION
Hepatitis C is a blood borne virus transmitted by the parenteral route. Infection
frequently results in a chronic asymptomatic carrier state for many years before the
development of symptomatic liver disease. HCY infected healthcare workers may
therefore be unaware of their condition and their potential to infect patients.
Healthcare workers, who perform exposure-prone procedures, where injury to the
worker may result in the exposure of the patient's open tissues to the blood of the
worker, are theoretically at increased risk of infection with blood borne viruses.
According to UK health departments' guidelines, these occupations include surgeons,
interventional physicians, intensive care unit and accident and emergency staff If
occupational transmission of HCY was common, staff performing exposure-prone
procedures might be expected to have a higher prevalence of hepatitis C antibodies
compared with staff in less exposed occupations. Our results reveal the overall
prevalence of hepatitis C antibodies in healthcare workers in Glasgow to be low
(0.28%) and comparable to those reported in two smaller studies from England
(Zuckerman, J., et al. 1994, Neal, K.R, et al. 1997). The data indicate that the
performance of exposure-prone procedures does not frequently result in the
acquisition of HCY by healthcare workers (exposure-prone 0.23% v non-exposure-
prone 0.30%, p = 0.59). The prevalence of HCY antibodies among surgeons [only 1
(0.23%) of 438 tested], the group perceived to be at greatest risk of occupational
exposure, was comparable with that observed among healthcare workers who have
little or no patient contact, including student nurses. However the similar prevalence
may not reflect similar routes of infection and we were unable to explore the presence
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of other risk factors for HCY transmission with this study design. Needlestick injuries
to surgeons in operating theatres are common. In a study from one of the hospitals
included in this study Glasgow the incidence of percutaneous exposure was 15.5 per
operator per 1000 operations (Camilleri, AE., et al. 1991). Even this is likely to
underrepresent the rate of needlestick injury as it is recognised that surgeons report
only one in 20 of the needlestick injuries that they receive (Nash, GF. & Goon, P.
2000). Even if we assume that all the infections occurring in exposure-prone staff
were occupationally acquired, the estimated maximum probability of occupationally
acquired HCY infection in surgeons is 1.4% (1 in 70) over a surgical career of thirty-
five years (0.04 per 100 person years). This figure agrees with a model-based estimate
of professional lifetime risk of HCY infection for a French surgeon of between 0.3%
and 3.1% (Yazdanpanah, Y, etal. 1999).
Studies have reported a higher prevalence of antibodies to HCY in healthcare workers
compared with blood donors, however they are a non-representative self-selected
group and exclude persons with high risk behaviour (Zuckerman, J., et al. 1994, Neal,
KR, et al. 1997). The population prevalence of antibodies to HCY in Glasgow is
unknown. From 1991 to 1997 there were 2161 individuals testing positive for Hey in
the Greater Glasgow Health Board catchment area (prevalence 0.24% [2161 /
905,100]) (SCIEH Weekly Report. 1999). This is likely to be an underestimate of the
true population prevalence, yet is comparable with the prevalence recorded in
healthcare workers in this study (0.28% v 0.24%). A mixed population of hospital
attenders (male outpatients or in-patients, aged 16 to 49 years) at two of the general
hospitals in our study were screened for Hev antibodies from July to December 1997
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using the same pooling protocol (manuscript in preparation). The prevalence of
antibodies to Hev in this population was 4.0% (107 / 2702 individuals tested)
significantly higher than the healthcare worker population prevalence (0.28% v 4.0%,
p < 0.0001). Thus healthcare workers, including those performing exposure-prone
procedures, have an estimated prevalence of antibodies to HeV which does not exceed
that already known in the local population and is less than that in a cohort of their
male hospital patients.
Pooling of sera allowed us to increase the number of third generation ELISA tests
performed without loosing sensitivity or generating an unacceptable number of false
positives requiring further testing. This is in keeping with earlier reports employing
similar pooling methods with second generation ELISA kits for epidemiological
studies in low prevalence populations (Garcia, Z., et al. 1996, Liu, P., et al. 1997). Of
the 30 healthcare workers with antibodies to HeV, only 12 were found to be viraemic.
This may reflect the sub-optimal storage condition of the sera for RNA analysis.
Alternatively it may reflect the high rate of clearance of HeV RNA from the serum of
healthy individuals exposed to HeV many years previously (Grellier, L., et al. I 997).
Most viraemic patients were infected with genotype I (6, 50%) or genotype 3 (4,
33%), similar to our local clinic population where genotypes I and 3 occur with equal
frequency. One individual was infected with genotype 5 suggesting acquisition of
infection abroad.
The risk posed to patients by an HeV infected healthcare worker is not known and
there are no guidelines to assist in their management. There have been two published
95
reports of Hey transmission to patients from infected anaesthetists as a result of
failure to observe infection control policies (Ross, R.S., et al. 2000) and negligent
medical practices (Bosch, X. 1998). Whether Hey infected healthcare workers
performing exposure-prone procedures should have their practice restricted is
controversial. There have been two published reports of Hey transmission from
surgeons to patients on whom they operated, despite universal precautions having
been observed. Esteban et al. from Spain first reported a transmission rate of 2.2% (5
of 222 operations) from an HeY-infected cardiac surgeon (Esteban, 1.I., et al. 1996).
In a report from the UK, the reported Hey transmission rate was 0.36% (1 of 278
operations) from an Hey infected cardiac surgeon (Duckworth, GJ., et al. 1999). In
the absence of guidelines regarding Hey infected healthcare workers, patients and
healthcare managers should be reassured by the low reported prevalence of Hey
infected healthcare workers in the health service, provided that appropriate infection
control policies are followed.
Healthcare personnel and patients can both be reassured that the reservoir of
healthcare personnel in the West of Scotland who are infected with Hey is extremely
small (2.8 per 1000). It appears that working in the healthcare environment and
performing exposure-prone procedures, in an area with a large Hey infected injecting
drug using population, only rarely leads to the acquisition of Hey by healthcare
workers. The risk that a patient may become infected by contact with the health
service is probably low. However these findings should not lead to any complacency
in the implementation of universal precautions and the reporting and follow-up of
needlestick injuries.
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Table 3.2 Comparison of ELISA-3 HCV antibody test on individual and
pooled sera from 2,190 health care workers who conduct exposure-prone
procedures.
Pooled sera*
ELISA positive ELISA negative Total
ELISA positive 5 0 5
RIBA positive
ELISA positive 1 1 2
~ RIBA indeterminateQ)
rJ)
~ ELISA positive 0 2 2"'0.....
:>.....
"'0..s RIBA negative
ELISA negative 2** 427 429
Total 8 430 438
* 438 pools containing 5 sera each.
**i.e. 10 sera tested in which no individual serum was ELISA or RIBA positive
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Figure 3.1 Results of testing 10,654 health care worker sera for antibodies to
Hev by ELISA-3 in pools of 5.
Pools tested
2131
1
Reactive Pools
38
Non-reactive Pools
2093
Further testing of individual sera in pools
/
Pools with> 1
sera ELISA-3
Positive
o
/
ELISA-3
positive
RIBA Dositive
Pool with 1 serum
ELISA-3
Positive
33
Further testing
1
ELISA-3 positive
RIBA indeterminate
3(0)*
Pool with all sera
ELISA-3
Negative
5
ELISA-3 positive
RIBA negative
o
* indicates numbers of sera positive by RT-PCR for HCV RNA
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4.2 SUMMARY
Serum a-glutathione s-transferase (a - GST) has been shown to be a sensitive
marker of liver injury. We compared the relationship of both serum a-GST and
alanine transaminase (ALT) with liver biopsy inflammatory activity in patients
who had chronic hepatitis C infection (HCV) and examined the effects of
a - interferon therapy on serum a-GST and ALT concentrations. Of thirty-two
patients with chronic HCV infection studied, seventeen patients received
a - interferon 4.5MU thrice weekly for three months and 15 patients acted as
controls. Liver biopsy just prior to treatment was scored for the grade of
inflammation (Scheuer histological activity index). Serum a-GST and ALT were
assayed just prior to biopsy and three months later.
Neither serum a-GST nor ALT levels showed any correlation with baseline
inflammation on liver biopsy. a - Interferon significantly reduced serum a-GST
concentration at three months (p = 0.01). ALT fell with treatment but not
significantly (p = 0.05). Small falls in a-GST and ALT were noted in the control
group and when these were considered the significance of the changes in a-GST
and ALT with treatment were lost (p = 0.35 and p = 0.09 respectively).
This study shows that serum a-GST is not a useful marker of the degree of liver
inflammation in chronic HCV infection, though it may be of more value than ALT
in monitoring response to treatment with a - interferon.
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4.3 INTRODUCTION
The hepatitis C virus (HCV) is the most common cause of parenterally-acquired
hepatitis in the western world. Following infection up to 80% of patients go on to
develop a chronic carrier state with mild chronic hepatitis and between 10 to 20%
of this group will develop cirrhosis, usually within 30 years (Seeff, L.B., et al.
1992, Alter, MJ., et al. 1992). This has significant health and economic
implications as an estimated 0.5% of the British population are chronic carriers.
It is known that standard liver function tests (serum aspartate and alanine
aminotransferase activity) do not accurately reflect the degree of inflammation
seen on liver biopsy in chronic HCV infection (Alberti, A., et al. 1992, Persico, M.
& Romano, M., et al. 1993). At best the correlation between the ALT and liver
grade and stage of chronic hepatitis is poor (Haber, M.M., et at. 1995). Serum
concentrations of the hepatocyte-derived enzyme a.-glutathione s-transferase (a. -
GST) have been shown as a more sensitive and specific marker of hepatocellular
damage, when compared to serum aminotransferases in a number of liver disorders
(Beckett, GJ., et al. 1989, Hayes, P.C., et al. 1988, Trull, A.K., et at. 1994). The
first aim of this study was to compare serum a. - GST levels with alanine
aminotransferase (ALT) as a means of grading the severity of inflammation in
chronic hepatitis C infection as assessed by liver histology.
a.-Interferon remains the mainstay of antiviral therapy against HCV whether used
alone or in combination with ribavirin. Large controlled studies of interferon
monotherapy have shown that although 50% of patients show an complete initial
biochemical response, in only 25% of cases is this response sustained, as defined
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by a persistently normal serum ALT six months after completing ex- interferon
therapy (Tine, F., et al. 1991). ALT remains the generally accepted method of
monitoring response to ex- interferon therapy, although normal serum
transaminases do not exclude continuing hepatic inflammation (Alberti, A., et al.
1992, Persico, M. & Romano, M. 1993). The second aim of this study was to
compare serum ex - GST with ALT as a means of monitoring response to
ex- interferon therapy in chronic hepatitis C infection.
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4.4 PATIENTS. MATERIALS AND METHODS
The study was approved by the West Glasgow Hospitals University NHS Trust
ethics committee and consent was obtained from each patient prior to recruitment.
4.4.1 Patients
Thirty-two consecutive asymptomatic blood donors were studied. Each had
serological evidence of HCV infection and had been referred to the regional
specialist Gastroenterology clinic by the blood transfusion service. Other causes of
chronic liver disease were sought and excluded. Each patient underwent
percutaneous needle liver biopsy at entry to the study and all showed evidence of
chronic hepatitis. A single pathologist (RN.M MacSween) reviewed liver
histology and graded the degree of necroinflammatory activity on a scale of 0 to 4
(Scheuer, PJ. 1991).
Thereafter the patients were randornised to receive either a. - interferon (Roferon,
Roche) at a dose of 4.5 MU three times a week subcutaneously or no treatment
(observation) for 3 months. There were 17 and 15 patients in each group
respectively.
4.4.2 HeV determination
Hepatitis C infection was confirmed by positive anti-HCV serology, using both
ELISA-3 (Ortho Diagnostic Systems, Raritan, NJ, USA) and RIBA-3 (Chiron
Corp., Emeryville, CA, USA) followed by detection of HCV-RNA using a reverse
transcription polymerase chain reaction (RT-Pf'R). Prior to entry into the study
each patient was confirmed to have chronic HeV infection by testing positive for
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anti-HCY and HCY RNA in serum on two occasions six months apart. The
qualitative RT-PCR used in the study was an in-house technique (Dow, B.C., et al.
1993). This assay performed well in the second EUROHEP HCY-RNA reference
panel study and had a lower limit of detection of at most 2000 genomes / ml
(Damen, M., et al. 1996). Twenty-six patients had virus genotype assessed by
restriction fragment length polymorphism analysis of the 5' non-coding region RT-
PCR products using a well established method (Davidson, F., et al. 1995).
4.4.3 Assessment of ALT and a -GST levels
Both serum a - GST and ALT were assayed at entry into the study, just prior to
liver biopsy, and again three months later. The analysis of specimens for ALT
took place immediately on an Olympus AU 5200 analyser (Olympus Optical
Company Ltd., Eastliegh, UK) using the International Federation of Clinical
Chemistry coupled enzyme reference method with reagents produced by Bio-stat
Ltd. (Stockport, UK). The reference range for ALT is 10-50 units/I.
Samples for a - GST analysis were centrifuged immediately and serum stored at -
20°C until the study was completed when all the specimens were assayed as a
batch. Although the effects of retrospective testing were not assessed in this study,
sample storage has already been shown not to influence testing (Nelson, D.R., et
al. 1996, Loguercio, C., et al. 1998b). a - GST was measured using an enzyme
immunometric assay (Hepkit, Biotrin, Dublin, Ireland). Serum samples and
calibrators were appropriately diluted (usually 1 in 5) in phosphate buffered saline
with 0.05%(v/v) Tween-20 (PBST). 100J,!1was added in duplicate to Nunc
Maxisorp microtiter plates previously coated with affinity-purified polyclonal anti-
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human a-GST IgG, shaken and incubated at 20-25°C for 1 hour. After extensive
washing with PBST, a conjugate IgG (anti a-GST-horseradish peroxidase) was
added to the microtiter plate (1OO~l/well) for 45 minutes and incubated as
described above. The assay plate was then washed with PBST and 100~1 of liquid
tetramethylbenzidine substrate (TMB) was added to each well and colour allowed
to develop for 15 minutes at 20-25°C. The reaction was terminated by addition of
IN H2S04 (100~l) and the absorbance measured at 450nm using a Dynatech
MR5000 plate reader (Dynatech, UK). Sample a-GST concentrations were
determined from a plot of absorbance versus concentration for assay calibrators.
The manufacturers reference range is 0-8 ng/ml in serum based on a population of
219 healthy blood donors.
4.4.4 Statistical Analysis
Analysis of the data produced was performed on Minitab for Windows 10 (Minitab
Inc., State College, PA, USA). The Kruskal-Wallis test was used to detect any
relation between levels of ALT and a - GST and liver inflammation on biopsy.
The correlation between ALT and a - GST was assessed using Pearson product-
moment correlation coefficient. The Wilcoxon signed rank paired test was
employed to look for changes over the treatment period in the ALT and a - GST
levels in both control and treatment groups. The comparison of these changes
between the treatment and control group was made using the Mann-Whitney test.
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4.5 RESULTS
4.5.1 Utility of ALT and a -GST in grading the necroinflammatory activity
In figures 4.1 and 4.2 the baseline serum ALT and ex. - GST levels are compared
with the severity of hepatic inflammation in the thirty-two patients. All of the
patients had evidence of chronic hepatitis on liver biopsy. Seven of the 32 patients
had serum ALT levels within the reference range whereas 6 had serum ex. - GST
levels within the reference range. There was no significant difference in ex. - GST
or ALT levels between the four liver inflammation groups (p = 0.19 and p = 0.31
respecti vely).
4.5.2 AL T response to a - interferon
In Figure 4.3 the changes in the serum ALT levels over the three month period are
demonstrated. In the treatment group thirteen of 17 patients had elevated ALT
levels at entry into the study and 7 (54%) of these had a complete initial response
to ex. - interferon with ALT levels within the reference range at three months.
Three patients (23%) had a partial response to ex. - interferon with ALT falling but
not to within the reference range. The three remaining patients (23%) who had
elevated ALT levels at entry had no response to ex. - interferon. Despite evidence
of inflammation on their liver biopsies, 4 patients had ALT' s within the reference
range throughout the 3 months of the study. There was a small but not statistically
significant fall in the ALT levels in the observation group over three months (p =
0.90).
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4.5.3 Utility of a. - GST in assessing the response to a. - interferon
In Figure 4.4 the changes in serum a. - GST levels over the three months are
demonstrated. a. - GST concentrations were raised in 12 of 17 patients in the
treatment group at the start of the study. After treatment only 4 (33%) subsequently
had a. - GST levels within the reference range, 6 (50%) had shown a fall but
outwith the reference range, and 2 (16%) had a rise in a. - GST. The 5 remaining
patients had serum a. - GST levels within the reference range throughout the study.
There was a fall in serum a. - GST levels in the control group over the three month
period of observation but this did not achieve statistical significance (p = 0.22). Of
the seven patients who had a complete response to a. - interferon as monitored by
ALT, five had a fall in their serum a. - GST levels, although in two patients the a. -
GST levels did not return to the reference range. The remaining two patients had a.
- GST levels within the reference range throughout.
The overall change in ALT levels in the treatment group over the three month
period of observation did not quite achieve statistical significance (p = 0.05) and
when this was considered in relation to the small change witnessed in the control
group (p = 0.90), there was less evidence of a significant change (p = 0.09). While
treatment lead to a fall in serum a. - GST which appeared significant (p = 0.01) this
was lost (p = 0.35) when the fall in a. - GST in the observation group (p = 0.22)
was taken into account.
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4.5.4 COI·relation between AL T and a - GST
Figure 4.5 is a plot of ALT levels against concentrations in the study patients.
There was a significant correlation between serum a - GST concentrations and
ALT levels (p < 0.01).
4.5.5 Relation between HCV genotype and necroinflammatory activity
Of the 32 patients studied we were able to determine the HCV on 26 patients.
Table 4.1 compares genotype with the necroinflammatory activity in the liver
biopsy. The majority of patients were either genotype 1 or 3 (10 and 13 patients
respectively). There did not appear to be any relation between the histological
activity index on liver biopsy and the HCV genotype, but the numbers are small
and difficult to assess formally.
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4.6 DISCUSSION
a - GST is known to be a useful serum marker of acute hepatocellular damage in
autoimmune hepatitis, following paracetamol overdose, in identifying acute liver
transplant rejection and more recently in hypertensive disorders of pregnancy
(Beckett, G.J. & Hayes, lD. 1989, Hayes, P.C., et al. 1988, Trull, A.K., et al.
1994, Knapen, M.F.C.M., et al. 1998). a - GST is uniformly distributed throughout
the hepatic acinus, is found in high concentrations within the cytosol of
hepatocytes, and is of low molecular weight, all of which favour its release
following any hepatic insult (Beckett, GJ., et al. 1989). The half-life of a - GST is
less than 1 hour so plasma levels rapidly fall back to normal when hepatic injury
ceases. This contrasts with ALT which has a long half-life (47 hours) and is
predominantly distributed within the periportal area (zone 1) of the hepatic acinus.
ALT levels are known to fluctuate over time in chronic HCV infection and patients
may have long periods (> 12 months) when ALT levels are normal despite
histological evidence of chronic hepatitis (Alter, M.l, et al. 1992, Alberti, A., et al.
1992, Persico, M. et al. 1993, Healey, CJ., et al. 1995). In our study there was no
relationship between serum ALT levels and the severity of inflammation on liver
biopsy, indeed six patients had normal serum ALT levels despite active hepatitis
on liver biopsy. The reason why liver function tests do not correlate with
histological features in chronic hepatitis C is not clearly understood. It is possible
that confounding variables not considered here could influence serum
transaminases without altering the necroinflammatory activity seen on biopsy. Two
studies of patients with chronic HCV infection have shown concomitant excess
alcohol ingestion may be associated with elevation of serum transarninases without
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evidence of alcohol related liver damage on liver biopsy (Zignego, A.L. et al.
1994, Fog, T., et al 1994). In this series of patients none were drinking at the time
of biopsy and there was no histological evidence of alcohol-induced liver disease
in any of the liver biopsies.
This study demonstrated no evidence of a relationship between serum a-GST
levels and severity of inflammation on liver biopsy in chronic hepatitis C. This is
in agreement with the only previously published data on this subject (Nelson, D.R.,
et aI. 1995). In our study, 6 patients had normal a - GST levels in the presence of
chronic hepatitis on liver biopsy indicating that serum a - GST is not a sensitive
marker of hepatic inflammation in chronic hepatitis C. Nothing is known about the
fluctuations in a-GST with time in chronic HCV infection. It is possible that the
short half-life of a-GST (approximately 1 hour) results in significant changes in
serum level over short periods of time and unless liver histology and serum
a-GST are checked simultaneously, true comparison cannot be made between
them. Nelson and colleagues assessed liver histology and serum a-GST levels in
89 patients with hepatitis C and found no correlation between them (Nelson, D.R.,
et al. 1995). Unfortunately only 67 patients had histological assessment of their
liver using the Knodell activity index and the time relationship of the serum
collection and biopsy were within three months (Knodell, R.G., et al. 1981). The
Knodell score is known to be of limited value in assessing the severity hepatic
inflammation because it includes a numerical score of the degree of fibrosis as well
as necroinflammatory activity on liver biopsy (Desmet, V.J., et al. 1994).
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Several similar studies assessing a-GST as a non-invasive marker of liver injury
in HCV have now been reported. Again the Knodell score was used for grading the
severity of chronic hepatitis in these studies (Namour, F., et al. 1999, Loguercio,
C., et al. 1998b, Vabourdelle, M., et al. 1995). Although there was a significant
correlation between ALT and a-GST reported in each, only one study reported a
significant association between a-GST and liver histology (Vabourdelle, M., et al.
1995). In all of these studies the interval between blood sampling and liver biopsy
was not reported. In conclusion therefore serum a-GST does not appear to be
useful in grading the severity of hepatitis caused by HCV. This is in keeping with
the evidence that a-GST is not a useful marker of hepatocellular damage in a
number of chronic liver disorders including primary biliary cirrhosis, chronic
hepatitis B and alcoholic liver cirrhosis (Mulder, T.PJ., et al. 1997). This is likely
to reflect the rapid clearance of a-GST from plasma after hepatocellular damage.
When this study was designed, serum transaminases were widely used to assess
response to a - interferon therapy in chronic HCV infection. Detection of HCV-
RNA in serum is now the gold standard for monitoring treatment and the
discrepancy between transaminases and virological response to interferon therapy
is well documented (Lau, 1.Y.N., et al. 1993). This study showed a promising
response of a-GST to interferon but reductions in both enzymes during the
observation period were sufficient to diminish the statistical significance of these
changes. In their series Nelson et al. treated 16 patients with a - interferon and
considered that a-GST may have some use in monitoring the response to
treatment and our study supports this suggestion (Nelson, D.R., et al. 1995).
Subsequently Loguercio et al. performed a larger study with longer follow-up and
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reported both biochemical and virological responses to interferon (Loguercio, C. et
at. 1998a). They found pre-treatment a-GST levels to be higher in patients that did
not have a sustained virological response to interferon. In addition they noted that
a-GST remained elevated during treatment in patients who experienced an end of
treatment biochemical response but subsequently relapsed after completing
therapy. This suggests that measurement of a-GST prior to and during treatment
can help predict those patients who will experience a sustained virological
response to interferon.
This study fails to show an advantage for a-GST in grading severity of liver
inflammation in chronic HCV infection but a - GST may have a role in monitoring
response to a - interferon therapy. Liver biopsy remains the only good marker for
the degree of hepatic inflammation in chronic hepatitis C.
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Table 4.1 HeV genotype and Scheuer histological activity index on liver
biopsy.
ncv genotype Histological activity index
1
2
3
1
2
1
2
2
4
o
3
3
2
4
2
3 5
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5.2 SUMMARY
Chronic hepatitis C virus (HCV) infection is frequently associated with elevated
markers of iron stores. Recessively inherited mutations in the HFE gene are
responsible for iron accumulation in most cases of hereditary haemochromatosis
and may have a role in HCV infection. They may also be associated with
progressive liver fibrosis although this remains controversial. The aim of this study
was to assess the prevalence of HFE mutations in HCV infected patients in the
West of Scotland and to explore the effect of the carrier state on serum and liver
iron stores and the severity of liver disease. One hundred and sixty-four patients
with antibodies to HCV who underwent liver biopsy were assessed prospectively.
Each patient was screened for HFE mutations (Cys282Tyr and His63Asp). Iron
markers were assessed in serum (ferritin, transferrin saturation) and on liver biopsy
(stainable iron, liver iron concentration (LIC) and Hepatic Iron index). There were
67 (41%, 26 Cys282Tyr, 33 His63 Asp, 8 compound) heterozygotes. Forty-four
(28%) patients had elevated serum iron markers, 24 (15%) had stainable liver iron
and 5 (3%) had elevated LICs. Carriage ofHFE mutations was not associated with
any clinical, biochemical, virological or pathological feature, including
accumulation of liver iron. Elevated serum iron markers were associated with male
gender, increased alcohol consumption and increased liver inflammation and
fibrosis. Patients with elevated LICs were older, acquired HCV infection earlier
and had more liver inflammation. Patients with chronic HCV infection frequently
have elevated serum iron markers although elevated LICs are uncommon. Elevated
serum iron studies and LICs occur in patients with more severe liver disease.
Carriage of HFE mutations, although frequently observed in these HCV infected
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patients, does not have a role in the accumulation of iron or the progression of liver
disease inHev infection.
124
5.3 INTRODUCTION
Approximately eighty percent of those who acquire acute hepatitis C virus (HCV)
infection develop a chronic low-grade, slowly progressive hepatitis which may
result in cirrhosis and hepatocellular carcinoma. The natural history of the chronic
liver disease caused by HCV remains controversial with varying rates of
progression to cirrhosis reported (Seeff, L.B. 1998a).
Several factors have been proposed to account for the variation observed, including
excess alcohol consumption, HCV genotype Ib, older age at acquisition of
infection and male gender (Seef, L.B. 1997). Of recent interest has been the role of
iron in chronic HCV infection. It has been long recognized that hepatic iron
overload promotes hepatic fibrosis in hereditary haemochromatosis (Bacon, B.R.
& Tavill, A. S. 1996). Serum iron stores are frequently increased in patients with
chronic hepatitis C (Riggio, 0., et al. 1997). Enhanced liver fibrosis has been
reported in HCV infected patients with stainable iron on liver biopsy compared to
controls with no detectable liver iron (Beinker, N.K., et at. 1996). The mechanism
by which iron accumulates in chronic HCV is not established but may in part be
the result of iron release from damaged hepatocytes (Bonkovsky, H.L., et al.
1997).
With the discovery that mutations in the HFE gene account for most cases of
hereditary haemochromatosis, there has much interest in their role in the
development and progression of other liver diseases. The two recognized
recessively inherited mis-sense mutations of the HFE gene result in amino acid
substitutions at position 282 (cysteine to tyrosine, Cys282Tyr) and at position 63
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(histidine to aspartic acid, His63Asp) (Feder, IN., et al. 1996, Feder, IN., et al.
1998). Over 90% of British patients with hereditary haemochromatosis are
homozygous for at least one of these mutations (The UK haemochromatosis
consortium. 1997). The significance of heterozygosity for these recessively
inherited lIFE mutations is unclear, however there have been reports of an
association with liver iron accumulation (piperno, A., et al. 1998) and increased
liver fibrosis in HCV associated liver disease (Smith, B.C., et al. 1998, Pirisi, M.,
et al. 2000, Martinelli, AL.C., et al. 1999).
The aim of this study was to assess the prevalence of HFE mutations and increased
serum and liver iron markers in Scottish patients infected with HCV and to then
explore any association between heterozygosity for the HFE gene mutations, serum
and liver iron stores and the severity ofHCV related liver disease.
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5.4 PATIENTS, MATERIALS AND METHODS
5.4.1 Patients
One hundred and sixty four consecutive patients with evidence of hepatitis C virus
infection were prospectively studied. All were anti-HCY positive with abnormal
liver function tests and underwent needle biopsy of the liver. History of alcohol
abuse, alcohol consumption at the time of biopsy and risk factors for HCY
acquisition were established.
One hundred and three patients were male and fifty-three had a history of excess
alcohol consumption, defined as alcohol consumption of >24g / d (>3U / d) for
males and> 16g / d (>2 U / d) for females. Ten (6.3%) patients were non-
Caucasian. Risk factors for acquisition of HCY infection were intravenous drug
use (77 patients, 47%), blood products (39 patients, 24%), sexual transmission (8
patients), needlestick injury (4 patients), tattooing (3 patients), human bite (1
patient) and thirty-two (19.5%) patients had no identifiable risk factors for the
acquisition of HCY infection. Twenty five patients had received previous anti-viral
therapy with alpha-interferon. The proportion of interferon treated patients was not
significantly different among the four groups. Duration of infection at the time of
liver biopsy was recorded for those patients who had an identifiable year of
infection. For those patients who acquired HCV through intravenous drug use, the
year of infection was assumed to be the year that injecting commenced. Local data
indicates that approximately half of those intravenous drug users who acquire HCY
infection are infected within one year of commencing injecting and almost all are
infected within three to five years (personal communication Avril Taylor, Scottish
Centre for Infection and Environmental Health).
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5.4.2 HeV Determination
Anti-HCV was assayed by third generation enzyme linked immunoabsorbent assay
(Ortho Diagnostics, Raritan, NJ, USA). Supplemental testing was by RIBA-3
(Ortho Diagnostics, Raritan, NJ, USA). Reverse transcription PCR was performed
on patient sera using an in-house method (Dow, B.C., et al. 1993). Genotyping of
HCV was performed by restriction fragment length polymorphism on RT PCR
positive samples (McKechnie, V.M., et al. 2000).
5.4.3 Iron Parameters
Iron status was assessed for each patient using biochemical tests, histological
grading of liver iron content and by measurement of liver iron concentration.
Serum iron (normal: males 10 - 40 umol/l, females 8 - 40 umol/l) was measured
by the ferrozine method, ferritin (normal: 15 - 300 nglml) was measured by
turbidimetry using a Chiron ACS 180 automatic analyzer (Bayer, USA) and
transferrin (normal: 2 - 4 gil) was measured by nephelometry (Beckmann Array
Analyser, USA). Transferrin saturation was calculated as follows: Serum Iron x
70.9/ Serum Transferrin (normal: 16 - 45%).
5.4.4 Histological evaluation
All liver biopsies were performed under ultrasound guidance. As is our practice,
two cores of liver tissue were obtained from each patient: one formalin fixed for
histological analysis and one stored immediately at -20°C for liver iron
concentration estimation. Formalin fixed specimens were paraffin embedded and
sections stained with Haematoxylin and Eosin and Perl's Prussian blue stain.
Slides were then evaluated by two experienced pathologists (RN.M. MacSween
and K. Oien) blinded to the clinical and laboratory information. All biopsy
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specimens were graded for the degree of necroinflammatory activity and staged for
the extent of fibrosis using the criteria ofIshak et al (Ishak, K., et al. 1995).
5.4.5 Determination of Hepatic Iron
Histological assessment of hepatocyte and macrophage iron stores were graded on
a scale of 0 to 4 on Perl's Prussian blue stained liver sections as previously
described (Searle, J., et al. 1994). In addition one hundred and twenty patients had
liver iron concentrations (LICs) measured by atomic absorption spectrometry with
results expressed as micrograms per gram of dry weight of liver tissue (normal
range 170 - 1400 ~glg dry weight liver tissue). The hepatic iron index was
calculated by dividing the LIC (in umol I g dry wt) by the age of the patient (in
years) (Summers, et al. 1990). Forty four patients did not have a second liver
biopsy specimen for hepatic iron assay for the following reasons: lack of patient
consent or reluctance of the radiologist to take a second biopsy specimen for
clinical reasons, inadequacy of specimens obtained for LIC estimation and
occasional omissions at the time of biopsy.
5.4.6 HFE mutation analysis
The presence of HFE gene mutations was verified by means of restriction fragment
length polymorphism on the PCR products of genomic DNA extracted from
peripheral blood mononuclear cells (Jazwinska, E.C., et al. 1996, Feder, J.N., et al.
1996). Extracted DNA fragments were amplified using oligonucleotide primers for
the Cys282Tyr and His63Asp loci synthesized according to previously reported
sequences (Feder, J.N., et al. 1996). Amplification, digestion and visualization of
the PCR products were performed as previously reported (Jazwinska, E.C. et al.
1996).
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5.4.7 Statistical analysis
Statistical analysis of the data was performed using SigmaStat (SPSS Science
Software UK Ltd, Birmingham, UK). Differences between nominal variables were
analysed by Chi-square tests. Differences among continuous variables were
evaluated using the Kruskal - Wallis test. Logistic regression analysis with a
stepwise approach was applied to determine those variables independently
associated with the presence of liver iron and the grade and stage of liver disease.
Consent to carry out this study was provided by the West Glasgow Hospitals
University NHS Trust ethics committee.
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5.5 RESULTS
5.5.1 HFE gene data
Table 5.1 shows the results of analysis for the Cys282Tyr and His63Asp mutations
in 164 patients with chronic hepatitis C. Seventy-four patients (45%) carried at
least one of the mutations. The allele frequencies for the Cys282Tyr and His63Asp
mutations were 12.2% and 14.9%.
Seven (4.2%) patients were homozygous for one of the mutations (3 Cys282Tyr, 4
His63Asp) and were excluded from further analysis (Table 5.2). All three patients
homozygous for the Cys282Tyr mutation had stainable iron on liver biopsy. LICs
and transferrin saturations were elevated in two (66.7%) of these patients but there
was little evidence of associated hepatic inflammation or fibrosis on liver biopsy.
Three of the patients homozygous for the His63Asp mutation had elevated serum
iron studies (2 transferrin saturation, 1 ferritin) but none had stainable iron on liver
biopsy. LIC was not increased in either of the His63Asp homozygotes in whom it
was estimated. One (25%) patient homozygous for the His63Asp mutation was
cirrhotic.
5.5.2 Clinical data
To ensure that the role of gender and menstruation on iron metabolism did not bias
the study, data for male and female patients in each of the four groups were
assessed separately. The proportion and ages of male and female patients in each
of the four groups were comparable. Analysis excluding female patients, and hence
the effects of menstruation, did not affect the results for any clinical, serum or liver
biopsy parameter. Analysis excluding the ten non-Caucasian patients, two of
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whom were heterozygous for the His63 Asp mutation, did not influence the results
and all analysis discussed included these patients. In comparison with interferon
naive patients, those previously treated with interferon therapy had comparable
serum and liver iron studies and severity of HCY related liver injury and all
analysis included these patients.
In Table 5.3, the remaining 157 patients including 67 with heterozygous HFE
mutations and 90 without were compared with regard to demographic, clinical and
virological data. No differences with respect to any of these features were found.
One hundred and fifty four patients were RT PCR positive for HCY RNA of whom
64 were infected with genotype 1 and 72 with genotype 3.
5.5.3 Serum iron markers
The association between serum iron markers and HFE gene status indices is shown
in Table 5.4. No significant differences were observed. Sixteen (10%) patients had
elevated serum ferritin levels, six (9%) carrying an HFE mutation (1
His63 Asp/Cys282Tyr, 1 Cys282Tyr1WT, 4 His63Asp1WT) and ten (11%) without
(p = 0.84). Transferrin saturation was elevated in thirty-six (23%) patients,
eighteen (27%) with (3 Cys282TyrlHis63 Asp, 3 Cys282TyrlWT, 12
His63 AspIWT), and 18 (20%) without an HFE mutation (p = 0.67). Either serum
ferritin or transferrin saturation was elevated in forty-four (28%) patients, twenty-
one (31%) of the 67 patients with and twenty-three (26%) of the 90 patients
without HFE gene mutations (p = 0.54). Patients with elevated serum iron markers
were more commonly male (37 /44 (84%) v 62 I 113 (55%), p = 0.001), drank
significantly more alcohol (median 12.5 v 4 u/wk p < 0.001), more frequently had
stainable iron on liver biopsy (13 (29%) v 11 (10%), p = 0.004), had higher LICs
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(median 0.540 v 0.375, P = 0.009), and had more active chronic hepatitis (median
necroinflammatory scores 5 v 4, P = 0.017) with more fibrosis (median fibrosis
scores 2 v 1, P = 0.025) than patients with normal iron studies.
5.5.4 Liver biopsy indices
The association between necroinflammatory and fibrosis scores, stainable iron,
liver iron concentrations and HFE gene status is also shown in Table 5.4. No
significant differences were observed.
Eleven (7%) patients had scores of four or more for stage of fibrosis, two (3%) of
the sixty-seven patients carrying an HFE mutation compared with nine (10%) of
the ninety without an HFE mutation (p = 0.16). Six (4%) patients had cirrhosis, one
(1%) with and five (6%) without HFE mutations (p = 0.37). By stepwise regression
using a backwards approach, fibrosis scores could be predicted by a combination
of age, alcohol consumption and liver biopsy scores for interface hepatitis and
confluent necrosis (all p < 0.001).
Stainable iron was detected on 24 (15%) biopsies, with hepatocyte staining alone
in eleven, macrophage staining in five and staining of both in eight. No patient had
an iron staining grade of 3 or 4 for hepatocyte iron and one only one patient had
macrophage iron staining of grade three. Hepatocyte or macrophage iron staining
was present on the liver biopsy of 13 (19%) of the 67 patients with an HFE
mutation (3 Cys282TyrlHis63 Asp, 6 Cys282TyrlWT, 4 His63AspIWT) and 11
(12%) of the 90 patients without (p = 0.31). Patients with stainable iron on liver
biopsy were older (p = 0.007), with higher serum ferritins (p < 0.001) and had
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higher LIes (p < 0.001). There was no significant difference in the grade and stage
of liver disease between patients with and without iron staining on liver biopsy.
One hundred and fifteen out of the 157 non-homozygous patients had liver iron
concentrations measured, five (3%) had LICs >1400J.1g/g dry wt (median 1650;
range 1480 - 3400) and only one (His63Asp/WT) carried an HFE mutation. Three
(60%) patients with an elevated LIC had stainable iron on liver biopsy (1
hepatocyte staining alone, 2 with hepatocyte and macrophage staining) compared
with 21 (l4 %) of the one hundred and fifty two patients with a normal LIC (p =
0.03). Patients with elevated LICs were older (p = 0.05), acquired HCV infection
earlier (p = 0.02), had higher serum ferritins (p=0.003), and had more severe
necroinflarnmatory activity on liver biopsy (p = 0.02). There was a trend towards
higher fibrosis scores in those patients with elevated LICs although this did not
reach statistical significance (median 2 v 1, P = 0.06). By stepwise regression
analysis with a backward approach, LICs could be predicted by a combination of
serum ferritin, transferrin saturation and hepatocyte staining with iron on liver
biopsy (all p< 0.001). No patient had an elevated HII diagnostic of hereditary
haemochromatosis (HII > 1.9) and there was no significant difference in HII
between patients with and those without HFE mutations.
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5.6 DISCUSSION
The prevalence of both HFE gene mutations in this population is higher than that
reported in studies of HCY infected populations from Europe, England and Brazil
(Kazemi-Shirazi, L., et al. 1999). This may reflect the high prevalence of HFE
mutations in the local population, which is of largely Nordic and Celtic extraction,
rather than a susceptibility to HCY infection in carriers of HFE mutations (Bacon,
B.R., et al. 1999b).
There was no evidence in this study that heterozygosity for either HFE mutation
was associated with more severe grade or stage of HCY related liver disease. This
contrasts with the study by Smith et al. which first proposed an association
between the carriage of HFE mutations and increased hepatic fibrosis scores
(Smith, B.C., et al. 1998). In that study ten Cys282Tyr heterozygotes of whom 4
(40%) had cirrhosis were compared with 127 normal controls of whom 11 (8.7%)
were cirrhotic (p = 0.01). Heterozygotes had more advanced liver disease (p =
0.01) and more commonly had iron staining on Perl's stained liver sections (p =
0.02). Further studies by other groups have supported (Pirisi, M., et al. 2000,
Martinelli, AL.C., et al. 1999) and refuted (Kazemi-Shirazi, L., et al. 1999, Knoll,
A, et al. 1998, Hezode, C; et al. 1999) these findings. Some studies included small
numbers of homozygous patients (pirisi, M., et al. 2000, Martinelli, AL.C., et al.
1999, Kazemi-Shirazi, L., et al. 1999, Hezode, c., et al. 1999). Factors, which are
known to be associated with the progression of HCY related liver disease, were
controlled for inconsistently in these studies. The lack of association between
carriage of HFE mutations and the stage of fibrosis in this study may have resulted
from excluding all homozygous patients from the analysis and controlling for
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many possible confounding variables including gender, age at HCV acquisition,
duration of HCV infection, route of HCV infection, HCV genotype, current
alcohol consumption and past history of alcohol excess. In this study factors
associated with stage of fibrosis were patient age and alcohol consumption at time
of biopsy, which is compatible with current understanding (Poynard, T., et al.
1997, Wiley, T.E., et a1. 1998). In addition the grade of hepatitis, in particular
scores for interface hepatitis and the presence of confluent necrosis, were
predictors of fibrosis. This is in keeping with studies that have shown these
features on liver biopsy to be associated with progressive disease and a worse
prognosis in chronic hepatitis (MacSween, R.N.M. 1980, Cooksley, W.G.E. 1986).
Patients carrying an lIFE mutation had no evidence of increased serum iron studies
or intrahepatic iron deposition assessed both directly and indirectly. The
prevalence in this study of increased serum iron stores in patients with chronic
HCV infection is comparable to that reported elsewhere, with twenty-eight percent
of patients having an elevated ferritin or transferrin saturation (Bonkovsky, HL., et
al. 1997). Patients with elevated serum iron markers were more commonly male,
drank more alcohol and had more active chronic hepatitis with more liver fibrosis.
This suggests that elevated serum iron markers in patients with chronic HCV
infection are the result of active hepatitis, either through leakage from damaged
hepatocytes or as part of the systemic inflammatory response (Bonkovsky, H.L. et
al. 1997)
Despite frequently elevated serum iron studies few patients had direct or indirect
evidence of increased liver iron with only 3% of patients having an elevated LlC
and 15% of biopsies having stainable iron almost exclusively of grades 1 or 2. The
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prevalence of elevated LIC in this study is lower than that reported in earlier
studies of patients with chronic hepatitis C, where a prevalence of 10 - 36% has
been recorded (Piperno, A., et al. 1998, Tung, B.Y. & Kowdley, KV. 1999,
Kazemi-Shirazi, L., et al. 1999). There was no evidence that carriage of the HFE
mutations was associated with liver iron accumulation. This finding is consistent
with earlier studies exploring the role of HFE mutations in HCV that assessed liver
iron histologically (Smith, B.C., et al. 1998, Pirisi, M., et al. 2000, Knoll, A., et al.
1998, Hezode, C., et al. 1999) and the only other study to have assessed liver iron
concentration (Kazemi-Shirazi, L., et al. 1999).
Significant iron deposition in the liver was uncommon and overall the quantity of
iron that was detectable histologically and biochemically was unrelated to the
grade and stage of HCV related liver injury. The mechanism by which liver iron
accumulates in a small number of patients is unclear. These patients have
significantly more liver inflammation and a trend towards increased fibrosis
compared with those with normal liver iron concentrations, however there is
considerable overlap between the two groups. Whether this iron accumulation is
the cause or result of liver injury is unclear.
In summary we found that although many patients with chronic HCV infection
have elevated serum iron studies, few have significant iron deposition within the
liver. Carriage of the recognized mutations in the HFE gene, although frequently
observed, do not account for the elevated serum iron studies and liver iron
deposition that is present nor are they associated with any clinical, biochemical,
virological or pathological feature. The severity of HCV related liver injury could
be predicted by patient age, alcohol consumption, and histological grades of
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interface hepatitis and confluent necrosis as previously described and overall the
concentration of liver iron did not have a significant role in the progression of
Hev related liver injury. These findings do not support a role for iron depletion by
venesection in patients with chronic HeV infection, including those with elevated
serum iron studies.
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Table 5.1 Distribution of HFE gene mutations in patients with chronic
hepatitis C infection.
Mutation Status Number(%)
Cys282Tyr / Cys282Tyr 3 (1.8)
His63Asp / His63Asp 4 (2.4)
Cys282Tyr / His63Asp 8 (4.9)
Cys282Tyr / Wild type 26 (15.8)
His63Asp / Wild type 33(20.1)
Wild type / Wild type 90 (54.9)
Total 164 (100)
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CHAPTER 6
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6.2 SUMMARY
The natural history of chronic HCV remains uncertain with variable rates of
progression of hepatic fibrosis observed. The mechanisms that account for these
variations are poorly understood. Activated human hepatic stellate cells are the
main effector cells in the development of hepatic fibrosis and have recently been
demonstrated to possess angiotensin II receptors. Binding of angiotensin II to these
receptors has been shown to induce further stellate cell activation and may
contribute to the generation of hepatic fibrosis. A number of polymorphisms in the
genes of the renin-angiotensin system are described and are recognised to
contribute to the variable outcomes observed in a number of cardiac and renal
diseases. The aim of this study was to explore the role of three renin-angiotensin
system polymorphisms (M235T angiotensinogen, 011 angiotensin I converting
enzyme and Al166C ATI angiotensin II receptor polymorphisms), known to
influence renin-angiotensin phenotype, on the progression of hepatic fibrosis in
chronic HCV.
One hundred and ninety one patients with chronic HCV were grouped by liver
biopsy Ishak fibrosis stage [97 group 1 (stage 0 or 1), 70 group 2 (stage 2 or 3),24
group 3 (stage 4 to 6)]. Renin-angiotensin polymorphisms were assessed using
PCR based methods. The allele frequencies of the T235 variant of angiotensinogen
gene, the 0 variant of the angiotensin I converting enzyme gene and the C 1166
ATI angiotensin II receptor gene were 58.9%, 50.8% and 24.3%. The prevalence
of these gene polymorphisms associated with increased renin-angiotensin activity
were comparable in each of the fibrosis groups [T235 angiotensinogen (p = 0.68),
D angiotensin I converting enzyme (p = 0.08), C1l66 ATI angiotensin II receptor
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(p = 0.68)]. Patients homozygous for one or more of the renin-angiotensin system
polymorphisms associated with increased renin-angiotensin activity did not exhibit
more advanced liver fibrosis on liver biopsy (p= 0.89).
In summary, renin-angiotensin polymorphisms resulting in phenotypes with
functional increases in the activity of the systemic renin-angiotensin system, and
that are already recognised to influence the progression of cardiac and renal
diseases, are not associated with accelerated progression of hepatic fibrosis in
chronic Hev infection.
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6.3 INTRODUCTION
Approximately eighty percent of patients who acquire hepatitis C virus (HeV)
infection develop a chronic low-grade, slowly progressive hepatitis, which may
result in cirrhosis and hepatocellular carcinoma. The natural history of the chronic
liver disease caused by HCV remains controversial with varying rates of
progression to cirrhosis reported (Seeff, L.B. 1998a).
Several factors have been proposed to account for the variation observed, including
excess alcohol consumption, HeV genotype Ib, older age at acquisition of
infection and male gender (Seeff, L.B. 1997). Despite this the exact mechanisms
that predispose to a poor prognosis in chronic HeV infection remain elusive.
Activated hepatic stellate cells are the main effector cells in the development of
hepatic fibrosis by producing excess extracellular matrix (review: Friedman, S.L.
2000). Initiation of stellate cell activation results from the release of a number of
factors from injured hepatocytes and the neighbouring Kupffer and endothelial
cells. The response is enhanced by the recruitment of further stellate cells by
autocrine and paracrine expression of cytokines by activated stellate cells. The
most influential of these profibrotic cytokines is the autocrine expression of
transforming growth factor-B 1 (TGF-p I). Several polymorphisms in the
transforming growth factor-B 1 gene are recognised. Individuals homozygous for a
proline (Pro) to arginine (Arg) substitution at codon 25 of the TGF-p 1 gene have a
phenotype with increased TGF-p 1 activity. A recent study found an association
between inheritance of the Arg / Arg TGF-pI genotype (high TGF-pI activity
phenotype) and more severe liver fibrosis in chronic HeV infection (Powell, E.E.,
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et at. 2000). Thus the variable course observed in chronic Hev infection may be
accounted for by host genetic factors which promote hepatic fibrosis.
Angiotensin IT is the principal effector molecule of the renin-angiotensin system. It
exerts its effects by binding to two cognate receptors, known as AT 1 and AT2
receptors. The primary effect of its action is mediated via the AT 1 angiotensin II
receptor resulting in an increase in blood pressure by increasing vascular tone and
decreasing renal salt excretion. In addition activation of the renin-angiotensin
system and generation of angiotensin II has been implicated in the pathogenesis of
hypertension and cardiac and renal fibrosis and pharmacological angiotensin
blockade is recognised to abrogate these effects (review: Border, W.A. & Noble,
N.A. 1998). Studies reveal that angiotensin II strongly induces transforming
growth factor-Bl production by mesangial cells, the renal equivalent of hepatic
stellate cells in tissue culture and in-vivo (Kagami, S., et at. 1994). This has led
investigators to conclude that the fibrogenic effects in the kidney that have been
attributed to angiotensin II are actually mediated by TGF-J31 (review: Border,
W.A. & Noble, N.A. 1998). Whether this process is relevant in the progression of
hepatic fibrosis is unclear. A recent study by Bataller et at. demonstrated that
angiotensin II binds to AT 1 angiotensin II receptors on activated human hepatic
stellate cells and stimulates their proliferation and contraction (Bataller, R., et at.
2000). Angiotensin II may therefore stimulate fibrogenesis in the human liver by
perpetuating stellate cell activation directly or through the autocrine expression of
TGF-J31 by activated hepatic stellate cells.
Many functional polymorphisms in the genes of the renin-angiotensin system have
been described and these polymorphisms have been postulated to contribute to the
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interindividual variability in the outcome of several renal and cardiovascular
diseases including hypertension, coronary artery disease and diabetic nephropathy.
Nine polymorphisms in the gene for angiotensinogen, which is cleaved by renin to
produce angiotensin I, have been identified (Sato, N., et al. 2000). These include a
threonine (T) for methionine (M) amino acid substitution at position 235 of the
amino-acid sequence (M235T angiotensinogen polymorphism), which is
associated with an increase in plasma angiotensinogen levels (Bloem, L.J. et al.
1997, Sato, N., et al. 2000). A polymorphism in the angiotensin I converting
enzyme (ACE) gene, which converts angiotensin I to angiotensin II, is recognised.
The absence of an insertion (D) within intron 16 in this gene is associated with
increased ACE and angiotensin II levels (Rigat, B. et al. 1990). A polymorphism in
the ATI angiotensin II receptor (AT 1 R) gene is also recognised. A C to A
nucleotide substitution at position 1166 within the 3 prime untranslated region of
the AT 1 R (A1166C polymorphism) has been shown to be associated with
increased sensitivity to physiological levels of angiotensin II (Spiering, W., et al.
2000).
The aim of the current study was to assess the prevalence of these rerun-
angiotensin system variants in Scottish patients with chronic HCV infection and to
then explore whether those variants associated with increased renin-angiotensin
activity contributed to the development of hepatic fibrosis in chronic HCV.
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6.4 PATIENTS. MATERIALS AND METHODS
6.4.1 Patients
One-hundred and ninety-one patients with evidence of hepatitis C virus infection
were retrospectively studied. All were anti-HCV positive with abnormal liver
function tests and underwent needle biopsy of the liver. History of alcohol abuse,
alcohol consumption at the time of biopsy and risk factors for HCV acquisition
were established.
One hundred and nineteen (62%) were male and sixty (31%) had a history of
excess alcohol consumption, defined as alcohol consumption of>24g / d (>3U / d)
for males and >16g / d (>2 U / d) for females. Fifteen (8%) patients were non-
Caucasian. Risk factors for acquisition of HCV infection were intravenous drug
use (91 patients, 48%), blood products (47 patients, 25%), sexual transmission (8
patients), needlestick injury (5 patients), human bite (1 patient) and thirty-four
(18%) patients had no identifiable risk factors for the acquisition of HCV infection.
Thirty-one patients (16%) had received previous anti-viral therapy with alpha-
interferon. The analysis of the role of renin-angiotensin polymorphisms on hepatic
fibrosis was not influenced when patients who had previously received interferon
therapy were excluded and all analysis discussed included all 191 patients.
Duration of infection at the time of liver biopsy was recorded for those patients
who had an identifiable year of infection. For those patients who acquired Hev
through intravenous drug use, the year of infection was assumed to be the year that
injecting commenced. Local data indicates that approximately half of those
intravenous drug users who acquire HCV infection are infected within one year of
commencing injecting and almost all are infected within three to five years
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(personal communication Avril Taylor, Scottish Centre for Infection and
Environmental Health).
6.4.2 HCV Determination
Anti-HCV was tested for by third generation enzyme linked immunoabsorbent
assay (Ortho Diagnostics, Raritan, NJ, USA). Reactive samples were confirmed
positive for anti-HCV by RIBA-3 testing assay (Ortho Diagnostics, Raritan, NJ,
USA). Reverse transcription PCR was performed on patient sera using an in-house
method (Dow, B.C., et al. 1993). Genotyping ofHCV was performed by restriction
fragment length polymorphism on RT PCR positive samples (McOmish, F., et al.
1993).
6.4.3 Histological evaluation
All liver biopsies were performed under ultrasound guidance. Formalin fixed
specimens were paraffin embedded and sections stained with Haematoxylin and
Eosin. Slides were then evaluated by two experienced pathologists (R N. M.
MacSween. and K. Oien) blinded to the clinical and laboratory information. All
biopsy specimens were graded for the degree of necroinflammatory activity and
staged for the extent of fibrosis according to the criteria of Ishak and colleagues
(Ishak, K., et al. 1995). Patients were grouped according to the stage of liver
fibrosis on liver biopsy: group 1 (fibrosis score 0 or 1), group 2 (fibrosis score 2 or
3) and group 3 (fibrosis score 4 to 6).
6.4.4 Testing for renin-angiotensin system polymorph isms
Polymorphisms in the renin-angiotensin system were assessed by means of
polymerase chain reaction based methods. Initially genomic DNA was extracted
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from 10 millilitres of whole blood collected in tubes containing potassium EDT A
After cell and nuclear lysis DNA was extracted using a standard method for salting
out proteins (Miller, S.A, et al. 1988).
The mis-sense M235T amino acid substitution in the angiotensinogen gene was
screened for using standard methods (Russ AP., et al. 1993). This involves
restriction enzyme digestion of the product (165 base pair) of a single round of
PCR using angiotensinogen specific primers. The products of this digestion were
then visualised against 1 kilobase molecular markers (Gibco-BRL) run on a 3%
MetaPhor agarose gel.
The DII polymorphism in the angiotensin 1 converting enzyme gene was screened
for as previously described (Rigat, B., et al. 1992). Briefly the product of a single
round of PCR reaction utilising angiotensin 1 converting enzyme gene specific
primers was visualised on 1% agarose gel run against 1 kilobase molecular marker
(Gibco-BRL). The PCR product is a 190 base pair fragment in the absence of the
insertion (D) and a 490 base pair fragment in the presence of the 287 kilobase
insertion (I) within the angiotensin 1 converting enzyme gene.
The ATI angiotensin II receptor A1l66C polymorphism was assessed by Dde 1
restriction enzyme digestion of the product of a single round of Pf'R using
previously published primer sequences (Tiret, L., et al. 1994). The C 1166 allele is
detected if digestion of the PCR product is observed after visualisation against
kilobase molecular marker run on 3% MetaPhor agarose gel.
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6.4.5 Statistical analysis
Statistical analysis of the data was performed using SigmaStat (SPSS Science
Software UK Ltd, Birmingham, UK). Differences between nominal variables were
analysed by Chi-square tests. Differences among continuous variables were
evaluated using the Kruskal - Wallis test. Multiple linear regression analysis was
applied to determine those variables independently associated with the grade and
stage of liver disease. Consent to carry out this study was provided by the West
Glasgow Hospitals University NHS Trust ethics committee.
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6.5 RESULTS
5.5.1 Fib.rosis scores
Ninety-seven patients (51%) with chronic hepatitis C virus infection had liver
biopsy fibrosis scores of 0 or 1 (group 1), 70 patients (37%) had fibrosis scores of
2 or 3 (group 2) and 24 patients (13%) had fibrosis scores of 4, 5 or 6 (group 3).
6.5.2 Distribution of polymorphisms in the renin-angiotensin system
Table 6.1 summarises the distribution of the polymorphisms in the renin-
angiotensin system that were studied. One hundred and eighty-seven patients
(98%) carried at least one of the alleles associated with increased activity in the
renin-angiotensin system. Eighty-two patients (43%) were heterozygous for at least
one of these alleles, eighty-one (42%) were homozygous for one abnormal allele,
23 ( 12%) were homozygous for two abnormal alleles and one patient was
homozygous for the three abnormal alleles studied. The allele frequencies of the
T235 variant of angiotensinogen gene, the D variant of the angiotensin I converting
enzyme gene and the Cl166 ATI angiotensin II receptor gene were 58.9%, 50.8%
and 24.3%.
The distribution of renin-angiotensin polymorphisms in each of the fibrosis groups
is shown in Figures 6.1 (M235T angiotensinogen polymorphisms), Figure 6.2 (D/l
angiotensin I converting enzyme polymorphisms) and Figure 6.3 (AI 166C AT I
angiotensin II receptor polymorphisms). The distribution of the gene
polymorphisms associated with increased renin-angiotensin system activity (T235,
D, Cl166 alleles) were comparable in each of the fibrosis groups. We examined
the effect of being homozygotes for none, one or more than one of the
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polymorphisms associated with increased activity of the renin-angiotensin (see
Figure 6.4). There was no significant difference in the distribution of RAS
polymorphisms among the fibrosis groups (p = 0.89).
6.5.3 Univariate and multivariate analysis of factors associated with HCV-
related fibrosis
Table 6.2 summarises the demographic, clinical, virological and liver biopsy data
for the 191 patients with chronic HCV who were studied. On univariate analysis
the factors associated with liver fibrosis were the severity of necroinflammatory
activity on liver biopsy «0.001), older age at the time of acquisition of infection (p
= 0.04) and liver biopsy (p = 0.002), non-Caucasian ethnic origin (p = 0.002) and a
past history of excess alcohol consumption (p = 0.014).
Multivariate analysis was performed to identify factors predictive of the Ishak
fibrosis score on liver biopsy. Multiple linear regression analysis was performed
using a model that included the presence of the three gene polymorphisms
associated with increased renin-angiotensin activity, the patients ethnic origin,
gender, age at the time of liver biopsy, age and route of acquisition of HCV
infection, duration of HeV infection, alcohol consumption at the time of liver
biopsy, past history of excess alcohol consumption, HCV genotype and
necroinflammatory score on liver biopsy. The factors significantly associated with
fibrosis were the necroinflammatory activity on liver biopsy (p < 0.001) and a
history of excess alcohol consumption (p = 0.01).
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6.6 DISCUSSION
The natural history of chronic HCY-related liver injury remains uncertain and the
mechanisms accounting for the variable rate of fibrosis progression observed are
poorly understood. This study was designed specifically to explore the role of
functional polymorphisms in the renin-angiotensin system on the rate of hepatic
fibrogenesis in chronic HCY. It is well recognised that patients with chronic liver
disease, even in the absence of cirrhosis and ascites, have activation of the
systemic renin-angiotensin system (Schweisfurth, H. & Wernze, H. 1979, Wernze,
E., et at. 1978). This is widely accepted to represent a homeostatic response to
counterbalance the vasodilation, arterial hypotension, and renal hypoperfusion
observed in portal hypertension. More recently Bataller and colleagues
demonstrated that activated hepatic stellate cells possess AT1 angiotensin II
receptors and that the binding of angiotensin II to these receptors induces
contraction and proliferation of hepatic stellate cells (Bataller, R., et al. 2000). This
has led to speculation that the activated renin-angiotensin system in chronic liver
disease could play a role in the response to liver injury by amplifying stellate cell
proliferation and activation directly. This process has been observed in cardiac and
renal tissues where angiotensin II induced production of transforming growth
factor-B 1 has been shown to be associated with the progression of fibrotic disease
(Border, W.A. & Noble, N.A. 1998).
Currently there is no data from human studies to support a fibrogenic role for
angiotensin II in the liver, however there is increasing evidence for this role in
animal studies. Wei and colleagues have demonstrated that primary cultured rat
hepatic stellate cells possess AT1 angiotensin II receptors but only when they are
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activated (Wei, H.S., et al. 2000). In a model of hepatic fibrosis induced by carbon
tetrachloride, they proceeded to demonstrate that angiotensin II induced rat hepatic
stellate cell proliferation and collagen synthesis and that this effect was abrogated
by the angiotensin I converting enzyme inhibitor enalapril and the AT I angiotensin
II receptor antagonist losartan. In a similar study, Jonsson and colleagues
demonstrated that four weeks of treatment with the angiotensin I converting
enzyme inhibitor captopril significantly reduced the intrahepatic production of
transforming growth factor-Bl and liver fibrosis in a rat bile duct ligation model of
hepatic fibrosis (Jonsson, J.R., et al. 2001). These findings are similar to studies of
renal fibrosis, with angiotensin II binding to activated stellate cells stimulating the
production of extracellular matrix and that this effect can be abrogated by
pharmacological angiotensin blockade with reduced production of TGF-J31 and
collagen. This contrasts with an earlier study where no fibrogenic response was
observed in rat liver after a continuous systemic infusion of angiotensin II for one
week, while significant cardiac and renal fibrosis were detected (Yoo, K.H., et al.
1998). These conflicting results can be explained by the finding from both human
(Bataller, R., et al. 2000) and rat studies (Wei, H.S., et al. 2000) that ATI
angiotensin II receptors are only expressed on activated hepatic stellate cells. In the
absence of initial liver cell injury, hepatic stellate cell activation will not occur and
angiotensin II receptors will not be expressed.
If the evidence from these animal studies can be extrapolated to human disease, it
can be speculated that systemic activation of the renin-angiotensin system
influences the progression of liver fibrosis in chronic liver disease and
pharmacological inhibition of this system may prevent progression of fibrosis.
Studies of the effects of angiotensin I converting enzyme inhibitors and AT 1
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angiotensin II receptor antagonists on hepatic fibrogenesis in chronic liver disease
are required. However it will take a number of years before the results of
prospective studies with prolonged follow-up are available.
This study was designed to study the role of the renin-angiotensin system in the
progression of chronic liver disease using a different approach. Many genetic
polymorphisms in the renin-angiotensin system exist and several of these are
recognised to account for interindividual variation in renin-angiotensin system
activity (Bloem, L.J. et al. 1997, Sato, N., et al. 2000, Rigat, B., et al. 1990,
Spiering, W., et al. 2000) and, probably as a result, the development and outcomes
of hypertension (Winkelman,B.R., et at. 1999), coronary artery disease (Tiret, L.,
et al. 1994) and renal diseases (Kennon, B., et al. 1999). We hypothesised that if
the renin-angiotensin system played a significant role in the progression of hepatic
fibrosis in chronic liver disease, those patients possessing renin-angiotensin
genotypes associated with increased renin-angiotensin system activity would
develop more severe hepatic fibrosis and that this mechanism might account for
the variable rate of progression observed in chronic HCV infection. We studied
three alleles already recognised to be associated with an increased renin-
angiotensin activity phenotype (T235 angiotensinogen allele, D angiotensin I
converting enzyme allele, C1166 AT1 angiotensin II receptor allele) and found
they had no effect on hepatic fibrosis scores either alone or in combination. In the
only other similar study to be performed Powell et at. examined the role of the 0
angiotensin I converting enzyme allele and a nucleotide substitution (G to A) 6
base pairs from the transcription start site in the promoter of angiotensinogen (AT-
6) on the progression of chronic HCV (Powell, E.E., et al. 2000). They found
homozygosity for the A substitution at position 6 of the angiotensinogen gene to be
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significar.tly associated with progressive hepatic fibrosis while no association with
the D allele of the angiotensin I converting enzyme was detected.
The lack of association between renin-angiotensin genotypes and hepatic fibrosis
in our study does not rule out a role for the renin-angiotensin system in the
progression of hepatic fibrosis in humans. Prospective studies of angiotensin I
converting enzyme inhibitors and AT 1 angiotensin II receptor antagonists in
patients with chronic liver disease are required to establish whether the
mechanisms speculated on in this study are clinically relevant. Recent publications
have highlighted the hazards of these therapies in patients who have established
cirrhosis and portal hypertension, where pharmacological inhibition of the renin-
angiotensin system resulted in arterial hypotension and reduced glomerular
filtration rates (Gonzalez-Abraldes, 1., et al. 2001, Schepke, M., et al. 2001). As a
result these treatments should be studied in patients with mild chronic liver disease
without evidence of portal hypertension and long-term follow-up would be
required to establish an effect on fibrosis progression.
On multivariate analysis the only factors observed to be associated with fibrosis
progression in chronic HCV infection were a history of excess alcohol
consumption and the severity of necrointlarnmatory activity on liver biopsy. The
role of excess alcohol consumption on fibrogenesis in chronic HCV is already well
established (poynard, T., et al. 1997, Corrao, G. & Arico, S. 1998). The association
between necrointlarnmatory activity and fibrosis on liver biopsy has been observed
previously in chronic hepatitis (MacSween, R.N.M. 1980, Cooksley, W.G.E.
1986). However the severity of necrointlammatory activity on biopsy is not
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predictive of the subsequent development of cirrhosis in chronic HeV (Paradis, V.,
et at. 1996, Yano, M., et aI. 1996).
In summary genetic polymorphisms in the renin-angiotensin system do not account
for the variable rate of progression observed in chronic HeV infection and an
effect of the renin-angiotensin system on hepatic fibrogenesis is not established.
Further study is required to identify the mechanisms of hepatic fibrogenesis in
chronic HeV infection and to establish if host genetic variability contributes to the
variable rates of progression observed.
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7.2 SUMMARY
Following the discovery of the GB virus-C (GBV-C) or hepatitis G virus (HGV) in
1995 there has been much interest in whether it is the cause of significant liver
disease alone or in combination with other known hepatitis viruses. The aim of this
study was to assess the prevalence and risk factors for the acquisition of HGV in a
group of asymptomatic blood donors found to have hepatitis C virus (HCY)
infection at blood donation. Thereafter we compared the grade and stage of chronic
hepatitis on liver biopsy in patients with and without HGV to assess the effect of
HGV co-infection on the severity of liver disease in these HCV infected
individuals. We studied 40 asymptomatic blood donors with serological evidence
of HCV infection (ELISA-2 and RIBA-2 positive) and chronic hepatitis on liver
biopsy. Full biochemical and haematological assessment was performed on the day
of liver biopsy. Retrospective polymerase chain reaction testing of serum stored on
the day of liver biopsy was performed for HCV and HGV RNA. The severity of
chronic hepatitis on liver biopsy was graded and staged by a pathologist blinded to
the HGV status of the patient.
HCV and HGV RNA were detectable in the serum of 37 (92%) and 7 (17%)
respectively of the forty patients studied. Patients co-infected with HGY did not
differ from those with serological evidence of HCV infection alone with regard to
demographics and risk factors for acquisition of viral hepatitis. The severity of
liver disease in both groups was comparable when assessed by standard liver
function tests and by the frequency of abnormalities on standard liver function
testing. There was no significant difference in the grade or stage of liver disease on
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liver biopsy between patients with HeV infection alone and those with HGV co-
infection.
Although HGV co-infection was observed frequently in these asymptomatic blood
donors with HeV infection there was no histological or biochemical evidence that
it influenced to the severity of HeV related liver injury.
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7.3 INTRODUCTION
Since the discovery of the hepatitis C virus (HCV) there has been a continuing
search for causes of non-A, non-B, non-C viral hepatitis agents. Hepatitis C virus
infection accounts for up to one-third of community-acquired hepatitis and the
majority of the post-transfusion associated non-A, non-B hepatitis however there
remains a proportion of patients with these disease states who have negative serum
markers for the known hepatitis viruses (A to E) (Rall, C. & Deinstag, 1. 1995). In
the early nineties two groups working independently identified novel flavivirus-
like viral sequences from the serum of two patients with unexplained, putatively
viral hepatitis. Using representational differential analysis, the full sequence of
these viruses has been identified and named hepatitis G virus (HGV) and GB
virus-C (GBV-C) virus respectively (Simons, J.N., et at. 1995, Linnen, J., et at.
1996). Characterisation of the full-length cloned genomic sequence of both viruses
allowed them to be compared directly. Initial comparison of the NS3 helicase
region of HGV and GBV-C sequences indicated that they were closely related
(Linnen, 1., et aI. 1996). Direct comparison of the complete genomes revealed
homology of 86% at the nucleotide level and greater than 95% amino acid
sequence identity confirming them to be independent isolates of the same RNA
virus from the Flaviviridiae family (Zuckerman, A.J. 1996). For clarity GBV-C
and HGV are collectivelyreferred to as HGV in this thesis.
In the initial report by Linnen et at. there was clear evidence that HGV virus was
transmitted by transfusion to three patients who went on to develop post-
transfusion £hepatitis (Linnen, 1., et at. 1996). They proceeded to study patients
with chronic liver disease and found that 19% (18 of 96 patients) of patients with
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chronic HCV infection were co-infected with HGV. In that study they did not
report what effect co-infection with HCV and HGV had on the severity and
progression ofHCV related liver injury.
The aim of this study was to assess the prevalence of HGV infection in
asymptomatic blood donors already known to be infected with HCV. The role of
HGV infection on the natural history of chronic HCV infection could then be
explored to see whether co-infection with HGV could contribute to the variable
rate of progression observed in patients with chronic HCV infection (Seeff, L.B.
1998a).
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7.4 PATIENTS. MATERIALS AND METHODS
7.4.1 Patients
Between September 1991 and September 1993, 305,012 voluntary blood donations
were processed by the Glasgow and West of Scotland Blood Transfusion Service
and screened for anti-hepatitis C antibody. Seven hundred and twenty one units
were reactive by second generation ELISA (Ortho Diagnostics, High Wycombe,
UK). Two hundred and fifty one (35%) of these were also positive by
supplemental recombinant immunoblot assay (RIBA-2, Chiron Corporation,
Emeryvilie, Ca, USA) with two or more antigens positive. These patients were
counselled by the Blood Transfusion Service and referred for further investigation
at a specialist Gastroenterology clinic at Gartnavel General Hospital. A full
assessment of risk factors for acquiring hepatitis C infection was performed for
each patient. Other causes of chronic liver disease were sought and excluded in the
laboratory. All patients that attended the clinic were further investigated by liver
biopsy regardless of the presence of liver function abnormalities.
Forty of these asymptomatic blood donors with serological evidence of hepatitis C
virus infection and histological evidence of chronic hepatitis were screened
retrospectively for hepatitis G virus infection by reverse transcriptase polymerase
chain reaction.
7.4.2 Patient Assessment
Each patient underwent percutaneous liver biopsy. Formalin fixed, paraffin
embedded liver sections were assessed by a single pathologist (R.N.M.
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MacSween) using Ishak's modified histological activity index (Ishak, K., et at.
1995). The pathologist was blinded to the patient's HGV status.
Haematological and biochemical assessments were performed using routine
laboratory methods on the day of liver biopsy. Additional sera which had been
collected on the day of biopsy, was separated within four hours of collection and
stored at -20°C to allow retrospective detection ofHCV and HGV RNA by reverse
transcription polymerase chain reaction (RT -PCR), which was not available
locally at the start of this study.
7.4.3 HeV determination
All patients studied were reactive by second generation ELISA (Ortho
Diagnostics, High Wycombe, UK) on initial screening and positive on
supplemental testing by recombinant immunoblot assay (RIBA-2, Chiron
Corporation, Emeryville, Ca, USA) with two or more antigens positive. These tests
were repeated and confirmed to be positive prior to inclusion in this study.
HCV RNA was detected using an in-house RT PCR method with primers for the
5' non-coding region of the HCV genome. RT peR was performed as described
(Dow, B.C., et al. 1993). This technique performed well in the EUROHEP HCV-
RNA reference panel study (Damen, M., et al. 1996). HCV genotyping was
performed on sera stored prior to treatment by restriction fragment polymorphism
as previously described (McOmish, F., et al. 1993).
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7.4.4 HGV determination
Screening for HGV RNA in serum was performed retrospectively on stored serum
by RT-PCR with primers for the NS3 helicase region of the HGV genome
(Heringlake, S., et al. 1996) (Figure 7.1). This method was developed and
performed by me in the Institute of Virology at the University of Glasgow and is
summarised here. The reaction mix for the reverse transcription (RT) step and the
first and second round of polymerase chain reaction (PCR) are shown in Appendix
4.
RNA was extracted from 140 J.l1 serum using a commercial spin column system for
RNA isolation from liquid samples (QIAmp HCV-kit, Qiagen) according to the
manufacturers recommendations. In a final step isolated RNA was eluted in 50 J.lI
of diethylpyrocarbonate (DEPC) treated water (pre-heated to 80°C) from the spin
columns (also pre-heated for 5 min. to 80°C). For reverse transcription 10 J.lI RNA
and anti-sense primer HGV -G9 were heated at 70°C for 10 min, chilled quickly on
ice, and converted to complementary DNA (cDNA) with reverse transcriptase
(Superscript, GmCO BRL) in a total volume of 20 ul. After one hour at 37°C the
RT-reaction was stopped by heating to 95°C for 10 min. Five micro litres ofcDNA
was subjected to the first round of PCR using antisense primer HGV -G9, sense
primer HGV-G7, and TAQ-DNA polymerase (GillCO BRL) in a total volume of
25 ,.11. The final Mg-concentration for the reaction was 1mM. A touchdown PCR
protocol was performed in the first 17 cycles [94°C - 2 min. (94°C - 30 sec, 60°C
- 30 sec, 72°C - 45 sec)] reducing the annealing temperature O.4°C per cycle,
followed by 25 cycles with a constant annealing temperature of 53°C and a final
extension step of 72°C for 7 minutes. One tenth (2.5 ul) of the product of the first
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PCR reaction was subjected to a second semi-nested PCR with the same sense
primer and an inner antisense primer HGV -G 11 using a similar touchdown PCR
protocol for 15 cycles [94°C - 2 min. (94°C - 30 sec, 61°C - 30 sec, 72°C - 45
sec)] reducing the annealing temperature 0.4°C per cycle followed by 25 cycles
with a constant annealing temperature of 55°C and a final extension step at 72°C
for 10 minutes. All RT and PCR reactions were performed using a Biometra
Thermoblock.
A PCR product of 140 base pairs was detectable after electrophoresis on a 2%
agarose gel against a 1 in 100 dilution of known HGV positive control serum
(kindly provided by L. Jarvis and P. Simmonds, The Department of Medical
Microbiology, The University of Edinburgh, Teviot PI, Edinburgh) and molecular
marker V (Boehringer-Mannheim). A sample of DEPC-treated water instead of
RNA served as a negative control during sample preparation, cDNA synthesis and
PCR amplification. Serum samples for each patient were analysed in two
independent RT PCR runs. Primer sequences were derived from the published
sequences of the NS3 region of the GBV-C prototype and the published isolates
(GenBank accession numbers U23338 - U25545).
7.4.5 Statistical analysis and Ethics Approval
Statisitical analyis for the study was performed using SigmaStat (SPSS Science
Software UK Ltd, Birmingham, UK). Comparison of those patients with and
without HGV infection were made using Chi-square test or Fisher exact test when
variables were nominal and using the t-test or Kruskal - Wallis test when
continuous variables were evaluated. Consent to carry out this study was provided
by the West Glasgow Hospitals University NHS Trust ethics committee.
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7.5 RESULTS
7.5.1 Patient demographics
Thirty-seven (92%) of the forty patients studied had HCV RNA detectable on
retrospective testing of serum obtained on the day of liver biopsy. Seven (17%)
patients had HGV RNA detectable in serum. All three patients who had antibodies
to HCV, chronic hepatitis on liver biopsy and had no detectable HCV RNA in
serum were RT PCR negative for HGV RNA. Co-infected patients were
comparable to those patients infected with HCV alone with regard to
demographics, risk factors for parenteral transmission and prevalence of HCV
genotypes (Table 7.1). Co-infected patients had a history of jaundice more
frequently although this difference was not statistically significant (43% v 18%, p
= 0.36).
7.5.2 Laboratory assessment
The biochemical and haematological assessment of samples obtained on the day of
liver biopsy are summarised in Table 7.2. There was no significant difference in
any of these parameters between the two groups. When the three patients who did
not have HCV RNA detectable in serum (and had normal liver function tests) were
excluded from the analysis there remained no significant difference in liver
biochemistry and haematology between the two groups. The prevalence of
abnormal liver function tests was comparable in the two groups when all patients
and only those with detectable HCV RNA in serum were studied (Table 7.3).
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7.5.3 Liver histology
The grade and stage of liver disease in patients infected with HCV alone and
patients co-infected with HGV are shown in Figure 7.2. There was no significant
difference in the grade or stage of liver disease on liver biopsy between the two
groups. There remained no significant difference in necroinflammatory and
fibrosis scores between the groups if patients who had no HCV RNA detectable in
serum at the time of biopsy were excluded (p = 0.53 and p = 0.23 respectively).
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7.6 DISCUSSION
In this study, we demonstrated that seven (17%) of 40 asymptomatic blood donors
with serological evidence of HCV infection and chronic hepatitis on liver biopsy
had stored serum samples positive for HGV RNA by RT PCR. This rate is
comparable to the range of HGV RNA prevalence reported in HCV infected
populations in other countries, such as England (15%), France (19%), Spain
(28%), the United States of America (10% - 20%) and Australia (19%) (Petrik, J.,
et al. 1998, Bouchardeau, F., et al. 2000, Sauleda, S., et al. 1999, Slimane, S.B., et
al. 2000, Brandhagen, 0.1., et al. 1999, Lin, R., et aI. 1998). In contrast the
frequency of detectable HGV RNA in the plasma of healthy HCV negative non-
remunerated blood donors in the East Coast of Scotland was 2.25% (23 of 1020
tested) (Blair, C.S., et al. 1998). Parenteral routes are the most important mode of
HGV transmission (Nubling, C.M. & Lower, 1. 1996) and there is evidence that
intravenous drug users are at particular risk (Diamantis, 1., et al. 1997). The
increased prevalence of HGV observed in HCV infected individuals probably
reflects the presence of risk factors for parenteral transmission of viruses in these
individuals who would be excluded from blood donation. The identification of
HGV RNA by RT PCR has limitations as a method of diagnosing HGV infection
and only identifies patient who are viraemic at the time of testing. When
serological methods for the detection of antibodies to the envelope protein E2 of
HGV are employed to screen for past exposure to HGV in HCV infected patients
rates of 40 - 50% are reported (Bouchardeau, F., et al. 2000, Sauleda, S., et al.
1999, Enomoto, M., et al. 1998). The prevalence of serological evidence of HGV
infection in the Scottish blood donor population has not been established.
Nevertheiess the prevalence of HGV RNA in the blood donor population is
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significantly higher than the prevalence of antibodies to Hev observed in blood
donations in the West of Scotland (0.31% of donations) on the introduction of
blood donor screening (Dow, B.C., et aI. 1993). Given that HGV infection is
common in the asymptomatic blood donor population and in HCV infected
populations it is important to establish the clinical consequences ofHGV infection.
Linnen at al showed that HGV was transmissible by transfusion and was associated
with post-transfusion hepatitis in three patients. This does not establish HGV as the
cause of post transfusion hepatitis in these patients. They proceeded to screen
blood donors for HGV RNA and found comparable rates of detectable HGV RNA
in the serum of blood donors with normal and those with elevated alanine
aminotransferase levels (1.7% v 1.5%) (Linnen, 1., et al. 1996). Further studies
have failed to show an association between HGV infection alone and community
acquired acute and chronic non-A-E hepatitis (Alter, H.J., et al. 1997, Alter, MJ.,
et aI. 1997). In this study there was no evidence that HGV infection, assessed by
the detection of HGV RNA in serum, was associated with biochemical or
histological exacerbation of liver disease in asymptomatic blood donors with HCV
infection. This is consistent with other reports (Alter, H.1., et al. 1997, Alter, MJ.,
et aI. 1997, Slimane, S.B. et al. 2000, Lin, R. et al. 1998). There is therefore little
evidence that HGV infection causes acute or chronic liver disease alone or in
combination with other hepatitis viruses. Whether HGV is even a hepatotropic
virus is now controversial. To allow replication in vivo it is essential for the
positive stranded RNA of HGV to be converted to a negative stranded replicative
template. Several groups have attempted unsuccessfully to show the presence of
the negative strand ofHGV RNA in human hepatocytes (Handa, A. & Brown, K.E.
2000, Shindo, M., et al. 1999, Kobayashi, M., et al. 1999, Mellor, 1., et al. 1998,
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Laskus, T., et al. 1997a, Laskus, T., et al 1997b) despite evidence of the positive
strand ofHGV RNA at low titres (Laskus, T., et aI. 1997a, Shindo, M., et al. 1999,
Mellor, I., et aI. 1998). Seipp and colleagues first identified the replicative template
of HGV in human hepatocytes using PCR based methods and in-situ hybridisation
(Seipp, S., et aI. 1999). This work has subsequently been reproduced by Halasz et
al. using in-situ hybridisation in human hepatocytes from HGV infected patients
without histological evidence of liver disease (Halasz, R., et al 2000). This
suggests that even if HGV replication is occurring within hepatocytes it does not
result in significant hepatitis and further questions the role of HGV as a hepatitis
virus. It remains possible that HGV is more like cytomegalovirus, causing hepatitis
only occasionally.
In summary although HGV co-infection was common in these HCV infected
individuals due to shared risk factors, there was no evidence that HGV infection
influenced HCV related liver disease. This is consistent with the findings of other
investigators. In the absence of clinical and laboratory evidence that HGV is a
hepatotropic virus or the cause of hepatitis in humans the significance of infection
with HGV remains poorly understood. Certainly the variable rates of progression
observed in HCV related liver disease cannot be explained by HGV co-infection.
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Table 7.1 Demographics of patients infected with the hepatitis C virus (HCV)
alone compared with those co-infected with HeV and hepatitis G virus
(HGV). There was no significant difference between the patient groups
(p>O.05)
HCValone HGV and HCV co-
Clinical Features
(n = 33) infection (n = 7)
Age, median years (range) 39 (26 - 53) 35 (29 - 44)
Sex, N males (%) 20 (61) 4 (57)
History of excess alcohol consumption,
2 (6) 1 (14)
N(%)
Alcohol consumption at time of biopsy,
median U / wk (range) 10 (0-100) 4 (0 - 175)
History of jaundice, N (%) 6 (18) 3 (43)
Source of hepatitis, N (%)
Transfusion 13 (39) 2 (29)
Parenteral drug use 12 (36) 1 (14)
Occupational exposure (3) 0 (0)
Tattoo / Body piercing 19 (58) 5 (71)
Unknown 5 (15) 1 (14)
HCV RNA RT-PCR negative, N (%) 3 (9) 0 (0)
HCV Genotyping N 30 7
] N(%) 14 (47) 2 (29)
2N(%) 3 (10) 2 (29)
3N(%) 13 (43) 3 (43)
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Table 7.2 Laboratory assessment of disease severity in those patients infected
with the hepatitis C virus (HCV) alone compared with those co-infected with
HCV and hepatitis G virus (HGV). There was no significant difference for
any parameter between the patient groups (p>O.05)
HCValone HGV and HCV co-
Median (Range)
(n = 33) infection (n = 7)
ALT (UIL) 115 (13 - 470) 91 (11 - 175)
AST (UIL) 56 (18 - 141) 63 (22 - 127)
Total bilirubin (umol) 10 (1 - 27) 10 (3 - 17)
Albumin (gIL) 44 (40 - 51) 44 (40 - 51)
Gamma GT (UIL) 67 (7 - 378) 44 (7 - 378)
Prothrombin time (sec) 15 (12 - 18) 15 (14 - 18)
Leukocyte count (xl091L) 6.3 (3.5 - 9.7) 6 (3.5 - 11.1)
Haemoglobin (g/dL) 14.7 (12.2 - 17.4) 14.6 (11.8 - 16.2)
Platelet count (xl091L) 236 (125 - 424) 208 (142 - 297)
Normal ranges: Albumin 36-50 gIL, ALT 10-50 UIL, AST 10-35 UIL, Total
bilirubin 3-18 umol, Gamma GT 5-50 UIL, Haemoglobin 13-18 g/dl., Leukocyte
count 4.5-6.5 xl09/L, Platelet count 140-450 x109/L, Prothrombin time 15 sec.
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Table 7.3 Prevalence of abnormal liver function tests in patients with hepatitis
C virus (HCY) infection alone and with hepatitis G virus (HGY) co-infection.
There was no significant difference in the prevalence of abnormal liver
function tests between the two groups.
HCValone HGV and HCV co-
N(%)
(n = 33) infection (n = 7)
ALT >50 UIL 24 (73) 5 (71)
AST >35 UIL 25 (76) 5 (62)
Total bilirubin (> 18 umol) 3 (8) 0 (0)
Albumin <36 gIL 0 (0) 0 (0)
Gamma GT >50 U/L 17 (52) 2 (29)
Prothrombin time> 15 sec 6 (18) 1 (14)
184
Figure 7.1 Primers for semi-nested RT-PCR protocol for the NS3 helicase
region of the HGV genome utilised in this study.
Primer Sequence 5'~3'
Reverse transcription / TCYTTGATGATDGAACTGTC
Outer antisense
HGV-G7 Sense (Inner and Outer) GAGATYCCCTTYTATGGGC
HGV-G11 Inner antisense TCYTTACCCCTRTAATAGGC
HGV-G9
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Figure 7.2 Comparison of Ishak grade and stage of liver histology in patients
infected with hepatitis C virus (HCV) alone and those co-infected with the
hepatitis G virus (HGV).
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8.2 SUMMARY
The management of asymptomatic blood donors with chronic hepatitis C virus
(HeV) infection remains uncertain but the concern is that if left untreated they will
develop progressive liver disease with the development of cirrhosis. There is little
data on the efficacy and safety of treatment for these individuals. The aim of this
study was to evaluate a novel regime of ex- interferon in the management of these
patients particularly to see if they would benefit from and tolerate this treatment.
We studied 40 asymptomatic blood donors with serological evidence of HCV
infection (ELISA-2 and RIBA-2 positive) and chronic hepatitis on liver biopsy in a
prospective randomised crossover study. Each patient received a decreasing course
of ex - interferon (4.5MU-1.0MU) t.i.w. for 48 weeks preceded or followed by a
year of observation. Patients were observed for a full year post-treatment. Twelve
weekly serum ALT levels were monitored and serum was stored to allow
retrospective testing for HCV-RNA. Liver histology was graded and staged at
baseline, 48 and 96 weeks.
Six of the forty patients withdrew prior to starting treatment and a further four
withdrew within twelve weeks of starting treatment. Response rates are reported
for the thirty-four patients who commenced ex - interferon therapy. Eight patients
(24%) showed no ALI response to treatment and discontinued therapy at 12
weeks. Twenty-two (65%) patients had a normal ALT level at 12 weeks and went
on to receive 48 weeks of therapy: Five (15%) had a breakthrough in ALT by 48
weeks despite continued treatment and 17 (50%) had a complete ALT response at
48 weeks. Fourteen (41%) of the complete responders had a sustained ALT
response 1 year after completing treatment and 3 (9%) had a biochemical relapse
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by 96 weeks. Eight (24%) of the patients with a complete sustained biochemical
response to treatment cleared HCV RNA from serum and remained RT PCR
negative one year after completing treatment.
Asymptomatic blood donors with chronic hepatitis C tolerate IFN therapy and
have comparable response rates to other patient groups with chronic hepatitis C
infection.
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8.3 INTRODUCTION
Screening of blood donors for serological evidence of hepatitis C virus (HCV) was
introduced in September of 1991. During the first 3 months of screening 0.3 1% of
donations in the West of Scotland were reactive for anti-HCV antibody by second
generation ELISA (Abott GmbH, Delkenheim, Germany) (Dow, B.C., et al. 1993).
HCV carriers detected in this manner usually have mild symptoms and mild
fibrosis on liver biopsy and are presumably at an early stage in the natural history
of the infection (Bird, G.L.A., et al. 1994). The natural history ofHCV infection in
asymptomatic blood donors with HCV is not documented. The natural history of
HCV infection is best documented in patients with post-transfusion hepatitis C
where up to 85% of patients become chronic carriers and of these 20% develop
progressive liver disease with the development of cirrhosis after 20-30 year (Seeff
L.B., et al. 1992). In contrast progression to cirrhosis was observed in only 0.4%
of a cohort of 1,018 women infected with HCV from anti-D immunoglobulin after
20 years (Wiese, M. 2000). There are a number of reasons why treatment of these
asymptomatic individuals may be indicated. There are obvious concerns that they
may develop cirrhosis and hepatocellular carcinoma. In addition there is evidence
that HCV infection can cause Iymphoproliferative disorders of the B-cell lineage
in the absence of significant liver disease and cases of hepatocellular carcinoma in
these patients have also been described which supports the eradication of HCV
infection even in those patients with mild disease (De Vita, S., et al. 1997,
Zuckerman, E., et al. 1997, De Mitri, M.S., et al. 1995). Finally as asymptomatic
HCV carriers are at risk of causing viral spread in the community or vertical
spread to infants, their treatment may prevent new cases of infection.
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A sustained biochemical and virological response to a - interferon monotherapy is
seen in approximately 6% of interferon naive patients after a 6 months and 16%
after 12 months treatment, however most studies have specifically excluded
patients with mild disease and normal serum transaminases (McHutchison, J.G. &
Poynard, T. 1999). It is recognised that the best responses to antiviral therapy are
seen in those with short duration of infection, low viral load and milder
histological disease (Davis, G.L. & Lau, 1.YN. 1997). Therefore asymptomatic
blood donors with mild HCV infection diagnosed at screening might be expected
to show improved response rates to a - interferon compared with other patient
groups with chronic HCV. Few data exist to support this with only small pilot
studies of treatment in patients with mild hepatitis as assessed by normal liver
function tests and these include some patients with advanced histological disease
(Marcellin, P., et al. 1997).
The aim of this study was assess the tolerability and response to treatment in
asymptomatic patients with chronic hepatitis C infection detected at blood donor
screening and to then study pre-treatment factors, such as HCV genotype and co-
infection with hepatitis G virus, which might help predict the response to
treatment.
192
8.4 PATIENTS. MATERIALS AND METHODS
This study was approved by the West Glasgow Hospitals University NHS Trust
ethics committee and on entry each patient provided written informed consent.
8.4.1 Patients
As outlined in Chapter 7, forty asymptomatic blood donors with serological
evidence of hepatitis C and histological evidence of chronic hepatitis were
recruited into this randomised crossover study between August 1993 and
September 1994. Patients were randomised into 2 groups, one which initially
received 48 weeks of a. - interferon (group A) and the other (group B), which
underwent 48 weeks observation prior to receiving the same course of a. -
interferon.
8.4.2 Interferon treatment regime
Each patient received 4.5 MU of recombinant a. - interferon (Roferon-A, Roche,
Welwyn Garden City, Herts, UK) subcutaneously thrice weekly for 12 weeks. Any
patient whose ALT was normal «50 U / 1) at 12 weeks went on to receive a
decreasing dose of a. - interferon thrice weekly for a further 36 weeks (3 MU, 2
MU, then 1 MU thrice weekly for 12 weeks respectively). The total dose of a. -
interferon given to each patient was 126 MU over 48 weeks. Non-responders with
an elevated ALT at 12 weeks discontinued a. - interferon therapy but remained
under observation. Any patient who had a biochemical breakthrough (a rise in
ALT out-with the normal range after twelve weeks while on treatment) had their
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interferon dose increased to the previous higher dose and remained on that dose to
48 weeks.
8.4.3 Patient Assessment
Each patient underwent percutaneous liver biopsy at entry and again at 48 and 96
weeks. Formalin fixed, paraffin embedded liver sections were assessed by a single
pathologist (R.N.M. MacSween) using Ishak's modified histological activity index
(Ishak, K., et al. 1995). The pathologist was blinded to the patient's treatment
status.
Haematological and biochemical assessments were performed usmg routine
laboratory methods at baseline and while on treatment weekly until week four and
again at six, eight and twelve weeks. Thereafter they were performed 12 weekly
throughout the course of the study. Additional sera were collected, spun down
within four hours of collection and stored at -20°C to allow retrospective detection
of HCV-RNA by reverse transcription polymerase chain reaction (RT-PCR),
which was not available locally at the start of this study.
8.4.4 HCV determination
All patients studied were reactive by second generation ELISA (Ortho
Diagnostics, High Wycombe, UK) on initial screening and the presence of
antibodies to HCV was subsequently confirmed by radio-immunoassay (RIBA-2,
Chiron Corporation, Emeryville, Ca, USA) with two or more antigens positive.
These tests were repeated and confirmed to be positive prior to inclusion in this
study.
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HCV RNA was detected using an in-house RT-PCR method with primers for the
5' non-coding region of the HCV genome (Figure 8.1). RT-PCR was performed as
described (Dow, B.C., et al. 1993). This technique performed well in the
EUROHEP HCV -RNA reference panel study and had a lower limit of detection of
at most 2000 genomes / mI (Damen, M., et al. 1996). HCV genotyping was
performed on sera stored prior to treatment by restriction fragment polymorphism
as previously described (McOmish, F., et a1. 1993).
RT PCR testing was performed retrospectively on all patients receiving treatment
at entry and again after four, twelve and forty-eight weeks treatment.
8.4.5 HGV determination
Screening for HGV RNA in serum was performed retrospectively on stored serum
by RT-PCR with primers for the NS3 region of the HGV genome. The method has
been published previously and modified as discussed in Chapter 7 (Heringlake, S.,
et al. 1996).
8.4.6 Study end points and Statistics
Primary end points in assessing response to therapy were normalisation of serum
alanine aminotransferase (ALT) and improvement in liver histology after
completion of therapy. The secondary endpoints in assessing response to treatment
were loss of detectable HCV RNA from serum and tolerability of interferon
treatment..
Patients were classified according to their biochemical and virological responses to
a. - interferon treatment. Non response was defined as an elevated (>50 lUlL) ALT
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after 12 weeks of treatment. An initial response was defined as a normal serum
ALT after 12 weeks of interferon therapy and the response was considered
complete if it remained normal until treatment was stopped at 48 weeks.
Breakthrough was defined as an elevation in ALTon interferon therapy between
12 and 48 weeks. A sustained response was defined as a normal ALT for six
months after completing interferon therapy. Relapse was defined as an elevation in
ALT above normal in complete responders after interferon was discontinued.
Responses were further defined as complete and sustained virological response if
HCV RNA was not detectable in serum on completion and six months after
interferon therapy respectively.
The two-sample Wilcoxon rank sum test and Chi-square tests were used to
compare the two groups at entry into the study and to compare responders and
non-responders to treatment. Changes in liver histology over the study were
assessed using the two-sample Wilcoxon rank sum test.
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8.5 RESULTS
Twenty patients were randomised into each study group. The patients in both
groups were similarwith respect to sex ratio, laboratory results, presence of HCY
RNA in serum, and liver histology (Table 8.2). The patients from group A were
significantly older and blood products were a more common source of infection in
this group.
8.5.1 Patient follow-up
The progress of the study after randomisation is summarised in Figure 8.1.
Eighteen patients from group A completed the treatment protocol. Two withdrew
during the first 12 weeks of treatment; one could not tolerate self-injection while
the other complied poorly with treatment. Four patients in group B were lost to
follow up after completing 48 weeks of observation and a further 2 patients were
withdrawn from group B prior to starting treatment as they were found to be
persistently RT PCR negative for Hey RNA. Fourteen patients from group B
went on to receive interferon therapy. Of these one stopped treatment after 1
month as he could not tolerate side effects and one defaulted after 12 weeks of
treatment. Consequently 12 patients from group B completed treatment according
to the protocol.
During the observation period of patients from group B, there was no significant
change in the ALT levels and the mean ALT levels remained elevated as
illustrated in Figure 8.2. None of the eighteen RT PCR positive patients from
group B cleared HCV RNA from serum after 48 weeks observation. Patients from
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group B showed no significant change in Ishak modified histological activity
scores over the observation period (Figure 8.3).
8.5.2 Response to treatment
Response rates to a. - interferon are reported for the 34 patients (20 from group A
and 14 from group B) who commenced treatment, excluding the 6 patients who
withdrew from group B before therapy was initiated. Response rates are reported
on an intention to treat basis for the thirty-four patients who commenced a. -
interferon. The patients who defaulted from the study or withdrew did not differ
significantly from those treated with regard to the histological severity of their
liver disease (p = 0.9).
8.5.2.1 ALT response
Four (12%) patients withdrew within twelve weeks of starting therapy. The
responses to a. - interferon observed in the remaining thirty patients treated
according to the protocol is summarised in Figure 8.4. Eight patients (24%)
showed no biochemical response to a. - interferon, with an elevated ALT level
after 12 weeks of treatment, and discontinued treatment at that time. Twenty-two
patients (65%) showed an initial response, with a normal ALT level after 12 weeks
of treatment, and went on to complete 48 weeks of a. - interferon. Five patients
(15%) who had an initial response to a. - interferon had a biochemical
breakthrough, with a rise in ALT out-with the normal range despite continuing on
a. - interferon to 48 weeks. The remaining 17 patients (50%) were complete
responders with normal ALT levels until they completed 48 weeks of treatment.
Five of these patients had a normal ALT level on repeat testing prior to the
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initiation of therapy and in each case the ALT remained normal until the
completion of therapy. Within six months of completing a. - interferon 3 patient
(9%) showed a biochemical relapse with a persistent elevation of ALT level
including one patient whose ALT had been persistently normal prior to therapy.
The remaining fourteen patients (41%) had a complete sustained biochemical
response, with normal ALT levels 1 year after stopping a. - interferon.
8.5.2.2 Histological response
The changes in necroinfiammatory activity on liver biopsy over the course of
treatment and follow up periods are shown in Figure 8.5. There was no significant
change in the scores for necroinflammatory activity and fibrosis in the group as a
whole on treatment or during the follow up year. When each response group was
considered individually a significant improvement in necroinflammatory activity
by 48 weeks was confined to patients who had a complete sustained clearance of
virus from serum (p < 0.02). There was no significant change in
necroinflammatory scores in this group over the follow-up year (p = 0.7). There
was no significant change in fibrosis scores in any of the individual response
groups over the course of the study (Figure 8.6).
8.5.2.3 BeV RNA response
The RT PCR results in the 30 patients who received a. - interferon treatment are
shown in Table 8.3. One patient from group A had a complete sustained
biochemical response to a. - interferon but was found to be repeatedly RT PCR
negative on testing serum from prior to entry into the study. The 29 remaining
patients were peR positive at entry into the study. Eight (24%) of the thirty four
patients commencing a. - interferon therapy experienced a sustained virological
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response and remained RT PCR negative for HCV RNA in serum 1 year after
completing therapy. Four patients with a sustained biochemical response were RT
PCR positive for HCV RNA on completion of treatment. One patient having
experienced a complete virological response had a virological relapse six months
after completing therapy. Of the three patients who relapsed after completing
therapy one was viraemic on completion of therapy and all were viraemic within
six months of stopping therapy. Two patients experiencing a breakthrough on
treatment remained RT PCR negative in serum to 48 weeks but all were viraemic
within six months of completing ex. - interferon. Despite transient loss of HCV
RNA from serum in three patients, all non-responders were viraemic by forty-eight
weeks. Overall no patient viraemic after 4 weeks of treatment had a sustained
clearance ofHCV RNA from serum.
8.5.3 Predictors of a complete sustained virological response to interferon
Pre-treatment factors predictive of a sustained biochemical and virological
response were analysed for those twenty-nine patients that completed the study
treatment protocol and were HCV PCR positive prior to treatment. Patients that
had a sustained to ex. - interferon therapy were comparable to those that did not
with regard to baseline liver function tests and pre-treatment grade and stage of
chronic hepatitis. Five patients had persistently normal ALT levels prior to
treatment, one was PCR negative prior to treatment and one had a sustained
virological response. Rates of sustained biochemical and virological response were
comparable in patients with persistently normal and those with elevated ALT
levels (one of 4, 25% v seven of 25, 28%, P = 1.0). Similarly patients with no
fibrosis on pre-treatment liver biopsy had comparable sustained response rates to
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those with fibrosis on pre-treatment biopsy (one of8, 12% v seven of21, 33%, p =
0.38)
The Hev genotypes of all 29 patients who were Hev peR positive and
commenced treatment were recorded. A complete sustained virological response
was observed in four (27%) of the fifteen patients infected with genotype 1, two
(40%) of the five with genotype 2 and two (22%) of the nine with genotype 3. No
significant differences in response rates to <X. - interferon were detected between
genotypes (p = 0.7).
Seven (18%) of the forty patients studied were found to be co-infected with HGV
prior to the initiation of <X. - interferon therapy. No additional patients acquired
HGV infection over the treatment period. Five of the seven patients co-infected
with HGV received treatment according to the study protocol. The biochemical
and Hev and HGV peR responses to <X. - interferon are summarised in Table 8.4.
Patients co-infected with HGV exhibited a comparable rate of sustained clearance
of HeV RNA from serum with <X. - interferon compared with those patients not
infected with HGV (40% v 25%, p = 1.0).HeV and HGV Pf'R responses were not
directly associated. Three (60%) of the co-infected patients were HGV peR
negative at the end of treatment. The two patients HGV peR positive at the end of
treatment had a sustained clearance of HeV RNA from their serum and in both
cases ALT levelswere persistently normal after treatment.
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8.5.4 Tolerability of a - interferon therapy
Twenty-eight (82%) of thirty-four patients who received a - interferon complained
of adverse side effects on treatment and these were generally mild. The
commonest complaints were of febrile reactions (17), myalgia or arthralgia (8),
anorexia (6), headache (6), fatigue (6), pruritus (5), low mood (4), abdominal pain
(4), exacerbation of psoriasis (2) and alopecia (2). Two (6%) patients could not
tolerate treatment and discontinued therapy; one was not able to perform self-
injection while the other experienced troublesome myalgia and fevers. No other
alteration in a - interferon dose was required as a result of adverse side effects.
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8.6 DISCUSSION
Infection with the hepatitis C virus becomes chronic in approximately 80% of
those that acquire it, causing a chronic hepatitis in the majority of cases and over a
number of years this can progress to cirrhosis. The natural history of the infection
has largely been established in individuals who acquired HCV infection through
blood transfusion where approximately 20% of individuals develop cirrhosis after
20 - 30 years (Seeff, L.B., et al. 1992). The natural history of the infection in
asymptomatic individuals who are found to have chronic HCV infection at blood
donor screening is not known. These individuals have mild symptoms and mild
fibrosis on liver biopsy and are presumably at an early stage in the natural history
of the disease (Bird, G.L.A., et at. 1995). Sustained response to treatment of
chronic HCV infection has been shown to improve quality of life, halt progression
of the liver disease and hopefully reduce the risk of subsequent hepatocellular
carcinoma. Several organisations have published consensus conference
recommendations concerning the indications for treatment of patients with chronic
hepatitis C infection (Booth, lC.L., et at. 2001, European Association for the
Study of Liver Disease. 1999, National Institute of Health Consensus
Development Panel Statement. 1997, Dhumeaux, D., et al. 1997). The consensus is
consistent in recommending that treatment is restricted to patients with elevated
transaminases for more than six months, active viral replication as indicated by
positive polymerase chain reaction for serum HeV RNA, and moderate or severe
inflammation on liver biopsy. Using these criteria asymptomatic blood donors with
mild disease would not be considered suitable candidates for treatment and there
are few data to guide their management. Most existing studies are small and have
focused on patients assessed as having mild hepatitis on the basis of normal liver
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function tests however this group of patients is ill defined and includes some
patients with advanced liver disease (Marcellin, P., et al. 1997, Di Bisceglie, A.M.
1999). A single trial from Italy reported a 42% sustained virological response to
interferon a.2a monotherapy in thirty-two asymptomatic blood donors with mild
disease on liver biopsy (Prati, D., et al. 2000). In the current study a complete
sustained biochemical response to a - interferon monotherapy was observed in
41% of patients and a sustained virological response was observed in 24% of
patients. The response rates in these two studies are at least as good as the
response rate reported in HCY infected patients with a definite indication for
antiviral therapy (10 - 25%) (Poynard, T., et al. 1996). The disparity in response
rates between the current study and that of Prati et al. may be explained by the
higher dose of a - interferon (4.5 MU thrice weekly for 6 or 12 months) used, the
inclusion of patients only under 45 years of age in that study or the presence of a
few patients with more severe liver fibrosis in the current study. Studies of patients
with overt liver dysfunction have shown that sustained response rates to a -
interferon are directly related to the total dose given and this may hold true for
patients with mild liver disease also (Poynard, T., et al. 1996). In addition, in
studies of patients with liver dysfunction who received treatment with a. -
interferon, mild chronic hepatitis on pre-treatment liver biopsy is an independent
factor predictive of response to treatment in chronic hepatitis (Davis, G.L. & Lau,
lY.N. 1997, Poynard, T. et al. 1998). In the current study, patients with no fibrosis
on pre-treatment liver biopsy had lower response rates to a - interferon compared
with patients with fibrosis although the difference was not statistically significant
(12% v 33%). This may reflect an anergic immune response to HCY in these
patients who will not respond to the immunostimulatory properties of a -
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interferon (prati, D., et al. 2000). The prevalence of HCY genotypes in these
patients was similar to that detected in other local patient populations (see Chapter
3). Surprisingly, the response rates in patients infected with genotype 1 were
similar, if not better, than that seen in patients infected with genotype 3 which
contrasts with studies of patients with more severe chronic hepatitis and liver
dysfunction (Davis, G.L. & Lau, 1.Y.N. 1997). The sample size in this study was
small but this raises the possibility that HCY genotype has less influence on
treatment response in patients with mild disease.
The patients in this study were asymptomatic at the time of diagnosis of hepatitis
C infection. Almost all patients who receive treatment doses (>3MU per injection)
of ct. - interferon experience some adverse side effects. More severe side effects
which may require dose modification are less common occurring in 10% to 15% of
patients and severe or life threatening side effects occur in O.1% to 1% of patients
(Dusheiko, G. 1997). When this study was designed the optimal interferon dosage
regime for chronic hepatitis C infection had not been established. Studies of initial
induction regimens followed by dose reduction had been shown to be effective
(Lee, W.M. 1997). In view of concerns about the tolerability of ct. - interferon
therapy in this asymptomatic patient group, a novel regimen of progressively
decreasing ct. - interferon dose was designed for those patients who responded to
the initial twelve weeks of induction therapy. This regimen proved to be well
tolerated by this previously asymptomatic population with only 6% of patients
stopping treatment on the induction dose, a rate that is comparable to other studies
(Dusheiko, G. 1997). No other dose modifications were required as a result of side
effects which contrasts with the rates of dose reduction of between 9% and 22%
observed in studies employing fixed dose regimens (Poynard, T., et al. 1996).
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Given that no patient showed a sustained virological response to treatment if they
remained PCR positive after four weeks of treatment, it may be possible to identify
earlier those patients who are not showing a virological response to therapy, to
avoid subjecting them to unnecessary therapy as is the case with patients with
more severe liver disease and liver dysfunction (Tong, MJ., et al. 1997).
Combination therapy with ex. - interferon and ribavirin has been shown in
randomised trials to produce improved response rates compared with ex. - interferon
monotherapy in the management of treatment naive patients with chronic HCY
(McHutchison, lG. & Poynard, T. 1999). a - Interferon monotherapy remains the
treatment of choice for selected patient groups in whom therapy with ribavirin is
contraindicated, in particular those with ischaemic heart disease, renal disease or in
those receiving inadequate contraception (Glue, P. 1999). Ribavirin is teratogenic
and is renally excreted. Conception in patients or their partners should be avoided
during treatment and for six months thereafter. Haemolysis is the most significant
adverse effect of ribavirin use and can be sudden and profound, particularly in
patients with renal impairment. Thus combination therapy with a - interferon and
ribavirin is not indicated for all treatment naive patients and this novel regimen of
ex. - interferon has been shown to be both a safe and effective alternative for these
patients.
This study showed that asymptomatic blood donors with chronic hepatitis C
infection detected at blood donor screening tolerated this novel ex. - interferon
regimen and demonstrated similar if not superior response rates compared with
other patient groups with chronic hepatitis C infection. The natural history of
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chronic hepatitis C infection in asymptomatic blood donors is not established and
it is unclear what the risks of disease progression are in this patient group. It may
well be that untreated these patients have an excellent prognosis, however in
waiting until there is evidence of significant disease the chances of a response to
treatment may be reduced. Further data in this area are required however this study
provides evidence that these patients tolerate and respond to a - interferon.
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Table 8.1RT-PCR Primen for the 5' non-coding region of the HeV genome
utilised in this study.
Primer Sequence 5'~3' Nucleotide
position"
HCV-22 Reverse TCGTCGTCATGGTGCACG -8 to 9
transcription
HCV-21 Outer sense CGACACTCCACCATGAATCAC -332 to -302
HCV-24 Outer antisense CATGGTGCACGGTCTACGAGACC -20 to 3
HCV-23 Inner sense TCACTCCCCTGTGAGGAACT -305 to -286
NCR-4 Inner antisense GCACCCTATCAGGCAGT -54 to -38
* Numbering according to Choo Q.L., et al. 1991
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Table 8.2 Entry characteristics of study groups.
Clinical Features Group A (n=20) Group B (n=20)
Age, median years (range) 40 (28-53) 33* (25-48)
Sex, N males (%) 12 60 12 60
History of jaundice, N (%) 4 (20) 5 (25)
Source of hepatitis, N (%)
Transfusion 12 (60) 3** (15)
Parenteral drug use 4 (20) 9 (45)
Occupational exposure 0 (0) (5)
Tattoo I Body piercing 11 (55) 13 (65)
Unknown 3 (15) 3 (15)
Laboratory, mean" (range)
ALT (UIL) 94 (11-220) 129 (13-470)
AST (UIL) 51 (18-126) 63 (18-141)
Total bilirubin (umol) 10 (1-27) 10 (1-23)
Albumin (gIL) 44 (40-49) 44 (41-51 )
Gamma GT (UIL) 62 (7-378) 63 (14-239)
Prothrombin time (sec) 14.6 (12-18) 14.9 (13-18)
Leukocyte count (x 1091L) 6.5 (3.5-11.1) 6.2 (3.5-9.7)
Haemoglobin (g/dL) 14.6 (12.2-17) 14.9 (11.8-17.4)
Platelet count (xl091L) 239 (125-359) 224 (142-424)
HCV RNA RT-PCR negative, N (%) 1 (5) 2 (10)
HCV Genotyping N 19 18
1N(%) 10 (53) 6 (33)
2N(%) 5 (26) 0 (0)
3 N(%) 4 (21) 12 (67)
Histology, median (range)
Inflammation 4 (2-10) 6 (1-10)
Fibrosis 1 (0-5) (0-3)
# Normal ranges: Albumin 36-50 gIL, ALT 10-50 U/L, AST 10-35 UIL, Total
bilirubin 3-18 umol, Gamma GT 5-50 UIL, Haemoglobin 13-18 g/dL, Leukocyte
count 4.5-6.5 xl091L, Platelet count 140-450 xl091L, Prothrombin time 15 sec
* p < 0.02 ** P < 0.003
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Table 8.3 Summary of RT peR for BeV RNA results of the 30 patients
completing the treatment protocol. The four patients who withdrew while
receiving treatment were all RT peR positive at entry, twelve weeks and
thereafter.
Biochemical response to treatment
Non Breakthrough Complete Relapsers
No of patients
Responders (n=5) Sustained (n=3)
HCVRNA
(n=8) Responders
negative at:
(n=14)
entry 0 0 1 0
4 weeks 3 2 10
12 weeks 1 3 11
48 weeks 0 2 10 2
6 months post 0 0 9 0
1 year post 0 0 9 0
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Table 8.4 Biochemical and virological responses to a. - interferon observed in
patients co-infected with hepatitis C and hepatitis G viruses.
No. (%) Complete Complete Biochemical Breakthrough No Total
sustained sustained Relapse response
virological biochemical
response response
(HCVPCR
positive)
HGV PCR at pre-treatment
HGV 6 4 2 5 7 24
Negative
HGV 2 1 1 0 5
Positive
End of treatment HGV peR results in those HGV positive at entry
HGV 2 0 0 0 3
Positive
HGV 0 1 1 0 0 2
Negative
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Figure 8.3 Group B liver biopsy scores (Ishak modified histological index) at
entry and after the observation period. Medians marked with horizontal bar
(a) Necroinflammatory scores
p=O,4
12
10 •e;-
80
~
• ie~ 6,_~ >c;:::: ',;:: 4s:: (),_ ~0 •...() 2~ : •z ..0 ~---~--I
0 48
Week of study
(b) Fibrosis scores
4
p= 0,5
....
•
•............... . ..
o +-------------~------------ ..-------------,
o 48
Week of Study
214
oC\J,.-
oo
Ct)
o
1.0
(\I
o 0o 1.0N ..-
11'9' ueaV'J
Figure 8.S Changes in necrointlammatory activity on liver biopsy in the 30
patients treated according to the protocol. The scores for patients that had a
complete sustained biochemical response to interferon and remained RT PCR
negative (0) are joined. The scores for patients that had a complete sustained
biochemical response but remained viraemic (~) and aU other response groups
(.) are also shown. Significant improvement in necrointlammatory scores were
seen only for patients who had a sustained clearance of HCV RNA from serum (p
values shown refer only to patients that had a sustained clearance of HCV RNA
from serum).
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Figure 8.6 Change in fibrosis scores over the treatment period in the 30
patients receiving treatment as per protocol. The scores for patients that had
a complete sustained biochemical response to interferon and remained RT
PCR negative (0) are joined. The scores for patients that had a complete
sustained biochemical response but remained viraemic (~) and all other
response groups ( • ) are also shown.
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9.2 Summary of findings and further research from Chapter 3
This study indicates that the healthcare setting is unlikely to account for significant
transmission of hepatitis C virus in an area with a large HCV infected injecting
drug using population. Healthcare personnel and patients can both be reassured
that the reservoir of healthcare personnel in the West of Scotland who are infected
with HCV is extremely small (2.8 per 1000). It appears that working in the
healthcare environment and performing exposure-prone procedures only rarely
leads to the acquisition of hepatitis C virus by healthcare workers. In addition the
risk posed to patients from hepatitis C virus infected healthcare workers is
probably low. In the absence of guidelines for the management of healthcare
workers infected with hepatitis C virus it is essential that needlestick injuries are
reported and rigorously followed-up by Occupational Health Services to establish
whether these conclusions are correct. In addition HCV infected healthcare
workers should be advised to train in areas where exposure-prone procedures are
not performed, as it is likely that in time their practises will be restricted.
9.3 Summary of findings and further research from Chapter 4
This study fails to show an advantage for <l-GST in grading the severity of liver
inflammation in chronic HCV infection but that <l - GST may have a role in
monitoring response to <l - interferon therapy. An accurate non-invasive tool for
the assessment of the severity of HCV related liver injury remains an important
goal in the management of chronic HCV to avoid the necessity for repeat liver
biopsy. A number of serum markers of liver fibrosis have been evaluated
individuaUy and have proved disappointing. This area is currently the target for a
great deal of research and it is hoped that the combination of a number of these
serum markers will provide a solution. Panels of these assays are being evaluated
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in large prospective multicentre studies with longitudinal follow-up and results are
awaited. In the mean time liver biopsy remains the gold standard for assessing and
following up the severity ofHCV related liver injury.
9.4 Summary of findings and further research from Chapter 5
In this chapter we found that although many patients with chronic hepatitis C virus
infection have elevated serum iron studies, few have significant iron deposition
within the liver. Carriage of the recognized mutations in the HFE gene, although
frequently observed, do not account for the elevated serum iron studies and liver
iron deposition that is present nor are they associated with any clinical.
biochemical, virological or pathological feature. The concentration of liver iron did
not have a significant role in the progression of HCV related liver injury. These
findings indicate that iron depletion by venesection is unlikely to influence the
natural history of chronic hepatitis C virus infection even in those patients with
elevated liver iron concentrations. Further studies are required to establish whether
the liver iron deposition in chronic hepatitis C virus infection is secondary to
hepatocellular damage or whether it is a primary problem in the few patients in
whom it is observed.
9.5 Summary of findings and further research from Chapter 6
This study reveals that genetic polymorphisms in the renin-angiotensin system.
which are associated with increased activity in the systemic renin-angiotensin
system, do not account for the variable rate of progression observed in chronic
HCV infection. Whether a tissue renin-angiotensin system exists within the liver
and whether angiotensin II stimulates human hepatic stellate cells to produce
extracellular matrix has not been established. Further in-vitro studies are required
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to establish whether exposure to angiotensin II stimulates the production of
transforming growth factor - ~1 by activated human hepatic stellate cells.
Prospective controlled clinical studies of pharmacological blockade of the renin-
angiotensin system are required to establish whether these therapies prevent the
progression of hepatic fibrosis in chronic Hev and other chronic liver diseases.
9.6 Summary of findings and further research from Chapter 7
This study reveals that hepatitis G virus co-infection is common in HCY infected
individuals due to shared risk factors. However there was no evidence that HGY
infection influenced the biochemical and histological severity of HCV related liver
disease. This is consistent with the findings of other investigators. In the absence of
clinical and laboratory evidence that HGV is a hepatotropic virus or the cause of
hepatitis in humans the significance of infection with this virus remains poorly
understood and it should not be referred to as a hepatitis virus. Further research is
required to establish whether the GB virus-C is a cause of disease in humans.
Recently it was reported that patients who are co-infected with GB virus-C and the
Human Immunodeficiency Virus (Hl'V) have a more favourable prognosis with
delayed development of the acquired immunodeficiency syndrome (AIDS)
compared with those infected with mv alone(Stosor, V. & Wolinsky, S. 2001).
Further study in this area is required. Certainly the variable rates of progression
observed in HCV related liver disease cannot be explained by co-infection with
HGV.
9.7 Summary of findings and further research from Chapter 8
This study revealed that asymptomatic blood donors with chronic hepatitis C
infection detected at blood donor screening tolerated this novel (l - interferon
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regimen and demonstrated similar if not superior response rates compared with
other patient groups with chronic HCY. The natural history of chronic hepatitis C
infection in asymptomatic blood donors is not established and it is unclear what
the risks of disease progression are in this patient group. Currently the consensus is
that these patients should be left untreated however in waiting until there is
evidence of significant disease the chances of a sustained virological response to
treatment may be reduced. A large multi-centre NHS Healthcare Executive study
is currently underway studying the combination of a - interferon and ribavirin in
the management of patients with mild chronic hepatitis C virus infection and until
the results of this study is available monitoring of these patients by serial liver
biopsy remains the management of choice.
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APPENDICES
Appendix 1. Algorithm for HCV testing employed by the Regional Vir-us
Laboratory in Glasgow (protocol updated May 2001). The assays employed for
testing are an third generation ELISA (Ortho Diagnostics, Raritan, N.J), the
Amplicor polymerase chain reaction (PCR) assay (Roche Diagnostics), and a third
generation third generation RIBA (Ortho Diagnostics, Raritan, NJ).
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Appendix 2. Greater Glasgow Health Board Hepatitis C strategy review - inclusion
and exclusion criteria for treatment of chronic hepatitis C.
AU patients with Hev are potential candidates for therapy. However, until th
natural history is better undentood, those with the greatest risk of progressing t
cirrhosis should receive priority. The foUowing are suggested inclusion an
exclusion criteria for selection of patients for combination therapy:
Inclusion criteria:
a. Age 70 years or less.
b. Either sex.
c. Serum PCR positive for HCV -RNA (within the last 6 months).
d. Elevated serum ALT for in excess of 6 months.
e. Liver biopsy evidence of moderate to severe chronic hepatitis C with or without
cirrhosis (when feasible).
Exclusion criteria:
a. Marked obesity (body mass index> 30).
b. Symptomatic HIV positive patients (or asymptomatic with CD4lymphocyte count <
350) or patients who are immunosuppressed.
c. Patients with cirrhosis and features of liver failure (consider for liver transplantation).
d. Evidence of primary hepatocellular careinoma.
e. Patients with evidence of another cause for chronic hepatitis such as alcohol excess or
auto-immune liver disease (smooth muscle antibody positive, high IgO).
f. Patients with significant co-morbidity due to neoplasia or cardiac, respiratory and
renal disease.
g. Patients thought unlikely to be able to co-operate with subcutaneous injections or
follow-up at the clinic.
h. Pregnancy, breast-feeding mother, or inability for either sex to use effective
contraception during and for 6 months after therapy.
I. Patients with contraindications to use of interferon or ribavirin such as epilepsy or
compromised CNS function, renal failure, congestive cardiac failure, psoriasis or
known hypersensitivity to either product.
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Appendix 3. Greater Glasgow Health Board Hepatitis C strategy review - pre-
treatment assessment, treatment regimen and monitoring of therapy.
Pre-treatment assessment
Patients will have been selected according to criteria above. The following data should be
available before treatment and one or more of these criteria indicate that the patient falls into a
poor response category.
• Genotype I with high viral load
• Cirrhosis or bridging fibrosis on liver biopsy
• Males aged > 40 years
The following categories of patients will be considered:
a. Untreated patient (naive)
b. Relapse after previous interferon monotherapy
c. Non-responders to previous interferon monotherapy
Naive and relapse patients should be treated in the same manner as indicated below. There is no
treatment yet recommended for non-responders, who should remain under observation.
TreatmentregUnen
All pre-menopausal women to have a negative pregnancy test before commencing therapy.
a. Standard
Alfa interferon 3 MU subcutaneously three times a week (TfW) plus oral Ribavirin 1-1.2 gm
daily for 24 weeks.
b. Poor Response
Alfa interferon 3 MU subcutaneously TIW plus oral Ribavirin 1-1.2 gm daily for 24 weeks
initially. IfPCR negative at 24 weeks continue for a total of 48 weeks.IfPCR positive at 24
weeks stop therapy.
Monitoring of therapy
It IS recommended that patients are seen at 1, 2 and 4 weeks and thereafter every 4 weeks for 24
or 48 weeks during therapy. A clinical nurse specialist with experience in this area is ideally
suited to this role. provided there is readily available medical support. Monitoring should
include support and encouragement for the patient, reminder about the need for contraception,
observation for any side-effects or complications, and blood tests including full blood count,
renal function and liver function tests. Marrow suppression may require a reduction in dosage.
Serum PCR for HCV -RNA should be checked at 24, 48 and 72 (poor response category) weeks
and thyroid function tests at 24 and 48 weeks. Liver biopsy may be repeated (optional) six
months after the end of treatment.
259
Appendix 4. BGV RT-PCR protocol. Reaction mixes per sample analysed.
RNA
antisense primer HGV -G8 (2OpmoV"u)
Total RNA/anti-sense I mix
10.5 III
1 III
11.5 III
Incubate for I0 min at 70°C, then quickly chill on ice
a. RT-Mix
5x RT-buffer
DTT
RNAsin (promega)
dNTP (IOmM stock)
Superscript RT (Gibco BRL)
4 III
2 III
1 III
0.5 III
1 III
Plus RNA/anti-sense I mix
Incubate for 1 hour at 37°C, 10min at 95°C
cDNA
Store at -20°C
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Appendix 4 (Continued)
HGV RT-PCR protocol. Reaction mixes per sample analysed.
b. Mix for outer peR
lOx peR buffer
Mg 50mM (lmM final concentration)
dNTP (10mM stock)
Sense primer HGV -G7 (10 pmol / J-LI)
Antisense primer HGV-G8 (10 pmol / J-Ll)
TAQ-polymerase (Gibco BRL)
Water
2.5,.11
0.5,.11
0.5 J-Ll
0.75 J-Ll
0.75 J-LI
0.25 J-Ll
14.75 III
plus cDNA
c. Mix for inner peR
lOx peR buffer
Mg 50mM (ImM final concentration)
dNTP (1OmM stock)
Sense primer HGV -G7 (20 pmol / J-LI)
Antisense primer HGV -G 11 (20 pmol / J-Ll)
TAQ-polymerase (Gibco BRL)
Water
2.5 III
0.5 III
0.75 J-LI
0.75 J-Ll
0.25 J-Ll
17.75 J-LI
plus peR 1 product
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2.5 J-LI
